Last updated: Apr 12, 2020 - 02:00 BST
| VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitätsklinikum Erlangen Psychosomatische und Psychotherapeutische Abteilung |
Universitatsklinikum Erlangen, Universitätsklinikum Bonn Klinik für Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Ulm Psychosomatik |
Germany |
2020-04-20 |
|
133_20 B, DRKS00021268, VOICE |
Phase Not Applicable |
Not yet recruiting |
5 |
|
2000 |
Andrea Borho, Eva Morawa |
2020-04-11 |
| Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers |
Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The National Institute of Mental Health |
National Institutes of Health Clinical Center |
US |
2020-04-15 |
2022-04-01 |
20-M-N085, 999920085, NCT04339790 |
Phase Not Applicable |
Recruiting |
0 |
23 Months |
5000 |
Alison Gibbons, Joyce Y Chung, M.D. |
2020-04-11 |
| HCQINRLGII: Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals |
Coronavirus disease 19 infection |
Bisolvon plus Plaquenil |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Rehabilitacion |
|
Mexico |
2020-04-10 |
2020-07-10 |
20/20, HCQINRLGII, NCT04340349 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
100 |
Julio Granados Montiel |
2020-04-10 |
| NODS-Cov2: Nosocomial Dissemination Risk of SARS-Cov2 |
Coronavirus disease 19 infection |
|
|
|
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-13 |
2020-06-15 |
APHP200417, NCT04339881, NODS-Cov2 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
100 |
Bich-Tram Huynh, Didier Guillemot, Didier Guillemot, Pr |
2020-04-10 |
| COVID-19 Risk Stratification |
Coronavirus disease 19 infection |
risk score validation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Brigham & Women's Hospital |
|
US |
2020-03-01 |
2020-04-15 |
2020P000944, NCT04339387 |
Phase Not Applicable |
Recruiting |
0 |
1 Month |
1500 |
David Levine, David Levine, MD, David M Levine, MD MPH MA |
2020-04-10 |
| FRENCH CORONA: French, Multicenter, Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-03 |
2021-04-30 |
2020-A00797-32, FRENCH CORONA, NCT04340466 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
220 |
Anissa MEGZARI, CLAIRE ROGER, CLAIRE ROGER, MD, PhD, Claire Roger, MD, PhD |
2020-04-10 |
| Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection |
Coronavirus disease 19 infection |
atovaquone plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HonorHealth Research Institute |
|
US |
2020-04-30 |
2021-04-30 |
HRI-COVID-19-ANTI-MALARIAL-001, NCT04339426 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
25 |
Heather Lane, Karen Lewandowski, RN, Michael Gordon, MD |
2020-04-11 |
| Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt (COVID-19) |
Coronavirus disease 19 infection |
|
|
|
Assiut University |
|
Egypt |
2020-05-01 |
2020-07-30 |
COVID-19 IN EGYPT, NCT04339322 |
Phase Not Applicable |
Not yet recruiting |
2 |
2 Months |
200 |
Haidi Karam |
2020-04-10 |
| POWER-COVID_CT: Multicentric, Retrospective, Observational Study of Thoracic Scanner Performance in COVID Screening |
Coronavirus disease 19 infection, Lung injury |
thoracic CT scan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation |
|
|
2020-04-30 |
2020-11-30 |
NCT04339686, POWER-COVID_CT, POWER-COVID_CT |
Phase Not Applicable |
Not yet recruiting |
0 |
7 Months |
56000 |
Guillaume HERPE |
2020-04-10 |
| Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection |
Acute lung injury, Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
losartan alone, standard of care alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sharp HealthCare |
|
US |
2020-03-27 |
2020-12-31 |
2003902, COVID-ARB, NCT04340557 |
Phase 4 Clinical |
Recruiting |
0 |
9 Months |
200 |
Adriana Valdez-Hernandez, RN, Cary Murphy, RN, George Sakoulas, MD, Katie Miller, Matthew Geriak, Matthew Geriak, PharmD |
2020-04-10 |
| Evaluation of the efficacy of Oral 25-hydroxyvitamin D3 on COVID-19 |
Coronavirus disease 19 infection |
25-hydroxyvitamin D3, Dishmen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-15 |
|
IR.TUMS.VCR.REC.1399.061, IRCT20200401046909N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
260 |
Arash Shirvani, Mohammadali Sahraian, Mohammadali Sahraian, Research Deputy, Zhila Maghbooli |
2020-04-10 |
| COVID-19 Convalescent Plasma |
Coronavirus disease 19 infection |
COVID-19 convalescent plasma therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-30 |
2021-12-31 |
IRB20-0523, NCT04340050 |
Phase 0 Clinical |
Not yet recruiting |
0 |
20 Months |
10 |
Maria Lucia Madariaga, Maria Lucia Madariaga, MD |
2020-04-10 |
| Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
CVVH machine alone, Low flow ECMO driving alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Peking Union Medical College Hospital |
|
China |
2020-03-03 |
2020-10-15 |
LOW FLOW-ECMO BY CVVH IN NCP, NCT04340414 |
Phase Not Applicable |
Recruiting |
2 |
7 Months |
10 |
Huaiwu He, MD, Wei Cheng, MD, Xiang Zhou, MD, Yun Long, Yun Long, MD |
2020-04-10 |
| Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy |
Coronavirus disease 19 infection |
|
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabula Rasa HealthCare Inc |
|
US |
2020-04-07 |
2021-04-06 |
COVID-PACE-2020-001, NCT04339634 |
Phase Not Applicable |
No longer recruiting |
0 |
12 Months |
12123 |
Jacques Turgeon, PhD, Malavika Deodhar, PhD, Sweilem B Al Rihani, PharmD, PhD, Veronique Michaud, PhD |
2020-04-10 |
| Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS) |
Coronavirus disease 19 infection |
point-of-care ultrasonography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Minnesota |
|
US |
2020-04-15 |
2020-10-31 |
NCT04339998, STUDY00009429 |
Phase Not Applicable |
Not yet recruiting |
0 |
6 Months |
500 |
Jon Kirsch, MD, Matthew Yocum, MD |
2020-04-10 |
| Eating Habits of Adults During the COVID-19 Quarantine |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Eastern Mediterranean University |
Cyprus Science University |
Cyprus |
2020-04-10 |
2020-05-31 |
NCT04339842, NUTR2020 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
400 |
Eliz Arter, Eliz Arter, MSc, Zalihe Yarkiner, PhD |
2020-04-11 |
| Max COVID19 Study |
Coronavirus disease 19 infection |
opted communication based data collection alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-02 |
2020-06-30 |
COVID-19/MHC/2020, NCT04339608 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
10000 |
Samreen Siddiqui, PhD, Sandeep Budhiraja, MRCP (U.K), MD, Sujeet Jha, MRCP (U.K) |
2020-04-10 |
| ONCOVID: Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic |
Anxiety disorder, Cancer, Coronavirus disease 19 infection, Mood disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Ziekenhuis Gent |
|
Belgium |
2020-03-30 |
2020-09-30 |
BC-07505-LGE, NCT04340219, ONCOVID |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
180 |
Emiel De Jaeghere, MD, Hannelore Denys, Hannelore Denys, MD, PhD, Heini Kanervo, RN |
2020-04-10 |
| AZIQUINE-ICU: Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomized, Controlled Trial |
Coronavirus disease 19 infection, Respiratory failure |
azithromycin plus hydrochloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Charles University |
Faculty Hospital Olomouc, General University Hospital, Prague, Masaryk Hospital Usti nad Labem, St. Anne's University Hospital Brno, Czech Republic, The Faculty Hospital Na Bulovce, University Hospital Motol, University Hospital Pilsen |
Czech Republic |
2020-04-20 |
2022-06-30 |
2020-001456-18, AZIQUINE-ICU, AZIQUINE-ICU-25032020, NCT04339816 |
Phase 3 Clinical |
Not yet recruiting |
1 |
26 Months |
240 |
Frantisek Duska |
2020-04-10 |
| Evaluation of Serum Zinc Levels Response to Treatment of Covid-19 Positive Patients |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-03-20 |
2020-05-03 |
NCT04339556, ZINCCOVID19 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
25 |
Pınar Yalcin bahat |
2020-04-10 |
| A Study on Melatonin and Vitamin C and Zinc Efficacy in Patients With COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including ascorbic acid , melatonin , zinc sulfate |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Semnan University of Medical Sciences |
|
Iran |
2020-04-07 |
|
IR.SEMUMS.REC.1399.005, IRCT20151228025732N52 |
Phase 3 Clinical |
Recruiting |
1 |
|
10 |
Fatemeh Ehsani, Mahboubeh Darban |
2020-04-10 |
| The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation |
Coronavirus disease 19 infection, Injury |
FAST+ examination alone, computed tomography alone, lung ultrasound alone |
|
Healthy volunteers accepted |
University of Colorado, Denver, US |
|
US |
2020-05-01 |
2021-05-01 |
20-0751, NCT04340479 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
20 |
Jose L Diaz-Miron, MD |
2020-04-10 |
| Evaluating the effect of marshmallow and licorice on COVID 19 patients |
Coronavirus disease 19 infection |
marshmallow and licorice mixed herbal drink intake alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ahvaz University of Medical Sciences |
|
Iran |
2020-04-09 |
|
IR.AJUMS.REC.1399.012, IRCT20200404046937N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
60 |
Mehran Varnaseri Ghandali, Mohammad Badavi, Niloofar Mohammad Rezaee Esferjani |
2020-04-10 |
| Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, human umbilical cord-derived MSCs alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Puren Hospital Affiliated to Wuhan University of Science and Technology |
Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Qingdao Co-orient Watson Biotechnology group co. LTD, Shanghai University |
China |
2020-02-01 |
2020-06-30 |
NCT04339660, PR20200402 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
5 Months |
30 |
Yan Liu, MD, Yue Zhu |
2020-04-10 |
| Physical Activity During Social Isolation |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul University |
|
Turkey |
2020-04-30 |
2020-06-30 |
30042020-1, NCT04339491 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
500 |
Ayse Zengin Alpozgen, PhD, Saliha Gurdal Karakelle, Saliha Gurdal Karakelle, MSc |
2020-04-10 |
| COMIHY: Hydroxychloroquine for the Treatment of Mild COVID-19 Disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
Bernhard-Nocht-Institute for Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-04-10 |
2022-09-30 |
COMIHY, COMIHY, NCT04340544 |
Phase 3 Clinical |
Not yet recruiting |
1 |
29 Months |
2700 |
Diane Egger-Adam, Dr., Peter Kremsner, Prof. |
2020-04-10 |
| Safety and Efficacy of Baricitinib for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
baricitinib alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Colorado, Denver, US |
|
US |
2020-04-30 |
2020-10-31 |
20-0738, NCT04340232 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
6 Months |
80 |
Angela Rachubinski, PhD, Joaquin Espinosa, PhD |
2020-04-10 |
| Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences |
Coronavirus disease 19 infection |
medications alone, Fenugreek syrup plus Viroherb capsule |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-05 |
|
IR.TUMS.VCR.REC.1399.099, IRCT20200402046923N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
110 |
Ali Asadollahi-Amin, Dr. Mohammad Ali Sahraeian, Hadise Hosami Roodsari, Roja Rahimi, Saeed Reza Jamali Moghaddam |
2020-04-10 |
| TCOutpatient: TXA and Coronavirus 2019 (COVID-19) in Outpatients |
Coronavirus disease 19 infection |
enoxaparin sodium plus tranexamic acid |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alabama at Birmingham |
|
US |
2020-04-15 |
2020-10-30 |
NCT04338074, TCOutpatient, TXACOVID1 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
100 |
Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD |
2020-04-10 |
| A first-in-human, phase I study of CORVax12 for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
APOLLO electroporation device alone, DNA vaccine targeting SARS-CoV-2 spike protein + tavokinogene telseplasmid (APOLLO electroporation, COVID-19), OncoSec Medical alone |
IL12 gene stimulator |
Healthy volunteers accepted |
Providence Cancer Institute at Providence Hospital |
OncoSec Medical Inc |
US |
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
Rom Leidner, MD |
2020-04-09 |
| CLOCC: Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 |
Coronavirus disease 19 infection |
camostat mesylate plus hydroxychloroquine |
Serine protease inhibitor, Trypsin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Heinrich Heine Universitat Dusseldorf |
Hospital Schwabing Munich, Germany, Klinikum St Georg, Missioklinik, Wuerzburg, Germany, University Hospital Frankfurt, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-06-01 |
2021-12-31 |
CLOCC, CLOCC-2020, NCT04338906 |
Phase 4 Clinical |
Not yet recruiting |
1 |
19 Months |
334 |
|
2020-04-10 |
| TCInpatient: Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients |
Coronavirus disease 19 infection |
enoxaparin sodium plus tranexamic acid |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alabama at Birmingham |
|
US |
2020-04-15 |
2020-12-15 |
NCT04338126, TCInpatient, TXACOVID2 |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
60 |
Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD |
2020-04-10 |
| Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
Cconventional medication alone, umbilical cord derived mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huangshi Hospital of Traditional Chinese Medicine |
|
China |
2020-02-01 |
2020-12-02 |
ChiCTR2000031494 |
Phase 1 Clinical |
Recruiting |
1 |
10 Months |
36 |
Feng Ganzhu, Leng Nannan |
2020-04-10 |
| Efficacy of Kelofan syrup on COVID-19 |
Coronavirus disease 19 infection |
Kelofan syrup alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ardabil University of Medical Sciences |
|
Iran |
2020-04-09 |
|
IR.ARUMS.REC.1399.009, IRCT20200405046960N1 |
Phase 1/Phase 2 Clinical |
Recruiting |
2 |
|
15 |
Dr.Shahab Bohlooli, Ramin Nasimi Doost Azgomi |
2020-04-10 |
| CAP-1002 in Severe COVID-19 Disease |
Coronavirus disease 19 infection |
CAP-1002 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Capricor Inc |
|
US |
|
|
CAP-1002-COVID-19, NCT04338347 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Khaled Alsabaawi, Mitch Gheoghiu, MD, Paula Williams, MS, Raj Makkar, MD, Siegfried Rogy, PhD |
2020-04-10 |
| Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-19 |
Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia |
nintedanib alone |
CSF-1 antagonist, FGF receptor antagonist, FGF1 receptor antagonist, FGF2 receptor antagonist, FGF3 receptor antagonist, Flt3 tyrosine kinase inhibitor, Lck tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor, PDGF receptor alpha antagonist, PDGF receptor antagonist, PDGF receptor beta antagonist, Src tyrosine kinase inhibitor, VEGF receptor antagonist, VEGF-1 receptor antagonist, VEGF-2 receptor antagonist, VEGF-3 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tongji Hospital |
|
China |
2020-04-02 |
2020-08-01 |
HUILANZ ZHANG, NCT04338802 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
96 |
Huilan Zhang, Huilan Zhang, PD, Xianglin Yuan, PD |
2020-04-10 |
| Effect of methylprednisolone in treatment of COVID-19 patients |
Coronavirus disease 19 infection |
methylprednisolone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shiraz University of Medical Sciences |
|
Iran |
2020-04-14 |
|
IR.SUMS.REC.1399.014, IRCT20200204046369N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
2 |
|
48 |
Dr. Mohsen Moghadami, Mohammad-Javad Fallahi, Mohsen Moghadami |
2020-04-10 |
| Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Royal Brisbane & Women's Hospital |
|
Australia |
2020-03-31 |
|
ACTRN12620000447954, ANZCTR12620000447954 |
Phase 2 Clinical |
Recruiting |
1 |
|
150 |
Prof Kevin B Laupland |
2020-04-10 |
| COVID-19 and Deep Venous Thrombosis |
Coronavirus disease 19 infection, Deep vein thrombosis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jessa Hospital |
|
Belgium |
2020-04-17 |
2020-12-30 |
JESSAH-COVID19-DVT, NCT04338932 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
12 |
Bjorn Stessel, Dr, Ina Callebaut, dr, Stessel Björn, Dr |
2020-04-10 |
| Evaluation of Safety and efficacy of anti-inflammatory regimens in COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , naproxen , pantoprazole , prednisolone |
H+ K+ ATPase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bagheiat-allah University of Medical Sciences, Iran University of Medical Sciences |
|
Iran |
2020-04-10 |
|
IR.BMSU.REC.1399.019, IRCT20200318046812N2 |
Phase 3 Clinical |
Recruiting |
4 |
|
906 |
Ali Qazvini, Dr Abolfazl Mozafari, Dr Mahtab Niroomand, Dr Mariam Qaraati, Dr Seyed Abbas Motevalian, Mostafa Ghanei, Seyed Hassan Saadat, ََAli Qazvini |
2020-04-11 |
| NOCOVID: Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection |
Coronavirus disease 19 infection |
Nitric oxide releasing solution (SaNOtize) alone, standard precautions alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
SaNOtize Research and Development Corp |
The Emmes Company, LLC |
Canada |
2020-04-06 |
2020-09-30 |
COVID-CTP-01, NCT04337918, NOCOVID |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
200 |
Chris Miller, Ph.D., Gilly Regev, Ph.D., Jeremy Road, MD |
2020-04-11 |
| Effect of IMFLUNA herbal compound on covid-19 pneumonia symptoms |
Coronavirus disease 19 infection, Viral pneumonia |
IMFLUNA herbal compound, HomaPharmed Pharmaceutical Company alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Medicinal Plants |
|
Iran |
2020-03-30 |
|
IR.BMSU.REC.1399.036, IRCT20080901001157N16 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
60 |
Fallah Huseini Hasan, Mohammadreza Gholibeikian, Morteza Khairabadi, Reza Mohtashami |
2020-04-11 |
| PROTECT: Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: an RCT |
Coronavirus disease 19 infection |
azithromycin alone, oseltamivir alone, Variable regimens including azithromycin , hydroxychloroquine phosphate , hydroxychloroquine sulfate , oseltamivir |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Health Sciences Lahore |
Federal Task Force on Science & Technology |
Pakistan |
2020-04-07 |
2020-11-30 |
12(06)/2016-COORD, NCT04338698, PROTECT |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
500 |
Javed Akram, FRCP, Shehnoor Azhar, Shehnoor Azhar, MPH |
2020-04-11 |
| Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19) |
Coronavirus disease 19 infection |
Algomed alone, herbal tea intake alone, treatment protocol alone |
|
|
Semnan University of Medical Sciences |
|
Iran |
2020-03-18 |
|
IR.SEMUMS.REC.1398.325, IRCT20151228025732N51 |
Phase Not Applicable |
Recruiting |
1 |
|
60 |
Parviz Kokhaie, Rahimeh Eskandarian |
2020-04-10 |
| Evaluation the Effect of Teicoplanin in Patients With Coronavirus Disease |
Coronavirus disease 19 infection |
Variable regimens including atazanavir + ritonavir , hydroxychloroquine , lopinavir + ritonavir , teicoplanin |
HIV protease inhibitor |
|
Iran University of Medical Sciences |
|
Iran |
2020-03-30 |
|
IR.IUMS.REC.1399.058, IRCT20161204031229N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Azadeh Eshraghi, Azadeh Eshraghi، Saeed Kalantari, Dr.Motevalian, Saeed Kalantari |
2020-04-10 |
| NO COV-ED: Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED |
Coronavirus disease 19 infection |
nitric oxide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
|
US |
2020-04-30 |
2022-04-30 |
2019P00XXXX, NCT04338828, NO COV-ED |
Phase 2 Clinical |
Not yet recruiting |
0 |
24 Months |
260 |
N. Stuart Harris MD MFA, N. Stuart Harris, MD, MFA |
2020-04-10 |
| SCOUT: Screening COVID by Point-of-care Lung Ultrasound: a Validation Study |
Coronavirus disease 19 infection, Viral pneumonia |
lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universiteit Hasselt |
Ziekenhuis Oost-Limburg |
Belgium |
2020-04-13 |
2020-04-30 |
CTU2020032, NCT04338568, SCOUT |
Phase Not Applicable |
Not yet recruiting |
1 |
|
50 |
David Ruttens, MD, PhD, Inge Thijs, PhD, Marc Daenen, MD, Michiel J Thomeer, MD, PhD, Michiel J Thomeer, MD,PhD, Michiel Thomeer, MD, PhD, Michiel Thomeer, MD,PhD, Prof. dr. Michiel Thomeer |
2020-04-10 |
| Evaluation of the Effects of Ozone Therapy on Covid-19 Positive Patients |
Coronavirus disease 19 infection |
ozone therapy group (covid positive alone, azithromycin plus hydroxychloroquine |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-01 |
2020-05-30 |
NCT04337866, OZONECOVID19 |
Phase Not Applicable |
No longer recruiting |
2 |
1 Month |
50 |
Pınar Yalcin bahat |
2020-04-10 |
| TRODVID-19: Dynamic Evaluation of COVID-19 Diagnostic Tests |
Coronavirus disease 19 infection |
antigenic rapid diagnostic orientation test (RODT) alone, polymerase chain reaction (PCR) alone, serological TROD alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier de Tourcoing |
|
France |
2020-04-30 |
2020-10-31 |
NCT04337996, RIPH_2020_6, TRODVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
176 |
Barthelemy LAFONDESMURS, MD, Pierre PATOZ, PharmD, Solange TREHOUX, PhD |
2020-04-10 |
| HOPEC: Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine (Amin Pharmaceutical company, Isfahan) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shahid Beheshti University of Medical Sciences |
|
Iran |
2020-04-07 |
|
HOPEC, IR.SBMU.RETECH.REC.1399.026, IRCT20130917014693N10 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Afshin Zarghi, Ali Saffaei, Minoosh Shabani, Omidvar Rezaiemirghaed, Zahra Sahraei |
2020-04-10 |
| Sleep COVID-19: Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic |
Coronavirus disease 19 infection, Insomnia |
online self-help leaflet alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Northumbria |
|
UK |
2020-03-25 |
2022-04-06 |
ISRCTN43900695, Sleep COVID-19 |
Phase Not Applicable |
Recruiting |
2 |
24 Months |
75 |
Dr Elder |
2020-04-10 |
| JUPITER: Beat COVID-19 - Observational Trial |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beat COVID LLC |
|
US |
2020-04-06 |
2021-07-31 |
20200835, JUPITER, NCT04337762 |
Phase Not Applicable |
Recruiting |
0 |
15 Months |
100000 |
Hollis Ledbetter, Rama Jager, M.D. |
2020-04-10 |
| A phase I study of PittCoVacc for the potential prevention of COVID-19 infection |
Coronavirus disease 19 infection |
PittCoVacc alone |
|
|
University of Pittsburgh School of Medicine |
|
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-09 |
| Effect of berberine on COVID-19 |
Coronavirus disease 19 infection |
berberine hydrochloride (Mashhad University School of Pharmacy) alone, standard coronavirus treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.030, IRCT20081019001369N2 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Hossein Hosseinzadeh, Javad Dehghan Nayyeri, Mohsen Tafaghdi |
2020-04-10 |
| RuxCoFlam: Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation |
Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia |
ruxolitinib alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Jena |
|
Germany |
2020-05-01 |
2021-08-31 |
NCT04338958, RUXCOFLAM, RuxCoFlam |
Phase 2 Clinical |
Not yet recruiting |
1 |
16 Months |
200 |
Andreas Hochhaus, Prof. Dr., Christian Fabisch, Dr. |
2020-04-10 |
| The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sheba Medical Center |
|
Israel |
2020-04-05 |
2022-04-01 |
NCT04338672, SMC-20-7078-YZ-CTIL |
Phase Not Applicable |
Not yet recruiting |
1 |
23 Months |
1000000 |
Roi Anteby, MD |
2020-04-09 |
| A clinical trial to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
allogeneic natural killer cells alone |
|
|
Green Cross LabCell |
|
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-09 |
| Impact of COVID-19 Emergency on Italian Surgical Residents |
Coronavirus disease 19 infection |
COVID-surgRES questionaire alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
IRCCS AOU San Martino – IST |
|
Italy |
2020-03-15 |
2020-05-01 |
COVID-SURGRES-ITALY, NCT04338945 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
1200 |
Fabio Barra |
2020-04-09 |
| A clinical study to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
allogeneic natural killer cells alone |
|
|
Green Cross LabCell |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| POCUSCO: Point Of Care Ultrasonography for Risk-stratification of COVID-19 Patients |
Coronavirus disease 19 infection |
lung ultrasonography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-04-06 |
2021-01-29 |
2020-A00782-37, NCT04338100, POCUSCO |
Phase Not Applicable |
Not yet recruiting |
6 |
9 Months |
300 |
Francis COUTURAUD, Dr, François MORIN, Dr, Karim TAZAROURTE, Pr, Laure BAUDIN, Dr, Louis SOULAT, Pr, Luc-Marie JOLY, Pr, Nicolas MARJANOVIC, Dr, Philippe LE CONTE, Pr, Pierre-Marie ROY, Pr, Thomas DELOMAS, Dr, Thomas FLAMENT, Dr |
2020-04-10 |
| Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 |
Coronavirus disease 19 infection |
COVID-19 convalescent plasma therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mayo Clinic Foundation |
|
US |
|
|
20-003312, NCT04338360 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Michael Joyner, MD |
2020-04-11 |
| LEOSS: Lean, European, Open Survey on SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection |
rapid tests alone |
|
|
Deutsches Zentrum für Infektionsforschung |
Willy Robert Pitzer Stiftung |
Italy, Portugal, Austria, Belgium, Germany, UK, Switzerland, France, Bosnia and Herzegovina, Iceland, Spain, Ireland |
2020-03-16 |
|
20-600, DRKS00021145, LEOSS |
Phase Not Applicable |
Recruiting |
51 |
|
20000 |
Jorg Janne Vehreschild |
2020-04-10 |
| PiCCOVID: Hemodynamic Characteristics of Patients With SARS-CoV-2 |
Coronavirus disease 19 infection |
echocardiography alone, transpulmonary thermodilution alone, transpulmonary thermodilution system alone |
|
|
Hopital de Bicetre |
|
France |
2020-04-15 |
2021-04-30 |
2020-A00793-36, NCT04337983, PiCCOVID |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Xavier Monnet, Xavier Monnet, MD.PhD |
2020-04-10 |
| A clinical trial of anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin alone |
|
|
Octapharma AG |
Bio Products Laboratory Ltd, Biotest AG, CSL Ltd, LFB SA, Takeda Pharmaceutical Co Ltd |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| Study of the effect of Chloroquine in addition to standard therapy in COVID-19 patients |
Coronavirus disease 19 infection |
chloroquine phosphate alone, standard therapy alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Command Hospital |
|
India |
2020-04-13 |
|
CTRI/2020/04/024479 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
32 |
SALIL GUPTA |
2020-04-10 |
| A phase I clinical study to assess IPT-001 for the prevention and treatment of COVID-19 infection |
Coronavirus disease 19 infection |
IPT-001 alone |
Coronavirus spike glycoprotein inhibitor, Nucleoprotein inhibitor |
|
INTELLiSTEM Technologies Inc |
|
|
2020-09-30 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-09 |
| A clinical trial of ADDomer for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
ADDomer alone |
|
|
Imophoron Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| A clinical trial to assess the efficacy and safety of tPA for the potential treatment of COVID-19-related respiratory failure |
Coronavirus disease 19 infection |
tissue plasma activator alone |
|
|
Beth Israel Deaconess Medical Center |
|
|
2020-04-06 |
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
Christopher D. Barrett, MD, Gyongyi Szabo |
2020-04-09 |
| WriteForIBD: Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
evidenced-based 4-day writing program alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Crohn's & Colitis Australia, Deakin University |
Barwon Health |
Australia |
2020-01-16 |
|
ACTRN12620000448943p, ANZCTR12620000457943, WriteForIBD |
Phase Not Applicable |
Not yet recruiting |
4 |
|
154 |
A/Prof Antonina Mikocka-Walus |
2020-04-10 |
| A largest Chinese study on epidemiologic characteristics of Coronavirus Disease 2019 (COVID-19) Outbreak in China |
Coronavirus disease 19 infection |
|
|
|
The Chinese Centre for Disease Control and Prevention |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
44672 |
|
2020-04-09 |
| SRA-COV: Renin Angiotesnin System - CoronaVirus |
Coronavirus disease 19 infection, Respiratory distress syndrome |
blood draw alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux De Marseille |
|
France |
2020-04-03 |
2020-07-31 |
2020-16, 2020-A00795-34, NCT04337008, SRA-COV |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
50 |
Emilie Garrido-Pradalie, Francois Silhol, MD, François Silhol, MD |
2020-04-10 |
| CoV-Mortality: CoV-Mortality |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-15 |
2020-10-31 |
54609, CoV-Mortality, NMRR-20-691-54609 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
|
Dr. Woon Yuan Liang |
2020-04-10 |
| Effects of vitamin C supplementation on patients with COVID-19 |
Coronavirus disease 19 infection |
vitamin C alone |
|
|
Hospital Raja Permaisuri Bainun |
|
Malaysia |
2020-04-14 |
2020-12-31 |
54478, IMVC 001, NMRR-20-684-54478 |
Phase Not Applicable |
Not yet recruiting |
2 |
8 Months |
|
Dr Leong Chee Loon, Dr. G.R. Letchuman Ramanathan, Dr. Sharon Linus Lojikip, LIM XIN JIE |
2020-04-10 |
| COVID-19 ARDS Cyto-MSC |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Cyto-MSC (umbilical cord derived mesenchymal stem cells) alone |
|
|
Cytopeutics Sdn Bhd |
|
Malaysia |
2020-04-13 |
2020-05-31 |
54521, NMRR-20-672-54521, POD0039/CP/R |
Phase 1 Clinical |
Not yet recruiting |
3 |
1 Month |
5 |
Dr Chin Sze Piaw, Dr Toh See Guan, Mohd Shahrizal Bin Mohd Yusoff, Prof S FADILAH ABDUL WAHID |
2020-04-10 |
| A expanded access program of opaganib to treat patients with COVID-19 infection |
Coronavirus disease 19 infection |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
Cosmo Pharmaceuticals NV |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-08 |
| A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection |
Coronavirus disease 19 infection |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
Cosmo Pharmaceuticals NV |
|
Israel |
|
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-09 |
| A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection with life-threatening clinical conditions |
Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection, Viral pneumonia |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
Cosmo Pharmaceuticals NV, RedHill Biopharma Ltd |
|
Italy |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
140 |
|
2020-04-08 |
| Physical Activity Level, Stress Level, Sleep Quality in Covid-19 Quarantine |
Coronavirus disease 19 infection |
social quarantine implementation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istanbul Kultur University |
Istanbul University-Cerrahpasa |
Turkey |
2020-04-10 |
2020-06-10 |
FADP-2, NCT04336787 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
100 |
Ayse Zengin Alpozgen, assistant professor, Ayşe Zengin Alpözgen, Assistant Professor, Basak Polat, PhD Student, Başak Polat, PhD Student, Cicek Duman, PhD Student, Funda Akuzum, PhD Student, Funda Aküzüm, PhD Student, Gamze Ertürk Uzunoglu, PhD Student, Gamze Ertürk Uzunoğlu, PhD Student, Halenur Evrendilek, PhD Student, Tugce Tahmaz, PhD Student, Tuğçe Tahmaz, PhD Student, Çiçek Duman, PhD Student |
2020-04-10 |
| A phase II, single-arm, non-randomized study to evaluate the safety and efficacy of autologous adipose-derived mesenchymal stem cells in patients with high risk COVID-19 infection |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
|
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
75 |
|
2020-04-08 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation |
Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia |
mavrilimumab alone |
C-reactive protein inhibitor, Chemokine CC22 ligand inhibitor, GM-CSF receptor antagonist, Hemoglobin scavenger receptor antagonist, Metalloprotease-1 inhibitor, Metalloprotease-3 inhibitor, Small inducible cytokine A17 ligand inhibitor, VEGF gene inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Virginia Commonwealth University |
|
US |
2020-04-30 |
2020-07-31 |
HM20019145, NCT04337216 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
10 |
Antonio Abbate, MD, PhD |
2020-04-10 |
| Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
allogeneic human dental pulp stem cells (BSH BTC and Utooth BTC) alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Renmin Hospital of Wuhan University |
Beijing Scitop Bio-Tech Shareholding Co.Ltd, Utooth Biological Technology Co., Ltd. Hubei |
China |
2020-04-06 |
2021-03-31 |
2020K-G005, HDPSC-COVID-2019-02-2020, NCT04336254 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
11 Months |
20 |
Chenliang Zhou, PhD, Prof. Qingsong Ye, PhD,DDS, Qingsong Ye, PhD,DDS, Ye Qingsong |
2020-04-09 |
| Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course |
Coronavirus disease 19 infection |
|
|
|
HELIOS Kliniken GmbH |
Hygiene Helios Klinik Wuppertal, Klinikum Hildesheim GmbH |
Germany |
2020-02-15 |
|
DRKS00021161, E-01-20200319 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Julius Dengler, Michael Hauptmann |
2020-04-10 |
| An expanded access clinical study of autologous adipose-tissue derived mesenchymal stem cells (AdMSCs) multiple dose infusions for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
autologous mesenchymal stem cell-derived exosomes (Alzheimers disease), Celltex Therapeutics alone |
|
|
Celltex Therapeutics Corp |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Dr. Derek W. Guillory |
2020-04-08 |
| COVID-ARA2: Impact of Angiotensin II Type 2 Receptor Agonists Treatment in Patients With COVID 19 |
Coronavirus disease 19 infection, Respiratory failure |
angiotensin II type 2 receptor agonists therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-04-03 |
2020-12-06 |
COVID-ARA2, COVID-ARA2, NCT04337190 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
100 |
Julien Demiselle, M.D., Julien Demiselle, MD, Pierre Asfar, MD, PhD |
2020-04-09 |
| CoCo Study: Corona Contact Study - Immunoreaction After Possible SARS-CoV-2/COVID-19 Contact |
Coronavirus disease 19 infection |
immunological analysis alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hannover Medical School |
Deutsche Forschungsgemeinschaft (DFG), Deutsches Zentrum für Infektionsforschung, German Federal Ministry of Education and Research, Novartis Pharma GmbH Germany |
Germany |
2020-04-05 |
|
8973_BO_K_2020, CoCo Study, DRKS00021152 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
1000 |
Georg Behrens |
2020-04-08 |
| Randomized, Comparison of Combination Azithromycin and Hydroxychloroquine versus Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Plaquenil alone, Plaquenil plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rutgers University |
|
US |
2020-04-06 |
2021-04-30 |
002011, NCT04336332, PRO2020000712 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
160 |
Sabiha Hussain, MD, Shobha Swaminathan, MD, Steven K. Libutti, MD, FACS |
2020-04-08 |
| A clinical trial of IVIEW-1201 for the treatment or prevention of COVD-19 infection in the eye |
Coronavirus disease 19 infection |
povidone iodine (long acting/extended-release/gel, adenoviral conjunctivitis), IVIEW therapeutics alone |
|
|
iVIEW Therapeutics Inc |
|
China |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-08 |
| A pan-india non-interventional virtual registry evaluating the prophylactic efficacy of different regimens against SARS-CoV2 infection (COVID-2019) in asymptomatic health care workers |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zifo RnD Solutions |
|
India |
2020-04-17 |
|
CTRI/2020/04/024482 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
10000 |
Arvind Sri Krishna Mani, Viswanathan Niranjan |
2020-04-10 |
| Knowledge, attitude and fear of COVID-19 in Bangladesh |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre for the Rehabilitation of the Paralysed |
|
Bangladesh |
2020-04-09 |
|
CTRI/2020/04/024413 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
K M Amran Hossain, Md Zahid Hossain, Md. Shahoriar Ahmed, Professor Md Obaidul Haque |
2020-04-10 |
| ONCOVID: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid-19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients |
Advanced solid tumor, Coronavirus disease 19 infection, Hematological neoplasm |
Plaquenil plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institut Gustave Roussy |
|
France |
2020-04-03 |
|
2020-001250-21, 2020/3078, ONCOVID |
Phase 2 Clinical |
Recruiting |
1 |
|
1000 |
|
2020-04-09 |
| CovidSurg-Cancer |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Birmingham |
|
Malaysia |
2020-04-08 |
2021-03-31 |
NMRR-20-693-54498 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
100 |
Andee Dzulkarnaen Zakaria |
2020-04-10 |
| Expanded-access study of GENOSYL DS for treating COVID-19 Infection Complicating Pulmonary Hypertension |
Coronavirus disease 19 infection, Pulmonary hypertension |
nitric oxide (GeNOsyl MV-2000, inhaled, ventilator platform), GeNO alone |
|
|
Vero Biotech |
|
|
2020-03-31 |
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-09 |
| EVALUATION: Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure |
Coronavirus disease 19 infection, Respiratory distress syndrome |
PiCCO-monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ludwig-Maximilians University of Munich |
Technical University of Munich |
Germany |
2020-03-11 |
2020-04-30 |
EVALUATION, ISRCTN10077335 |
Phase Not Applicable |
Recruiting |
2 |
1 Month |
25 |
Prof. Wolfgang Huber |
2020-04-09 |
| A phase II clinical study to assess VIR-7832 in the treatent of patients with SARS-CoV-2 infection |
Coronavirus disease 19 infection |
VIR-7832 alone |
Coronavirus spike glycoprotein inhibitor |
|
GlaxoSmithKline plc |
Vir Biotechnology Inc |
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-08 |
| A phase II clinical study to assess VIR-7831 in the treatent of patients with SARS-CoV-2 infection |
Coronavirus disease 19 infection |
VIR-7831 alone |
Coronavirus spike glycoprotein inhibitor |
|
GlaxoSmithKline plc |
Vir Biotechnology Inc |
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-08 |
| EasyCoV: Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2 |
Coronavirus disease 19 infection, SARS coronavirus infection |
sample collection alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
Skillcell, Sys2Diag |
France |
2020-04-07 |
2020-04-17 |
EasyCoV, NCT04337424, RECHMPL20_0170 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
180 |
REYNES Jacques, PU PH |
2020-04-08 |
| Imaging Findings In Covid-19 |
Coronavirus disease 19 infection |
|
|
|
Hospital Tawau |
|
Malaysia |
2020-04-13 |
2020-04-30 |
NMRR-20-698-54570 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
70 |
Dr Mohana A/P Letchumanan |
2020-04-08 |
| Evaluation of Blood Results of Covid 19 Positive Pregnants |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-03-21 |
2020-05-22 |
COVID19PREGNANCIES, NCT04337294 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
100 |
Pınar Yalcin bahat |
2020-04-10 |
| Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone, supportive care alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
ASST Fatebenefratelli Sacco |
|
Italy |
2020-03-25 |
2020-07-31 |
HS216C17-PHASE III, NCT04336904 |
Phase 3 Clinical |
No longer recruiting |
1 |
4 Months |
100 |
Giuliano Rizzardini, Md |
2020-04-09 |
| REMOTE-COVID: Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus) |
Coronavirus disease 19 infection |
SensiumVitals wearable sensor alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Imperial College London |
|
UK |
2020-04-01 |
2021-04-01 |
NCT04337489, REMOTE-COVID, REMOTE-COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Ara Darzi, Prof, Fahad M Iqbal, MBChB (hons), Sadia Khan, Dr |
2020-04-08 |
| Clinical and Radiomic Model of COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Universiteit Maastricht |
Wuhan Central Hospital |
China |
2019-12-23 |
2020-03-03 |
NCT04337502, UM_2020_GY_COVID-19 |
Phase Not Applicable |
Completed |
1 |
2 Months |
300 |
|
2020-04-10 |
| UZH COVID-19 Cohort Study: Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center |
Coronavirus disease 19 infection |
Phone calls alone |
|
|
University of Zurich |
|
Switzerland |
2020-03-20 |
2020-12-31 |
ISRCTN77353041, UZH COVID-19 Cohort Study |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
200 |
Dr Dominik Menges, Prof Jan Fehr, Prof Milo A. Puhan |
2020-04-09 |
| Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-01 |
2020-06-20 |
COVID19PREGNANCYNEWBORN, NCT04337320 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
70 |
Pınar Yalcin bahat |
2020-04-08 |
| Evaluation of the Effect of High-dose Vitamin C Use in Covid 19 Positive Pregnants |
Coronavirus disease 19 infection |
vitamin C alone |
|
Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-01 |
2020-05-30 |
HIGHDOSEVITCINCOVID19, NCT04337281 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
50 |
Pınar Yalcin bahat |
2020-04-09 |
| Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Xiaotan Sanjiefang granule alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Beijing University of Chinese Medicine |
Chinese Ministry of Science and Technology |
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000031672, ChiMCTR2000003188 |
Phase 2 Clinical |
Not yet recruiting |
1 |
10 Months |
150 |
Yingshuai Li |
2020-04-09 |
| Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System |
Coronavirus disease 19 infection |
Surgical facial mask alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rigshospitalet, Denmark |
Denmark Technical University, HS Hvidovre Hospital, Nordsjaellands Hospital |
Denmark |
2020-04-02 |
2020-07-01 |
2020-04-02, NCT04337541 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
6000 |
Christian Torp-Pedersen, Prof., DMSc, Henning Bundgaard, Prof., DMSc, Henrik Ullum, Prof., DMSc, Kasper Karmark Iversen, Prof., DMSc, Thomas Benfield, Prof., DMSc |
2020-04-08 |
| Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
interferon treatment alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Wenzhou Central Hospital |
|
China |
2020-02-01 |
2021-01-31 |
ChiCTR2000031699 |
Phase 1 Clinical |
No longer recruiting |
1 |
12 Months |
33 |
Tangshaohua |
2020-04-09 |
| Evaluation of Covid 19 Anxiety in Endometriosis Patients |
Coronavirus disease 19 infection, Endometriosis, Generalized anxiety disorder |
|
|
Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-05 |
2020-04-25 |
ENDOCOVID19, NCT04337346 |
Phase Not Applicable |
No longer recruiting |
1 |
|
80 |
Pınar Yalcin bahat |
2020-04-09 |
| COVID-CHD: Impact of Covid-19 in Congenital Heart Disease |
Congenital heart defect, Coronavirus disease 19 infection |
|
|
|
University Hospital, Montpellier |
|
France |
2020-03-01 |
2020-12-30 |
COVID-CHD, NCT04336384, RECHMPL20_0155 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
5000 |
Adeline BASQUIN, MD, Alexis BLANC, MD, BERTRAND LEOBON, MD, Caroline OVAERT, MD, Céline GRUNENWALD GRONIER, MD, Daniela LAUX, MD, Jean-Benoît THAMBO, MD, PhD, Karine WARIN-FRESSE, MD, Magalie LADOUCEUR, MD, Nicolas COMBES, MD, Pascal AMEDRO, MD-PHD, Pascal AMEDRO, MD-PhD, Sébastien HASCOET, MD, Xavier IRIART, MD |
2020-04-09 |
| Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease |
Coronavirus disease 19 infection |
Ig G test alone, Questionnaire alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assiut University |
|
Egypt |
2020-04-30 |
2020-05-31 |
ASSIUTU11, NCT04336657 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
100 |
Aliae AR Mohamed-Hussein, Aliae Mohamed-Hussein |
2020-04-09 |
| HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
|
2020-04-30 |
2020-08-31 |
HCQ PROPHYLAXIS FOR COVID19, NCT04336748 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
440 |
Matthias Vossen |
2020-04-09 |
| CAPTION AI to Minimize Risk of COVID Exposure |
Coronavirus disease 19 infection, Viral pneumonia |
Caption AI alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
Caption Health Inc |
US |
2020-04-30 |
2020-11-09 |
NCT04336774, PRO00105212 |
Phase Not Applicable |
Not yet recruiting |
0 |
6 Months |
500 |
Kristine Arges, BSN, Sreekanth Vemulapallli, MD |
2020-04-09 |
| INCOVPED: Prevalence of Covid-19 in Children Admitted to Pediatric Emergency Departments During the Pandemic Period in France |
Coronavirus disease 19 infection |
nasopharyngeal swab alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00811-38, 2020_21, INCOVPED, NCT04336761 |
Phase Not Applicable |
Not yet recruiting |
5 |
8 Months |
914 |
Camille BREHIN, MD, Christèle LE GUEN, MD,PhD, Flora JOANNES, MD, François DUBOS, MD,PhD, François Dubos, MD,PhD, Hervé HAAS, MD, Marie Chinazzo-Vigouroux, MD |
2020-04-09 |
| A trial to assess brilacidin in the potential treatment of novel coronavirus COVID-19 treatment |
Coronavirus disease 19 infection |
brilacidin alone |
PDE 3 inhibitor, PDE 4 inhibitor |
|
Innovation Pharmaceuticals Inc |
|
Europe |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-08 |
| Rutgers COVID-19 Cohort Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rutgers University |
|
US |
2020-03-28 |
2021-10-21 |
2020000679, NCT04336215 |
Phase Not Applicable |
Recruiting |
0 |
18 Months |
750 |
Jeffrey L Carson, MD, Reynold A Panettieri, MD |
2020-04-09 |
| MexCOVID-19: Outcomes of Patients With COVID-19 in the Intensive Care Unit |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Ciencias Medicas y Nutricion |
|
Mexico |
2020-04-01 |
2020-05-30 |
MexCOVID-19, NCT04336345, TEI-3336-20-20-1 |
Phase Not Applicable |
Not yet recruiting |
2 |
1 Month |
150 |
Eduardo Rivero-Sigarroa, MD, Guillermo Dominguez-Cherit, MD, Silvio A. Ñamendys-Silva, MD, MSc |
2020-04-09 |
| Viral Infection and Respiratory illness Universal Study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Society of Critical Care Medicine |
|
US, UK, Italy, India |
2020-04-01 |
|
CTRI/2020/04/024473 |
Phase Not Applicable |
Recruiting |
3 |
|
50000 |
Dr Mradul Kumar Daga, Dr Naresh Kumar |
2020-04-09 |
| A clinical trial of remestemcel-L for the treatment of COVID-19 patients with acute respiratory distress syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome |
remestemcel-L alone |
|
|
Mesoblast Ltd |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-08 |
| Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/very Severe COVID-19 Illness |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
|
|
|
|
CINC424A2001M, NCT04337359 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Novartis Pharmaceuticals, Novartis Pharmaeuticals |
2020-04-09 |
| PANDOR: Covid-19 Pediatric Observatory |
Coronavirus disease 19 infection |
real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Centre Hospitalier Intercommunal Creteil |
ACTIV, France, GFRUP, GPIP (FR), Societe Francaise de Pediatrie |
France |
2020-04-01 |
2021-06-30 |
NCT04336956, PANDOR, PANDOR |
Phase Not Applicable |
Not yet recruiting |
1 |
15 Months |
250 |
Corinne Levy, MD |
2020-04-10 |
| Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent |
Coronavirus disease 19 infection, Viral pneumonia |
novel coronavirus pneumonia (COVID-19) antigen reagent alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese PLA General Hospital, Chongqing Infectious Disease Medical Center, Wuhan Huoshenshan Hospital |
Beijing Savant Biotechnology Co Ltd |
China |
2020-04-07 |
2020-05-31 |
ChiCTR2000031700 |
Phase Not Applicable |
Not yet recruiting |
3 |
1 Month |
600 |
Zhang Chunyan |
2020-04-09 |
| Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
Surface swab and air sample collection alone, Surface swab from personal protective equipment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000031712 |
Phase 1 Clinical |
Recruiting |
1 |
12 Months |
60 |
Christopher KC Lai |
2020-04-09 |
| Clinical trial of KTH-222 (alone and/or in combination with anti-viral drugs)for the treatment of cancer patients infected with the COVID-19 virus or in suspected patients with the symptoms |
Coronavirus disease 19 infection |
KTH-222 alone, anti-viral drug therapy alone |
MAP kinase inhibitor |
|
Kalos Therapeutics Inc, Oncology Pharma Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| Safety, Tolerability and Immunogenicity of INO-4800 in Healthy Volunteers |
Coronavirus disease 19 infection |
CELLECTRA 2000 alone, INO-4800 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Inovio Pharmaceuticals Inc |
Coalition for Epidemic Preparedness Innovations |
US |
2020-04-30 |
2020-11-30 |
COVID19-001, NCT04336410 |
Phase 1 Clinical |
Not yet recruiting |
0 |
7 Months |
40 |
Inovio Call Center, Program Manager Barbara Bradshaw, Program Manager Eileen Donaghy, ShuPing Yang, MD, PhD |
2020-04-09 |
| A phase III in-home, self-dosing clinical trial to assess ENU-200 in the treatment of patients with asymptomatic, mild to moderate coronavirus infections (COVID-19) utilizing their iClickCare secure clinical reporting software service to monitor the in-home trials |
Coronavirus disease 19 infection |
ENU-200 alone, iClickCare alone |
Coronavirus spike glycoprotein inhibitor |
|
Ennaid Therapeutics |
|
US |
|
|
|
Phase 3 Clinical |
Planned |
0 |
|
|
|
2020-04-09 |
| Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
AMS-H-03 Gas Nebulizer alone, Hydrogen-Oxygen Generator alone, conventional treatment alone, hydrogen/ oxygen inhaled therapy alone, oxygen inhaled therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Asclepius Meditec Co., Ltd |
First People's Hospital of Yunnan Province, Guangdong Provincial Hospital of Chinese Medicine, Henan Province People's Hospital, Shanghai First People's Hospital, Shanghai Public Health Clinical Center, Shanghai Sixth People’s Hospital, The First Affiliated Hospital of Guangzhou Medical College, The Third People’s Hospital of Shenzhen |
China |
2020-02-15 |
2020-08-01 |
JT202002LZ, NCT04336462 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
100 |
Hu J Ying, master, Xin Yong Lin, master, Zhang Ze Guang, doctor, Zheng Z Guang, doctor |
2020-04-09 |
| Cardiovascular Manifestations of COVID-19 |
Cardiovascular disease, Coronavirus disease 19 infection |
echocardiography alone, serial electrocardiography alone, serial laboratory testing alone, telemetry monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Memorial Hermann Hospital |
|
US |
2020-03-30 |
2022-03-31 |
HSC-MS-20-0286, NCT04335630 |
Phase Not Applicable |
Recruiting |
0 |
24 Months |
500 |
Efstratios Koutroumpakis, Efstratios Koutroumpakis, MD, Heinrich Taegtmeyer, MD, DPhil |
2020-04-09 |
| EPICOS: Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel |
Coronavirus disease 19 infection |
emtricitabine + tenofovir disoproxil alone, hydroxychloroquine alone, emtricitabine + tenofovir disoproxil Placebo plus hydroxychloroquine |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Effice Servicios Para la Investigacion |
|
Spain |
2020-04-01 |
2020-07-31 |
EPICOS, NCT04329520, NCT04334928, PREP COVID-19 |
Phase 3 Clinical |
No longer recruiting |
1 |
4 Months |
4000 |
Julia del Amo, PhD, Miguel Hernán, MD,PhD, Rosa Polo, MD,PhD |
2020-04-10 |
| get.calm_move.on: Tackling worries and finding strength for the crisis (COVID-19) in ten steps |
Coronavirus disease 19 infection |
get.calm and move.on online training alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Leuphana Universität Lüneburg Stiftung Öffentlichen Rechts |
|
Germany |
2020-04-06 |
|
DRKS00021153, EB-Antrag_202003_12_Lehrgetcalm, get.calm_move.on |
Phase Not Applicable |
Not yet recruiting |
1 |
|
352 |
Dirk Lehr, Hanna Heckendorf |
2020-04-08 |
| An international, multicenter, randomized, double-blind, adaptive, placebo-controlled study of the efficacy and safety of a single administration of olokizumab and RPH-104 with standard therapy in patients with severe SARS-CoV-2 virus infection (COVID-19) |
Coronavirus disease 19 infection |
RPH-104 alone, olokizumab alone |
IL-6 receptor antagonist, Interleukin-1 beta ligand inhibitor |
|
R-Pharm |
|
Russian Federation |
2020-04-15 |
2021-04-30 |
CL04041078 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
6 |
12 Months |
250 |
|
2020-04-08 |
| Multicenter, double-blind, placebo-controlled, adaptive, randomized, comparative study of the efficacy and safety of Polyoxidonium, lyophilisate for solution for injection and topical use, 6 mg (LLC NPO Petrovax Pharm, Russia) in patients with coronavirus infection (COVID-19) |
Coronavirus disease 19 infection |
Polyoxidonium alone |
|
|
NPO Petrovax Pharm LLC |
|
Russian Federation |
2020-04-03 |
2022-04-01 |
PO-COV-III-20 |
Phase 3 Clinical |
Status not specified |
7 |
23 Months |
454 |
|
2020-04-07 |
| CORSER: Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Healthy volunteers accepted, Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institut Pasteur |
|
France |
2020-03-13 |
2023-02-28 |
2020-007, CORSER, NCT04325646 |
Phase Not Applicable |
Recruiting |
12 |
35 Months |
1000 |
Bruno HOEN, Pr, Christian CHIDIAC, Pr, Elisabeth BOTELHO-NEVERS, Pr, Eric SENNEVILLE, Pr, France CAZENAVE-ROBLOT, Pr, François GOEHRINGER, Jean-François FAUCHER, Pr, Jean-Marc Chapplain, Dr, Jean-Philippe LANOIX, Dr, Louis BERNARD, Pr, Marie-Noëlle UNGEHEUER, Dr, Pascal CHAVANET, Pr, Thierry PRAZUCK, Pr |
2020-04-08 |
| A clinical study of Hyperimmune globulin for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
Hyperimmune globulin alone |
|
|
Food and Drug Administration, National Institute of Allergy and Infectious Diseases |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| PRAETORIAN-COVID: Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease |
Coronavirus disease 19 infection, Respiratory distress syndrome |
valsartan alone |
Angiotensin I receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Radboud University |
|
Netherlands |
2020-04-30 |
2021-08-31 |
2020-001320-34, NCT04335786, NL73547.091.20, PRAETORIAN-COVID |
Phase 4 Clinical |
Not yet recruiting |
1 |
16 Months |
651 |
Frank Gommans, MD PhD, Niels van Royen, MD PhD, Roland RJ van Kimmenade, MD PhD |
2020-04-09 |
| An expanded access program to assess the safety and efficacy of convalescent plasma in the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Food and Drug Administration, Mayo Clinic Foundation |
Biomedical Advanced Research and Development Authority (BARDA) |
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| Clinical trial of therapeutic antibody (corona virus disease 19 infection), Abclon for the treatment of Coronavirus disease 19 infection |
Coronavirus disease 19 infection |
therapeutic antibody (COVID-19), Abclon alone |
Coronavirus spike glycoprotein inhibitor |
|
AbClon Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-08 |
| Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 |
Coronavirus disease 19 infection |
bacTRL-Spike alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Symvivo Corp |
|
Canada |
2020-04-30 |
2021-12-31 |
BACTRL-SPIKE-1, NCT04334980, bacTRL-IL-Spike-1 |
Phase 1 Clinical |
Not yet recruiting |
2 |
20 Months |
84 |
Alexander Graves, Eric Sievers, Jill Mutch, Joanne Langley, MD, MSc, FRCPC, Karen Simmons, M. Sc., Manish Sadarangani, BM BCh DPhil, Mel Krajden, MD PhD, Michelle Jones, Muhammad Morshed, PhD, Scott Halperin, MD, Shelly McNeil, MD, FRCPC, Soren Gantt, MD PhD |
2020-04-08 |
| Investigator-Initiated Trial to Assess The Effect of AT-001, Applied Therapeutics in Patients with Acute Lung Inflammation, Cardiomyopathy and COVID-19 |
Coronavirus disease 19 infection, Lung inflammation, Myocardial disease |
AT-001, Applied Therapeutics alone |
Aldose reductase inhibitor |
|
Applied Therapeutics Inc |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-08 |
| Investigator-Initiated Trial to Assess The Effect of AT-001, Applied Therapeutics in Patients with Acute Lung Inflammation, Cardiomyopathy and COVID-19 |
Coronavirus disease 19 infection, Lung inflammation, Myocardial disease |
AT-001, Applied Therapeutics alone |
Aldose reductase inhibitor |
|
Applied Therapeutics Inc |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-07 |
| Investigator-Initiated Trial to Assess The Effect of AT-001, Applied Therapeutics in Patients with Acute Lung Inflammation, Cardiomyopathy and COVID-19 |
Coronavirus disease 19 infection, Lung inflammation, Myocardial disease |
AT-001, Applied Therapeutics alone |
Aldose reductase inhibitor |
|
Applied Therapeutics Inc |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-08 |
| Study of Open-Label Losartan in COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
losartan alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Kansas Medical Center |
|
US |
2020-03-25 |
2020-10-31 |
NCT04335123, STUDY00145514 |
Phase 1 Clinical |
Recruiting |
0 |
7 Months |
50 |
Carolina Aguiar, Charles Bengtson, MD, Lewis Satterwhite, MD, Matthias Salathe, Matthias Salathe, MD, Usman Nazir, MD |
2020-04-07 |
| A placebo-controlled prophylaxis study of chloroquine and hydroxychloroquine in preventing COVID-19 in at-risk health care workers, frontline staff, and other high-risk groups |
Coronavirus disease 19 infection |
chloroquine alone, hydroxychloroquine alone |
|
|
The Mahidol Oxford Tropical Medicine Research Unit |
|
Asia, UK, Europe |
2020-04-30 |
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
40000 |
|
2020-04-07 |
| LIBA: LIBA Trial in COVID-19 |
Coronavirus disease 19 infection |
ibuprofen (Flarin) alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King's College London |
Guy's & St Thomas' Hospital NHS Trust |
UK |
2020-04-06 |
2020-11-05 |
282009, LIBA, NCT04334629 |
Phase 4 Clinical |
Not yet recruiting |
1 |
7 Months |
230 |
Chloe Farrell, PhD, Manu Shankar-Hari, MBBS, Ndaba Mazibuko, MD |
2020-04-07 |
| A clinical study of INOmax for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
nitric oxide (inhaled), Ikaria alone |
Hemoglobin modulator |
|
Mallinckrodt plc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| A Study to Assess the Effect of siRNA-based SARS-CoV-2 therapies (COVID-19), Alnylam/ Vir Biotechnology in the Treatment of COVID-19 Patients |
Coronavirus disease 19 infection |
siRNA-based SARS-CoV-2 therapies (COVID-19), Alnylam/ Vir Biotechnology alone |
|
|
Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects |
Coronavirus disease 19 infection |
BLD-2660 alone, standard of care alone |
Calpain-I inhibitor, Calpain-II inhibitor, Calpain-IX inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Blade Therapeutics |
|
|
2020-05-31 |
2020-09-30 |
B-2660-204, NCT04334460 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
120 |
|
2020-04-07 |
| APN01-COVID-19: Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 |
Coronavirus disease 19 infection |
APN-01 alone |
Angiotensin converting enzyme 2 stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
APEIRON Respiratory Therapies GmbH, Apeiron Biologics GmbH |
|
Austria, Germany, Denmark |
2020-04-30 |
2020-11-30 |
2020-001172-15, APN01-01-COVID19, APN01-COVID-19, NCT04335136 |
Phase 2 Clinical |
Not yet recruiting |
9 |
7 Months |
200 |
Alexander Zoufaly, Priv.-Doz. Dr., CRO, Christian Søborg, Christoph D. Spinner, PD DR. med., Claudia Haider, Mag., Günter Weiss, Univ.-Prof. Dr., Henning Bundgaard, Prof. Dr. med., Jan Gerstoft, Prof. Dr. med., Roman Ullrich, Prof. Dr., Sonja Höller, Dr., Stefan Schmiedel, Dr. med., Thomas L. Benfield, Prof., Troels B. Knudsen |
2020-04-08 |
| A clinical study to assess biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
Asian Ancestry |
The Third People’s Hospital of Shenzhen |
|
China |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
12 |
Liu et al |
2020-04-08 |
| Hydroxychloroquine for COVID-19 in moderately to severely ill hospitalized patients |
Coronavirus disease 19 infection, Viral pneumonia |
Plaquenil alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sanofi-Aventis Research and Development |
|
France, UK |
2020-04-02 |
|
2020-001270-29, EFC16858, U1111-1249-6096 |
Phase 2/Phase 3 Clinical |
Recruiting |
2 |
|
350 |
Direction des Opérations Cliniques, Medical Information |
2020-04-08 |
| Dynamics of regional lung aeration non-invasive determined by electrical impedance tomography in patients with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
tomography alone, ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitätsmedizin Rostock |
|
Germany |
2020-04-12 |
|
A2020-0072, DRKS00021276 |
Phase 4 Clinical |
Not yet recruiting |
2 |
|
24 |
Sven Pulletz |
2020-04-07 |
| Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019 |
Coronavirus disease 19 infection, Pulmonary fibrosis |
anluohuaxian alone, regular treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Peking University First Hospital |
|
China |
2020-04-01 |
2020-12-01 |
2020 RESEARCH 110, NCT04334265 |
Phase 2 Clinical |
Not yet recruiting |
9 |
8 Months |
750 |
Dingyu Zhang, Guiqiang Wang, Hong Zhao, Junhua Yu, Qin Ning, Sibin Zhang, Xi Zheng, Xianxiang Chen, Yongping Chen, Zhenshun Cheng |
2020-04-07 |
| Screening for symptoms of COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Max Super Speciality Hospital |
|
India |
2020-04-08 |
|
CTRI/2020/04/024442 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
5000 |
DrSujeet Jha |
2020-04-08 |
| A compassionate use program to assess remdesivir in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
Europe |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| Sensor Based Vital Signs Monitoring of COVID-19 Patients During Home Isolation |
Coronavirus disease 19 infection, SARS coronavirus infection |
biosensor (Welfare technology) alone, general recommendation alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ullevaal University Hospital |
Oslo University Hospital, Universidad del Pais Vasco, Universitetssykehuset Nord-Norge Hf, University of Stavanger |
Norway |
2020-04-07 |
2025-12-20 |
127157, HSC19, NCT04335097 |
Phase Not Applicable |
Not yet recruiting |
1 |
68 Months |
214 |
Lars Wik, Lars Wik, MD |
2020-04-07 |
| A clinical study of gut microbiome derived therapeutics for the potential prevention of COVID-19 |
Coronavirus disease 19 infection |
gut microbiome derived therapeutics (COVID-19), Persephone Biosciences alone |
|
|
Persephone Biome Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| CORON-ACT: Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Inselspital, Berne |
Roche Holding AG |
Switzerland |
2020-04-30 |
2020-10-31 |
2020-00691, 2020DR2044, CORON-ACT, NCT04335071 |
Phase 2 Clinical |
Not yet recruiting |
3 |
6 Months |
100 |
Peter M. Villiger, Prof. Dr. med., Stephan Reichenbach, Prof. Dr.med. |
2020-04-10 |
| HyAzOUT: Hydroxychloroquine Versus Azithromycin for Outpatients in Utah With COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Intermountain Health Care Inc |
University of Utah, Utah Department of Health |
US |
2020-04-02 |
2021-12-31 |
1051360, HyAzOUT, NCT04334382 |
Phase 3 Clinical |
Recruiting |
0 |
20 Months |
1550 |
Brandon Webb, MD, David P Tomer, MS, Estelle Harris, MD, Jake Krong, Valerie T Aston, MBA |
2020-04-10 |
| A clinical study of EIDD-2801 in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
EIDD-2801, Drug Innovation Ventures/Georgia State University/Emory University alone |
RNA polymerase inhibitor |
|
Ridgeback Biotherapeutics LP |
Drug Innovation Ventures at Emory LLC |
US |
2020-04-30 |
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-08 |
| EPA-FFA to Treat Hospitalized Patients With SARS-CoV-2 |
Coronavirus disease 19 infection |
eicosapentaenoic acid (oral, familial adenomatous polyposis/inflammatory bowel disease/Crohns disease), SLA Pharma alone, standard of care treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
SLA Pharma AG |
|
|
2020-04-13 |
2020-07-31 |
EPA-COV-001, NCT04335032 |
Phase 3 Clinical |
Not yet recruiting |
0 |
3 Months |
150 |
Justin Slagel |
2020-04-09 |
| HELPCOVID-19: A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , vitamin C , vitamin D , zinc |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ProgenaBiome |
|
US |
2020-04-30 |
2021-07-31 |
HELPCOVID-19, NCT04335084, PRG-042 |
Phase 2 Clinical |
Not yet recruiting |
0 |
15 Months |
600 |
Jordan Daniels, MS, Sabine Hazan, MD |
2020-04-08 |
| Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia |
Coronavirus disease 19 infection |
questionnaire alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jessa Hospital |
|
Belgium |
2020-04-17 |
2023-12-20 |
JESSAH_COVID19_PRESCREENING, NCT04334252 |
Phase Not Applicable |
Not yet recruiting |
1 |
44 Months |
5000 |
Ina Callebaut, Ina Callebaut, dr, Janneke Cox, Dr |
2020-04-10 |
| eChoVid: Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 + |
Coronavirus disease 19 infection |
pulmonary ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-05-31 |
2020-A00768-31, APHP200390, NCT04335019, eChoVid |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
300 |
Mehdi BENCHOUFI, MD |
2020-04-08 |
| TOSCA: Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection, Viral pneumonia |
tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita Degli Studi Di L'Aquila |
|
|
2020-04-01 |
2021-03-31 |
0064468/20, NCT04332913, TOSCA |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
30 |
Roberto Giacomelli, MD, PhD |
2020-04-09 |
| HERO-HCQ: Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
Patient Centered Outcome Research Institute |
US |
2020-04-30 |
2020-07-31 |
HERO-HCQ, NCT04334148, PRO00105274 |
Phase 3 Clinical |
Not yet recruiting |
0 |
3 Months |
15000 |
Adrian Hernandez, MD, Donna Parker, Rachel Olson, RN |
2020-04-08 |
| COVID-19 REAL: A non-interventional, retrospective, database, cohort study based on anonymized and routinely collected health care data from COVID-19 patients |
Coronavirus disease 19 infection |
|
|
|
TFS AB |
IOMED Inc |
|
|
|
COVID-19 REAL |
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-07 |
| COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University Hospital, Akershus |
Alesund Hospital, Haukeland University Hospital, Helse Fonna, Helse Stavanger HF, Levanger Hospital, Nordlandssykehuset HF, Norwegian Institute of Public Health, Oslo University Hospital, St Olavs Hospital, Sykehuset Innlandet HF, Sykehuset Ostfold, University Hospital of North Norway, University of Bristol, University of New South Wales, Vestre Viken HF |
Norway |
2020-04-01 |
2030-12-31 |
20/03794, NCT04335773 |
Phase Not Applicable |
Not yet recruiting |
1 |
129 Months |
350 |
Christopher Inchley, Mr, Christopher Inchley, Phd, Lise Beier Havdal |
2020-04-09 |
| A study to assess the effect of blood plasma in the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
blood plasma alone |
|
|
Karolinska Institutet |
|
Sweden |
|
|
|
Phase Not Applicable |
Not yet recruiting |
2 |
|
30 |
Joakim Dillner |
2020-04-07 |
| A multi-site clinical trial investigating whether hydroxychloroquine can effectively prevent COVID-19 in participants already exposed to the infection |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
University of Washington |
New York University School of Medicine, US |
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
2000 |
|
2020-04-07 |
| A compassionate use program of CAP-1002 for the treatment of ARDS pneumonia in COVID-19 patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
CAP-1002 alone |
|
|
Capricor Therapeutics Inc |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-07 |
| ORCHID: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease |
Coronavirus disease 19 infection, SARS coronavirus infection |
Hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
National Heart Lung and Blood Institute |
US |
2020-04-02 |
2021-07-31 |
NCT04332991, ORCHID, PETAL 05 ORCHID |
Phase 3 Clinical |
Recruiting |
0 |
15 Months |
510 |
Boyd Taylor Thompson, MD, Katie Oldmixon, RN, Nancy Ringwood, BSN |
2020-04-09 |
| A Canadian pilot study of inhaled formulation of nitric oxide (NO) for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
Nitric Oxide Delivery Device (INODD) alone, nitric oxide (inhalant, cystic fibrosis/non-tuberculous mycobacteria infection), Novoteris alone |
|
|
Mallinckrodt plc, Novoteris LLC |
|
Canada |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-07 |
| COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases |
Arthritis, Coronavirus disease 19 infection, Psoriatic arthritis, Rheumatoid arthritis, Spondylarthritis, Systemic lupus erythematosus |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Region Nordjylland Aalborg Sygehus |
|
Denmark |
2020-04-08 |
2021-09-01 |
20200401, NCT04335747 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
333 |
Line Uhrenholt, MD, Salome Kristensen, MD, PhD |
2020-04-08 |
| Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers |
Coronavirus disease 19 infection |
Hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Baylor Research Institute |
|
US |
2020-04-03 |
2020-07-30 |
020-132, NCT04333225 |
Phase 2 Clinical |
Recruiting |
0 |
3 Months |
360 |
Laura Clariday, CCRC, Peter A McCullough, MD, MPH, Rebecca Baker, MSN, APRN |
2020-04-09 |
| ATCO: Angiotensin-(1,7) Treatment in COVID-19 |
Coronavirus disease 19 infection, Respiratory failure, Respiratory insufficiency, Viral pneumonia |
angiotensin 1-7 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Erasme Hospital |
Fonds Erasme |
Belgium |
2020-03-31 |
2020-06-15 |
ATCO, NCT04332666, P2020/201 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
2 Months |
60 |
Fabio S Taccone, PD,PhD, Filippo Annoni, MD, Robson AS Santos, MD,PhD |
2020-04-08 |
| Study Testing Convalescent Plasma versus Best Supportive Care |
Coronavirus disease 19 infection, Pneumonia, SARS coronavirus infection |
high-titer anti-Sars-CoV-2 plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baylor Research Institute |
|
|
2020-04-01 |
2022-12-31 |
020-123, NCT04333251 |
Phase 1 Clinical |
Not yet recruiting |
0 |
33 Months |
115 |
|
2020-04-09 |
| COVID-19 Registry Rhineland-Palatinate (Germany) |
Coronavirus disease 19 infection |
|
|
|
IHF GmbH - Institut für Herzinfarktforschung |
Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz |
Germany |
2020-04-06 |
2021-09-30 |
COVID-19 REGISTRY, NCT04335188 |
Phase Not Applicable |
Recruiting |
1 |
17 Months |
4000 |
Anselm Gitt, MD, Sebastian Diebold, PhD |
2020-04-09 |
| Recovery-RS: Respiratory support: respiratory strategies in patients with coronavirus COVID-19 - CPAP, high-flow nasal oxygen and standard care |
Coronavirus disease 19 infection |
continuous positive airway pressure therapy alone, high flow nasal oxygen therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Warwick University |
|
UK |
2020-03-30 |
2021-05-05 |
IRAS 282338, ISRCTN16912075, Recovery-RS, SPONSOR: 26/19-20 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
4002 |
Dr Keith Couper |
2020-04-08 |
| DEFI-VID19: Defibrotide in COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
defibrotide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
IRCCS San Raffaele |
|
Italy |
2020-04-06 |
2020-12-31 |
DEFI-VID19, DEFI-VID19, NCT04335201 |
Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
50 |
Ciceri Fabio,, Fabio Ciceri, MD, Stefania Trinca |
2020-04-08 |
| A Case Study on Treating COVID-19 in a Patient with Multiple Myeloma |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Male, Asian Ancestry |
Anhui Provincial Hospital |
|
China |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
1 |
Changcheng Zheng, MD |
2020-04-09 |
| CP-COVID-19: Convalescent Plasma for Patients With COVID-19: a Randomized, Open-label, Parallel, Controlled Clinical Study |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including azithromycin , convalescent plasma , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Del Rosario University |
CES University, Fundación Universitaria de Ciencias de la Salud, Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud |
Colombia |
2020-04-01 |
2020-12-31 |
ABN011-2, CP-COVID-19, NCT04332835 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
9 Months |
80 |
Adriana Rojas Villarraga, MD, Anha M Robledo Moreno, Bernardo Camacho Rodríguez, MD, MSc, Carlos E Perez, MD, Cristian A Ricaurte Perez, MSc, Diana M Monsalve Carmona, PhD, Gustavo A Salguero López, MD, PhD, Gustavo Quintero, MD, MSc, Heily C Ramírez Santana, MSc, PhD, Isaura P Torres Gómez, MSc, PhD, Jeser S Grass Guaqueta, MSc, Juan C Diaz Coronado, MD, MSc, Juan E Gallo Bonilla, MSc, PhD, Juan M Anaya Cabrera, MD, PhD, Luisa P Duarte Correales, Manuel E Rojas Quintana, MD, MSc, Oscar M Gómez Guzmán, MSc, PhD, Paula A Pedroza Rodríguez, Paula Gaviria, MSc, Ruben D Manrique Hernández, MSc, PhD, Ruben D Mantilla, MD, Sara Velez Gomez, Yeny Y Acosta Ampudia, PhD, Yhojan A Rodríguez Velandia, MD |
2020-04-08 |
| HAZCpaC: A Study of Quintuple Therapy to Treat COVID-19 Infection |
Coronavirus disease 19 infection |
Variable regimens including Plaquenil , azithromycin , vitamin C , vitamin D , zinc |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
ProgenaBiome |
|
US |
2020-04-30 |
2021-07-31 |
HAZCpaC, NCT04334512, PRG-044 |
Phase 2 Clinical |
Not yet recruiting |
0 |
15 Months |
60 |
Jordan Daniels, MS, Sabine Hazan, MD |
2020-04-08 |
| A Study to Assess the Effect of Repurposed Camostat in the Treatment of Coronavirus Disease 19 Infection (COVID-19) Patients |
Coronavirus disease 19 infection |
repurposed camostat (COVID-19), University of Tokyo alone |
Serine protease inhibitor, Trypsin inhibitor |
|
University of Tokyo |
|
|
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| A phase I trial to evaluate safety and immunogenicity of vaccine (coronavirus disease 19 infection), State Research Center of Virology and Biotechnology VECTOR for the treatment of patients with coronavirus disease 19 infection |
Coronavirus disease 19 infection |
vaccine (coronavirus disease 19 infection), State Research Center of Virology and Biotechnology VECTOR alone |
|
|
State Research Center of Virology and Biotechnology VECTOR |
|
|
2020-06-29 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
60 |
|
2020-04-07 |
| A phase III clinical trial to evaluate the safety and efficacy of remdesivir in the treatment of patients with moderate COVID-19 infection |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
UK |
2020-04-02 |
|
|
Phase 3 Clinical |
Recruiting |
1 |
|
|
|
2020-04-07 |
| A Study to Assess the Effect of Nafamostat in the Treatment of Coronavirus Disease 19 Infection (COVID-19) Patients |
Coronavirus disease 19 infection |
nafamostat (Middle East respiratory syndrome), University of Tokyo alone |
Serine protease inhibitor |
|
University of Tokyo |
|
|
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-08 |
| A phase III clinical trial to evaluate the safety and efficacy of remdesivir in the treatment of patients with severe COVID-19 infection |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
UK |
2020-04-02 |
|
|
Phase 3 Clinical |
Recruiting |
1 |
|
|
|
2020-04-07 |
| Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Providence Health & Services |
Providence Cancer Center, Earle A. Chiles Research Institute |
US |
2020-03-30 |
2023-09-30 |
2020000186, NCT04334967 |
Phase 4 Clinical |
Recruiting |
0 |
42 Months |
1250 |
Brian Kendal, MD, Trista Johnson, PhD, MPH |
2020-04-08 |
| CovCardioVasc: Cardiovascular Complications and COVID-19 |
Cardiovascular disease, Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-02-28 |
2020-08-28 |
20REAMEDCOVID19, CovCardioVasc, NCT04335162 |
Phase Not Applicable |
Recruiting |
2 |
6 Months |
100 |
Denis DOYEN, Mathieu Jozwiak |
2020-04-08 |
| COPERNICO: Checkpoint Blockade in COVID-19 Pandemic |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
pembrolizumab plus tocilizumab (intravenous), Roche/Chugai |
IL-6 receptor antagonist, IL-6 receptor modulator, Programmed cell death protein 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medica Scientia Innovation Research |
|
|
2020-03-30 |
2020-05-15 |
COPERNICO, MEDOPP376, NCT04335305 |
Phase 2 Clinical |
Not yet recruiting |
0 |
1 Month |
24 |
Alicia García, Javier Cortés |
2020-04-08 |
| Safety in Convalescent Plasma Transfusion to COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
Convalescent Plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital San Jose Tec de Monterrey |
Instituto Tecnologico y de Estudios Superiores de Monterrey |
Mexico |
2020-04-15 |
2021-04-30 |
NCT04333355, PC-TECSALUD FASE I |
Phase 1 Clinical |
Not yet recruiting |
1 |
12 Months |
20 |
José Fe Castilleja-Leal, MD., Servando Cardona-Huerta, MD., Ph. D., Sylvia De la Rosa, MD |
2020-04-09 |
| A clinical trial of mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19 |
Coronavirus disease 19 infection |
mRNA-encoded neutralizing anti-SARS-CoV-2 antibodies alone |
|
|
Ethris GmbH, Neurimmune Holding AG |
|
|
2020-12-31 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| SOVECOD: Comparative assessment of the efficacy and safety of add on treatment with 'Sofosbuvir plus Velpatasvir' to 'standard of care therapeutic regimen' in patients with COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , lopinavir + ritonavir , sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead |
HIV protease inhibitor, Hepatitis C virus NS5B polymerase inhibitor, Hepatitis C virus protein NS5A inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kermanshah University of Medical Sciences |
|
Iran |
2020-04-08 |
|
IRCT20130812014333N145, Ir.kums.rec.1399.044, SOVECOD |
Phase 3 Clinical |
Recruiting |
2 |
|
80 |
Dr. Babak Sayad, Dr. Farid Najafi, Dr. Reza Khodarahmi, Samin Sharifi |
2020-04-09 |
| Phase II Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection |
Coronavirus disease 19 infection, SARS coronavirus infection |
Standard of care alone, azithromycin alone, hydroxychloroquine alone, azithromycin plus hydroxychloroquine |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-30 |
2020-08-01 |
NCT04335552, PRO00105339 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
500 |
Jason Stout, MD |
2020-04-09 |
| Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers (COVID-Antibody) |
Coronavirus disease 19 infection, SARS coronavirus infection |
SARS-CoV-2 IgG Antibody Testing Kit (Ray Biotech) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Indiana University |
|
US |
2020-04-01 |
2021-01-01 |
2003973826, NCT04334876 |
Phase Not Applicable |
Not yet recruiting |
0 |
9 Months |
340 |
Courtney Rowan, MD, Kirsten Ramberg |
2020-04-08 |
| Comparison of therapies for COVID-19 |
Coronavirus disease 19 infection |
chloroquine alone, hydroxychloroquine alone, lopinavir + ritonavir alone, remdesivir alone, standard of care alone, Interferon plus lopinavir + ritonavir |
HIV protease inhibitor, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ministry of Health and Medical Education, IRAN |
|
Iran |
2020-04-08 |
|
IR.NREC.1399.001, IRCT20200405046953N1 |
Phase 3 Clinical |
Recruiting |
29 |
|
3000 |
Ahmad Hormati, Alireza Musavi, Alireza Soleimani, Atousa Hakami Fard, Behnam Mahmoodieh, Behnaz Khodabakhshi, Farhang Baba Mahmoodi, Fariborz Mansour Ghanaie, Farzin Khorvash, Hadiseh Hosami, HamidReza Najjari, Hassan Mozaffar, Hossein Poustchi, Hossein Sarmadian, Ilad Alavi Darazam, Khalil Ansarin, Kiana Shirani, Mahnaz Amini, Mehdi Mesri, Mehrdad Salahi, Minoo Mohraz, Mitra Ranjbar, Mohammad Reza Ghadir, Mohammad Reza Salehi, Mohsen Moghadami, Mostafa Ghanei, Mostafa Javanian, Payam Tabarsi, Roya Ghasemian, Saeid Hafizi Lotfabadi |
2020-04-09 |
| HOPE COVID 19: International COVID-19 Clinical Evaluation Registry |
Coronavirus disease 19 infection |
|
|
|
Hospital Clinico San Carlos |
|
Spain |
2020-03-23 |
2020-05-05 |
20/241-E, EUPAS34399, HOPE COVID 19, NCT04334291 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
2500 |
IVAN J NUNEZ GIL, MD, PhD, MSc, IVAN J NUÑEZ GIL, IVAN J NUÑEZ J NUÑEZ GIL, MD |
2020-04-09 |
| IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection |
Advanced solid tumor, Coronavirus disease 19 infection, Hematological neoplasm, Metastasis, SARS coronavirus infection |
GNS-561 alone, Standard of care alone, nivolumab alone, tocilizumab alone |
Autophagy protein inhibitor, Programmed cell death protein 1 inhibitor, Solute carrier family inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Leon Berard |
|
France |
2020-04-30 |
2020-08-31 |
2020-001373-70, ET20-076 - IMMUNONCOVID-20, IMMUNONCOVID, NCT04333914 |
Phase 2 Clinical |
Recruiting |
1 |
4 Months |
273 |
Julien GAUTIER, Philippe CASSIER, Philippe Cassier |
2020-04-09 |
| Investigation of the influence of the new coronavirus pandemic (COVID-19) on pain, mood and everyday life of patients with painful polyneuropathy |
Coronavirus disease 19 infection, Neuropathic pain, Polyneuropathy |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitatsklinikum Schleswig-Holstein Campus Kiel |
|
Germany |
2020-04-05 |
|
D453/20, DRKS00021254 |
Phase Not Applicable |
Recruiting |
1 |
|
50 |
Dilara Kersebaum |
2020-04-08 |
| STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection |
umbilical cord Wharton's jelly-derived mesenchymal stromal cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-01 |
2021-05-31 |
2020-001287-28, APHP200395, NCT04333368, STROMA-CoV2 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
2 |
14 Months |
60 |
Antoine A MONSEL, MD, PhD, Antoine MONSEL, MD, PhD, Jean-Luc DIEHL, MD, PhD, Philippe MENASCHE, MD, PhD, Philippe MENASCHÉ, MD, PhD |
2020-04-08 |
| C-19-ACS: Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomized, Controlled Trial |
Acute coronary syndrome, Coronavirus disease 19 infection |
Aspirin alone, atorvastatin alone, clopidogrel alone, omeprazole alone, rivaroxaban alone |
Factor Xa antagonist, H+ K+ ATPase inhibitor, HMG CoA reductase inhibitor, P2Y12 purinoceptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Imperial College London |
|
UK |
2020-04-03 |
2021-03-30 |
20HH5868, C-19-ACS, NCT04333407 |
Phase 4 Clinical |
Recruiting |
2 |
11 Months |
3170 |
Alena Marynina, BSc, MSc, Clare Coyle, BMBCh, BA, MRCP, Prapa Kanagaratnam, FRCP, PhD |
2020-04-10 |
| PANAMO: Open-label, Randomized Study of IFX-1 in Patients with Severe COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
IFX-1 alone, best supportive care alone |
Complement C5a factor inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
InflaRx GmbH |
|
Netherlands |
2020-03-31 |
2020-12-31 |
IFX-1-P2.9, NCT04333420, PANAMO |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
9 Months |
130 |
A Vlaar, MD, A. V., MD, PhD, Korinna Pilz, MD |
2020-04-08 |
| Piclidenoson for Treatment of COVID-19 |
Coronavirus disease 19 infection, Respiratory tract infection |
piclidenoson alone |
Adenosine A3 receptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Can-Fite BioPharma Ltd |
Rabin Medical Center |
Israel |
2020-04-06 |
2020-07-06 |
CAN-COR-1, NCT04333472 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
40 |
Zivit Harpaz |
2020-04-08 |
| Application of Desferal to Treat COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
deferoxamine mesylate alone, standard treatment regimens alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kermanshah University of Medical Sciences |
|
Iran |
2020-04-30 |
2021-03-31 |
1398.1224, NCT04333550 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
11 Months |
50 |
Alireza Ghaffarieh, MD, Amir Kiani, PhD, Yadollah Shakiba, MD, PhD |
2020-04-08 |
| Mindfulness-based 'STOP (Stop, Take a Breath, Observe, Proceed) Touching Your Face' Intervention |
Coronavirus disease 19 infection |
Mindfulness-based 'STOP touching your face' practice alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shao Yifu Hospital |
|
China |
2020-04-02 |
2020-04-30 |
2020S001, NCT04330352 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Yanhui Liao, Yanhui Liao, MD |
2020-04-10 |
| FingoCov: Effect of Fingolimod for treatment of COVID-19-induced cytokine storm |
Coronavirus disease 19 infection, Viral pneumonia |
fingolimod alone, standard regimen alone |
Cannabinoid receptor antagonist, Sphingosine-1-phosphate receptor-1 modulator, Sphingosine-1-phosphate receptor-3 modulator, Sphingosine-1-phosphate receptor-4 modulator, Sphingosine-1-phosphate receptor-5 modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-08 |
|
FingoCov, IR.TBZMED.REC.1399.001, IRCT20200317046797N2 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Dr Khalil Ansarin, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed |
2020-04-09 |
| TOCI-RE: EEfficacy of Tocilizumab - COVID-19 Effectiveness of Tocilizumab - COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Unita Sanitaria Locale di Reggio Emilia |
|
Italy |
2020-03-27 |
|
2020-001386-37, RCT-TCZ-COVID-19, TOCI-RE |
Phase 2 Clinical |
Recruiting |
1 |
|
398 |
Trial Information Support Line-TISL |
2020-04-09 |
| EPI-COVID-19: Household Transmission Investigation Study for COVID-19 in French Guiana |
Coronavirus disease 19 infection, SARS coronavirus infection |
Blood sample alone, Nasopharyngeal swab alone |
|
Healthy volunteers accepted |
Institut Pasteur |
Centre Hospitalier de Cayenne, Institut Pasteur de Guyane |
French Guiana |
2020-03-23 |
2022-03-23 |
2020-009, EPI-COVID-19, NCT04328129 |
Phase Not Applicable |
Recruiting |
2 |
24 Months |
450 |
Claude Flamand, PhD, Claude Flamand, Phd, Dominique Rousset, MD |
2020-04-07 |
| Evaluation of the effect of traditional Iranian medicine product on improvement of clinical manifestation of COVID-19 |
Coronavirus disease 19 infection |
Traditional Medicine (Astragalus gossypinus with food spice) alone |
|
|
Kerman University of Medical Sciences |
|
Iran |
2020-03-24 |
|
IR.KMU.REC.1399.003, IRCT20101219005416N2 |
Phase 3 Clinical |
Recruiting |
1 |
|
80 |
Haleh Tajadini |
2020-04-07 |
| Umifenovir effectiveness in the treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including Arbidol (Pharmstandard) , atazanavir + ritonavir , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Progress and Development of Iran |
|
Iran |
2020-03-28 |
2020-04-20 |
IR.TUMS.VCR.REC.1398.1037, IRCT20200322046833N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Azar Haddadi, Behnam Bayatani, Bita Shahrami, Farhad Najmeddin, Morteza Pirali |
2020-04-08 |
| Hemoperfusion in patients with COVID-19 |
Coronavirus disease 19 infection |
HA230 hemoperfusion filter (Jafron Company) alone, HA280 hemoperfusion filter (Jafron Company) alone, hemoperfusion alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Babol University of Medical Sciences |
|
Iran |
2020-03-24 |
|
IR.MUBABOL.HRI.REC.1399.038, IRCT20150704023055N2 |
Phase 2 Clinical |
No longer recruiting |
1 |
|
10 |
Masoumeh Asgharpour, Reza Ghadimi, Simin Mouodi |
2020-04-08 |
| Comparison of efficacy of oral levamisole and formoterol + budesonide inhaler with standard treatment of Corona infection |
Coronavirus disease 19 infection |
Variable regimens including budesonide + formoterol fumarate, AstraZeneca , hydroxychloroquine sulfate , levamisole (Poursina pharmaceutical Company) , lopinavir + ritonavir |
Beta 2 adrenoceptor agonist, HIV protease inhibitor |
|
Fasa University of Medical Sciences |
|
Iran |
2020-04-01 |
|
IR.FUMS.REC.1399.002, IRCT20200324046852N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
30 |
Dr. Jalal Karimi, Dr. Mojtaba Farjaam, Dr. Siamack Afazeli, Dr.Siamack Afazeli |
2020-04-07 |
| Supplementation in COVID-19 |
Coronavirus disease 19 infection |
Soluvit (Fresenius Kabi New Zealand) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-02 |
|
IR.TUMS.VCR.REC.1399.090, IRCT20200319046819N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Dr. Mohammad Ali Sahraian, Sama Bitarafan |
2020-04-07 |
| A clinical study to assess KL4 surfactant for treatment of lung injury resulting from severe COVID-19 infection |
Coronavirus disease 19 infection, Lung injury |
lucinactant (aerosol), Windtree Therapeutics/ Esteve/ Lee's Pharmaceutical alone |
BMP10 gene inhibitor, BMP15 gene inhibitor |
|
Windtree Therapeutics Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-06 |
| The effect of dental pulp mesenchymal stem cells in treatment of corona virus disease |
Coronavirus disease 19 infection, Viral pneumonia |
dental pulp mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kerman University of Medical Sciences |
|
Iran |
2020-04-04 |
|
IR.KMU.REC.1399.018, IRCT20140911019125N6 |
Phase 2 Clinical |
Recruiting |
2 |
|
10 |
Abbas Pardakhty, Alireza Farsinejad, Mehrdad Farrokhnia |
2020-04-07 |
| TOVID-49: Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19 |
Coronavirus disease 19 infection |
Telephony alone, Videophony alone |
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-03-27 |
2020-09-30 |
2020/29, NCT04333849, TOVID-49 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
100 |
Cedric ANNWEILER, MD, PhD |
2020-04-09 |
| HOPE: Chroloquine Phosphate Against Infection by the Novel Coronavirus |
Coronavirus disease 19 infection, Viral pneumonia |
chroloquine phosphate, Uni-Pharma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories Sa |
|
Greece |
2020-04-02 |
|
2020-001345-38, HOPE, UNIKINON-01/HOPE |
Phase 2 Clinical |
No longer recruiting |
1 |
|
60 |
Regulatory Affairs department |
2020-04-09 |
| COVID-19 in Patients With HIV |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
|
University of Missouri |
|
US |
2020-04-01 |
2020-10-01 |
262095, NCT04333953 |
Phase Not Applicable |
Recruiting |
0 |
6 Months |
500 |
Dima Dandachi, Dima Dandachi, MD |
2020-04-09 |
| Efficacy and safety of sofosbuvir in the treatment of SARS-CoV-2: an open-label, phase II trial |
Coronavirus disease 19 infection, SARS coronavirus infection |
sofosbuvir alone, standard of care treatment alone |
Hepatitis C virus NS5B polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-04 |
|
IR.SBMU.RETECH.REC.1399.001, IRCT20200328046882N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
60 |
Afshin Zarghi, Mostafa Alavi-Moghaddam |
2020-04-08 |
| COVITD-19: Vitamin D on Prevention and Treatment of COVID-19 |
Coronavirus disease 19 infection |
ACE2 inhibitor therapy alone, Angiotensin II Receptor Blockers therapy alone, NSAIDs therapy alone, Vitamin D alone, thiazolidinediones therapy alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University of Granada |
|
Spain |
2020-04-10 |
2020-06-30 |
COVITD-19, COVITD-19, NCT04334005 |
Phase Not Applicable |
Not yet recruiting |
2 |
2 Months |
200 |
Manuel J Castillo, MD, PhD, Manuel J. Castillo Garzón, Proffesor Amaro Gahete, PhD student |
2020-04-09 |
| Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
camostat mesylate alone, standard regimen alone |
Serine protease inhibitor, Trypsin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-08 |
|
IR.TBZMED.REC.1398.1312, IRCT20200317046797N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Dr Khalil Ansarin, Mohammad Reza Ardalan, Sepideh Zununi Vahed |
2020-04-09 |
| ReciGen for treatment of Covid-19 |
Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Hypoxia |
standard treatment alone, chloroquine plus interferon beta-1a follow-on biologic (subcutaneous), CinnaGen |
Interferon beta ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-27 |
|
IR.TUMS.VCR.REC.1399.026, IRCT20150914024017N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Pooya Payandemehr |
2020-04-08 |
| Escape: Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction |
Coronavirus disease 19 infection, Multiple organ failure |
anakinra alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator, Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hellenic Institute for the Study of Sepsis |
|
Greece |
2020-04-01 |
2022-04-01 |
2020-001039-29, Escape, NCT04339712 |
Phase 2 Clinical |
Not yet recruiting |
17 |
24 Months |
20 |
Antigoni Kotsaki, MD, PhD, Apostolos Armaganidis, MD, PhD, Evangelos Giamarellos-Bourboulis, MD, PhD |
2020-04-10 |
| CROWN CORONA: CROWN CORONATION: Chloroquine Repurposing to healthworkers for Novel CORONAvirus mitigation |
Coronavirus disease 19 infection |
chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University School of Medicine, US |
|
Australia, US, Canada, UK, Ireland, South Africa |
2020-04-30 |
2021-02-28 |
202004XXX, CROWN CORONA, NCT04333732 |
Phase 2 Clinical |
Not yet recruiting |
6 |
10 Months |
55000 |
Catherine Martin, MBBCh MSc, David Mazer, MD, David Story, MD, Dermot McGuckin, MD, Ellen O'Sullivan, MD, FRCA,FCAI, Eric Dubberke, MD, Gemma Jones, MsC, Gloria Maimela, MBBCh MBA, Hakim-Moulay Dehbi, PhD, Helen Rees, MD, Jessica Spence, MD, FRCPC, Laurence Lovat, MD, PhD, Linda Yun, BS, Mary Politi, MD, Michael S. Avidan, MBBCh, Michael S. Avidan, MBBCh, FCASA, Michelle Moorhouse, MBChB, Nick Freemantle, PhD, Ramani Moonesinghe, MD, Saiqa Mullick, MBBCh PhD, Sherry McKinnon, Sherry McKinnon, BS, Sinead Delany-Moretlwe, MBChB, PhD, DTM&H |
2020-04-08 |
| Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy |
Coronavirus disease 19 infection |
desynchronization strategy alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Inselspital, Berne |
|
Switzerland |
2020-03-19 |
2021-12-31 |
2020-00563, NCT04333862 |
Phase Not Applicable |
Recruiting |
1 |
21 Months |
500 |
Guido Beldi, Guido Beldi, Prof. Dr. |
2020-04-08 |
| Effect of febuxostat against coronavirus |
Coronavirus disease 19 infection, Lung injury |
acetaminophen plus febuxostat |
Xanthine oxidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-03-16 |
2020-04-09 |
IR.MAZUMS.REC.1398.1452, IRCT20190727044343N1 |
Phase 3 Clinical |
No longer recruiting |
1 |
|
60 |
Lotfollah Davoodi, Majid Saeedi |
2020-04-07 |
| Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Gastrointestinal disease, Viral pneumonia |
chloroquine plus rabeprazole |
H+ K+ ATPase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fifth Affiliated Hospital, Sun Yat-Sen University |
|
China |
2020-02-12 |
2021-07-31 |
ChiCTR2000031454 |
Phase 0 Clinical |
Recruiting |
1 |
17 Months |
56 |
Xiao Fei |
2020-04-09 |
| Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial |
Coronavirus disease 19 infection, Viral pneumonia |
2019-nCov IgG test alone, PCR Nucleic acid detection alone |
|
|
First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) |
Taizhou Zecheng Biotechnology Co. Ltd. |
China |
2020-03-25 |
2021-03-31 |
ChiCTR2000031465 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
200 |
Pang Jifeng, Xiang Changgang |
2020-04-07 |
| Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study |
Coronavirus disease 19 infection, Viral pneumonia |
earplugs alone, eye patch alone |
|
|
Shanghai East Hospital |
|
China |
2020-02-10 |
2020-02-25 |
ChiCTR2000031499 |
Phase Not Applicable |
Completed |
1 |
|
55 |
Li Chen, Ma Shaolin |
2020-04-07 |
| ARMS-I COVID: A randomized, placebo-controlled, crossover study to evaluate whether the ARMS-I helps prevent airborne transmission of coronavirus COVID-19 and whether it reduces the symptoms of healthcare providers who have tested positive for the virus |
Coronavirus disease 19 infection, Upper respiratory tract infection |
ARMS-I alone |
Viral envelope glycoprotein inhibitor |
|
University Hospitals Of Cleveland |
ARMS Pharmaceutical LLC, Case Western Reserve University |
US |
2020-04-30 |
|
ARMS-I COVID |
Phase Not Applicable |
Planned |
0 |
|
|
Robert Salata |
2020-04-07 |
| Effect of hydroxychloroquine on prevention of Covid-19 virus |
Coronavirus disease 19 infection, Viral infection |
hydroxychloroquine, Amin Pharmaceutical alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-29 |
|
IR.TUMS.VCR.REC.1399.001, IRCT20120826010664N6 |
Phase 2 Clinical |
Recruiting |
1 |
|
310 |
Mohammad Ali Sahraian, Reihaneh Pirjani, Reihaneh Pirjani MD. |
2020-04-07 |
| A multicenter, randomized Phase II clinical trial of plitidepsin for the treatment of patients with COVID-19 pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
plitidepsin alone |
Elongation factor 1 alpha 2 modulator, VEGF-1 receptor modulator |
|
PharmaMar SA |
|
Spain |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
160 |
|
2020-04-06 |
| The Effect of Tanacetum parthenium (L) sch Syrup on Clinical Manifestations of Patients with COVID-19 |
Coronavirus disease 19 infection, Respiratory tract infection |
Trachyspermum copticum syrup (Barij Essence and Shahid Beheshti Pharmaceutical Group) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Ghoum University of Medical Sciences |
|
Iran |
2020-04-07 |
|
IR.MUQ.REC.1399.012, IRCT20180610040049N4 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Ehsan Sharifipour, Mohammad KamaliNejad, Mohsen Bahrami, Reza Shirvani |
2020-04-07 |
| Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
cold outdoor environment alone, temperature measuring distance alone |
|
Young Adults (18-44 yrs) |
Peking University First Hospital |
|
China |
2020-03-07 |
2020-04-12 |
ChiCTR2000031500 |
Phase 0 Clinical |
No longer recruiting |
1 |
1 Month |
58 |
LI HANG, PENG RUI |
2020-04-07 |
| Study of the effect of vitamin C in patients with COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including chloroquine phosphate (Pars) , hydroxychloroquine sulfate (Tehran) , lopinavir + ritonavir , vitamin C |
HIV protease inhibitor |
|
Abadan School of Medical Sciences |
|
Iran |
2020-04-19 |
|
IR.ABADANUMS.REC.1398.119, IRCT20200324046850N5 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Sara Mobarak, سارا مبارک |
2020-04-07 |
| The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Nanjing General Hospital of Nanjing Military Command, PLA |
|
China |
2020-03-17 |
2020-07-17 |
ChiCTR2000031501 |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
20 |
Lu Ke, Weiqin Li |
2020-04-07 |
| Clinical trial to assess Vicromax in the treatment of patients with Coronavirus disease 19 infection (COVID-19) |
Coronavirus disease 19 infection |
merimepodib alone |
Inosine monophosphate dehydrogenase inhibitor |
|
Biosig Technologies Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-07 |
| Effects of nano curcumin supplementation on the reduction of inflammation and mortality in patients with coronavirus 2019 admitted to ICU ward of Imam Reza hospital in Tabriz |
Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia |
Variable regimens including hydroxychloroquine , lopinavir , nano curcumin, Exir Sina , oseltamivir , ribavirin |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-03-29 |
|
IR.TBZMED.REC.1398.1314, IRCT20200324046851N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
86 |
Hamed Valizadeh, Hassan soleimanpor, Majid Ahmadi, Ramin Pourakbari |
2020-04-07 |
| A Prospective Study on Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Peking University First Hospital |
|
China |
2020-04-01 |
2020-09-15 |
2020 RESEARCH 112, NCT04333589 |
Phase 2 Clinical |
Not yet recruiting |
8 |
5 Months |
210 |
Dingyu Zhang, Guiqiang Wang, Hong Zhao, Junhua Yu, Sibin Zhang, Xianfeng Han, Xianxiang Chen, Xinghuan Wang, Xinsheng Chen, Yongping Chen |
2020-04-07 |
| A phase IIb/III clinical study to assess leronlimab in the treatment of critically ill patients with COVID-19 infection |
Coronavirus disease 19 infection |
leronlimab alone |
CCR5 chemokine antagonist |
|
CytoDyn Inc |
|
|
2020-04-11 |
|
|
Phase 2/Phase 3 Clinical |
Planned |
0 |
|
342 |
|
2020-04-08 |
| A pilot feasibility study of INTERCEPT coronavirus convalescent plasma (CCP)system for the treatment of severe COVID-19 |
Coronavirus disease 19 infection |
INTERCEPT system alone, coronavirus convalescent plasma alone |
|
|
Cerus Corp, University Hospital Basel |
|
Switzerland |
2020-04-02 |
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-07 |
| Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 |
Coronavirus disease 19 infection |
chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HaEmek Medical Center |
|
Israel |
2020-04-30 |
2021-12-31 |
EMC 0045-20, NCT04333628 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
20 Months |
210 |
Lee Goldstein, MD, gilat ron avraham |
2020-04-08 |
| Hydroxychloroquine in Outpatient Adults With COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sanofi SA |
|
US |
2020-03-31 |
2020-05-31 |
2020-001269-35, EFC16855, NCT04333654, U1111-1249-6168 |
Phase 1b Clinical |
Recruiting |
0 |
2 Months |
210 |
Clinical Sciences & Operations |
2020-04-08 |
| Covid-VAS: Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study |
Coronavirus disease 19 infection |
vascular surgery alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sociedad Espanola de Angiologia y Cirugia Vascular |
|
Spain |
2020-04-01 |
2020-11-01 |
Covid-VAS, NCT04333693, RIV-2020-1 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
50 |
Alvaro Torres, MD, PhD, Carlos Vaquero, MD, PhD, Prof, Enrique M San Norberto, MD, PhD, MsC, Investigator Council, Joaquin de Haro, MD, PhD, Jorge Cuenca, MD, PhD, Jorge Fernández-Noya, MD, PdD, Luis Riera, MD, PhD, Raul Lara, MD, PhD, Sergi Bellmunt, MD, PhD |
2020-04-07 |
| Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune |
Coronavirus disease 19 infection, Viral pneumonia |
isolate blood monocyte therapy alone |
|
Healthy volunteers accepted, Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
2nd People's Hospital of Fuyang City, Institute of Blood Transfusion, Chinese Academy of Medical Sciences |
|
China |
2020-04-20 |
2021-04-20 |
ChiCTR2000031627 |
Phase 0 Clinical |
Not yet recruiting |
2 |
12 Months |
60 |
Shasha Li, Xiuyong Li |
2020-04-09 |
| Treatment of SARS Caused by COVID-19 With Ruxolitinib |
Coronavirus disease 19 infection, Dyspnea, SARS coronavirus infection, Viral pneumonia |
chest CT-scan alone, ruxolitinib alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cooperative Group of Malignant Hemopathies |
|
Mexico |
2020-04-01 |
2020-06-01 |
HAL 345/2020, NCT04334044 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
2 Months |
20 |
|
2020-04-08 |
| Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
celecoxib alone |
Cyclooxygenase 2 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou 8th People's Hospital |
|
China |
2020-02-17 |
2020-06-17 |
ChiCTR2000031630 |
Phase 0 Clinical |
Recruiting |
1 |
4 Months |
60 |
Hong wenxin |
2020-04-07 |
| Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
non-invasive multi-channel cardiopulmonary monitor alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Sixth People’s Hospital |
|
China |
2020-04-01 |
2022-10-31 |
ChiCTR2000031503 |
Phase Not Applicable |
Not yet recruiting |
1 |
31 Months |
100 |
Chen Yu, Shen Chengxing |
2020-04-07 |
| A phase II clinical study to assess ifenprodil in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
ifenprodil (long-acting, oral, COVID-19/acute lung injury), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
Novotech (Australia) Pty Ltd |
Australia |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
|
|
2020-04-06 |
| An investigator-initiated feasible phase II clinical study to assess ifenprodil in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
ifenprodil (long-acting, oral, COVID-19/acute lung injury), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
Asian Ancestry |
Algernon Pharmaceuticals |
Novotech (Australia) Pty Ltd |
South Korea |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
|
|
2020-04-06 |
| A multicenter telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province |
Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000031504 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
2000 |
Ji-Xin Zhong, Lingli Dong |
2020-04-08 |
| Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial |
Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia |
nintedanib alone |
CSF-1 antagonist, FGF receptor antagonist, FGF1 receptor antagonist, FGF2 receptor antagonist, FGF3 receptor antagonist, Flt3 tyrosine kinase inhibitor, Lck tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor, PDGF receptor alpha antagonist, PDGF receptor antagonist, PDGF receptor beta antagonist, Src tyrosine kinase inhibitor, VEGF receptor antagonist, VEGF-1 receptor antagonist, VEGF-2 receptor antagonist, VEGF-3 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-04-02 |
2020-08-01 |
ChiCTR2000031453 |
Phase 4 Clinical |
Not yet recruiting |
1 |
4 Months |
80 |
Huilan Zhang, Xianglin Yuan |
2020-04-08 |
| A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan medical care center for women and children |
|
China |
2019-03-15 |
2020-06-30 |
ChiCTR2000031539 |
Phase Not Applicable |
Not yet recruiting |
3 |
15 Months |
180 |
Zhang Hua-nian |
2020-04-07 |
| A multicenter, national, follow-up study to evaluate the effectiveness of convalescent serum therapy against the COVID-19 virus infection |
Coronavirus disease 19 infection |
convalescent serum therapy alone |
|
|
Houston Methodist |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-06 |
| Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
rehabilitation Nursing Program alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zunyi Medical University |
|
China |
2020-02-05 |
2020-12-05 |
ChiCTR2000031540 |
Phase 1 Clinical |
Recruiting |
1 |
10 Months |
100 |
Huang Di, Jiang ZhiXia |
2020-04-07 |
| A paired clinical study for novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huazhong University of Science and Technology |
|
China |
2020-01-27 |
2022-12-31 |
ChiCTR2000031587 |
Phase 0 Clinical |
Recruiting |
1 |
35 Months |
2000 |
Xiaomei Guo |
2020-04-08 |
| CORA: Survey of the Anxiety Associated With the SARS-CoV-2 Pandemic |
Anxiety disorder, Coronavirus disease 19 infection |
online questionnaire alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Charite University |
|
Germany |
2020-03-27 |
2021-09-30 |
CORA, EA1/071/20, NCT04331106 |
Phase Not Applicable |
Recruiting |
1 |
18 Months |
5000 |
Andreas Ströhle, Prof.Dr., Antonia Bendau, M.Sc.Psych. |
2020-04-08 |
| COVID-19 Symptom Tracker |
Coronavirus disease 19 infection |
COVID-19 symptom tracker app alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King's College London |
Harvard TH Chan School of Public Health, Massachusetts General Hospital, Stanford University, Zoe Global Ltd |
US, UK |
2020-03-23 |
2022-03-23 |
COVID-19 SYMPTOM TRACKER, NCT04331509 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
10000000 |
Andrew Chan, Andrew T. Chan, MD, David A Drew, PhD, Tim D Spector, Victoria Vazquez |
2020-04-08 |
| QUARANTINE2020: Chloroquine as Antiviral Treatment in Coronavirus Infection 2020 |
Coronavirus disease 19 infection, SARS coronavirus infection |
chloroquine phosphate alone, standard of care alone, telemedical supervision alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wroclaw Medical University |
|
|
2020-04-06 |
2020-12-31 |
NCT04331600, QUARANTINE2020, QUARANTINE2020 |
Phase 4 Clinical |
Not yet recruiting |
0 |
8 Months |
400 |
Marta Duda-Sikula, MBA |
2020-04-06 |
| COVIPRIM: Accompanying monitoring of primary care in GP practices during the COVID-19 pandemic |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Graz, Paracelsus Medical University |
J.W. Goethe University Hospital |
Austria, Germany |
2020-04-03 |
|
20-619, COVIPRIM, DRKS00021231 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
2000 |
Ms. Dr. Dagmar Schaffler |
2020-04-06 |
| PrEP_COVID: Pre-exposure Prophylaxis With Hydroxychloroquine for High-risk Healthcare Workers During the COVID-19 Pandemic |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Barcelona Institute for Global Health |
Hospital Clinic of Barcelona, Laboratorios Rubio SA |
Spain |
2020-04-03 |
2020-10-30 |
NCT04331834, PREP_COVID, PrEP_COVID |
Phase 3 Clinical |
Recruiting |
1 |
6 Months |
440 |
Jose F Muñoz Gutiérrez, MD, PhD, Jose Munoz Gutierrez, MD, PhD, Marc Fernández Pardos, MSc |
2020-04-08 |
| Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last computed tomography (CT) criteria Scores From Sequential Chest CT |
Coronavirus disease 19 infection, Viral pneumonia |
computed tomography (CT) scoring criteria alone |
|
|
American Roentgen Ray Society |
|
China |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
25 |
Erpeng Cai, Guangbin Wang, Guoquan Huang, Jianwen Wang, Liangjie Lin, Shirong Li, Tao Gong, Xiaohu Li, Xinfu Guo, Yongqiang Yu |
2020-04-06 |
| DIIC19: Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 |
Coronavirus disease 19 infection |
standard treatment alone, Variable regimens including dexamethasone , hydroxychloroquine , interferon beta , intravenous immunoglobulin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Gorgan University of Medical Sciences |
|
Iran |
2020-04-18 |
2020-06-19 |
DIIC19, IR.GOUMS.REC.1399.004, IRCT20120225009124N4 |
Phase 2 Clinical |
Not yet recruiting |
1 |
2 Months |
105 |
Dr Nafiseh Abdolahi, Gholamreza Roshandel, Mohammadreza Honarvar |
2020-04-06 |
| The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak |
Coronavirus disease 19 infection, Viral pneumonia |
mindfulness exercise alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Asian Ancestry |
China European International Business School (CEIBS) |
|
China |
2020-02-20 |
2020-03-02 |
ChiCTR2000031272 |
Phase Not Applicable |
Completed |
1 |
|
110 |
Zheng Xue |
2020-04-07 |
| ACTION: Azithromycin for COVID-19 Treatment in Outpatients Nationwide |
Coronavirus disease 19 infection, SARS coronavirus infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California San Francisco |
|
US |
2020-04-01 |
2021-07-30 |
20-30504, ACTION, NCT04332107 |
Phase 3 Clinical |
Not yet recruiting |
0 |
15 Months |
2271 |
Catherine Cook, MPH, Catherine Oldenburg, ScD, MPH, Jessica M Brogdon, MPH, Thuy Doan, MD, PhD |
2020-04-09 |
| Hyperbaric Oxygen for COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
hyperbaric oxygen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
|
US |
2020-04-06 |
2020-07-31 |
NCT04332081, S20-00399 |
Phase 2 Clinical |
Recruiting |
0 |
3 Months |
40 |
David Lee, David Lee, MD, Scott Gorenstein |
2020-04-10 |
| C19REG: COVID-19 Public Image Registry |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
RAD-AID International |
BioClinica Inc, Google Inc |
US |
2020-03-30 |
2025-03-30 |
C19REG, C19REG, NCT04331860 |
Phase Not Applicable |
Recruiting |
0 |
60 Months |
500000 |
Dan Gebow, PhD, Daniel Mollura, MD, TBD TBD |
2020-04-06 |
| CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Pilot Study |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Del Rosario University |
CES University, Fundación Universitaria de Ciencias de la Salud, Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud |
Colombia |
2020-04-01 |
2020-12-31 |
ABN011-1, CP-COVID-19, NCT04332380 |
Phase 2 Clinical |
Not yet recruiting |
1 |
9 Months |
10 |
Adriana Rojas Villarraga, MD, Anha M Robledo Moreno, Bernardo Camacho Rodríguez, MD, MSc, Carlos E Perez, MD, Cristian A Ricaurte Perez, MSc, Diana M Monsalve Carmona, PhD, Gustavo A Salguero López, MD, PhD, Gustavo Quintero, MD, MSc, Heily C Ramírez Santana, MSc, PhD, Isaura P Torres Gómez, MSc, PhD, Jeser S Grass Guaqueta, MSc, Juan C Diaz Coronado, MD, MSc, Juan E Gallo Bonilla, MSc, PhD, Juan M Anaya Cabrera, MD, PhD, Luisa P Duarte Correales, Manuel E Rojas Quintana, MD, MSc, Oscar M Gómez Guzmán, MSc, PhD, Paula A Pedroza Rodríguez, Paula Gaviria, MSc, Ruben D Manrique Hernández, MSc, PhD, Ruben D Mantilla, MD, Sara Velez Gomez, Yeny Y Acosta Ampudia, PhD, Yhojan A Rodríguez Velandia, MD |
2020-04-06 |
| An adaptive, multicenter, randomized controlled clinical study to evaluate the safety and efficacy of IFX-1 in patients with severe COVID-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
IFX-1 alone |
Complement C5a factor inhibitor |
|
InflaRx GmbH |
|
Netherlands |
|
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-03 |
| A Study to Assess The Effect Of AP-1189 in the Treatment of Coronavirus Disease 19 Infection (COVID-19) Patients |
Coronavirus disease 19 infection |
AP-1189 alone |
Melanocortin MC1 receptor agonist, Melanocortin MC3 receptor agonist |
|
SynAct Pharma ApS |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-03 |
| COVID-Lambda: Mild COVID-19 Peginterferon Lambda |
Coronavirus disease 19 infection, SARS coronavirus infection |
peginterferon lambda-1a alone, standard of care treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Stanford University |
|
US |
2020-04-15 |
2022-05-31 |
55619, COVID-Lambda, NCT04331899 |
Phase 2 Clinical |
Not yet recruiting |
0 |
25 Months |
120 |
Julie Parsonnet, Upinder Singh |
2020-04-06 |
| A clinical trial of Veyonda in patients at risk of developing COVID-19 associated acute respiratory distress syndrome (ARDS) and multi-organ failure |
Coronavirus disease 19 infection, Multiple organ failure, Respiratory distress syndrome |
idronoxil (suppository, cancer), Noxopharm alone |
CASP8-FADD-like regulator inhibitor, Ecto NOX disulfide thiol exchanger 2 inhibitor, Sphingosine kinase inhibitor, Sphingosine-1-phosphate receptor-1 antagonist, Stimulator of interferon genes protein stimulator, Topoisomerase inhibitor, X-linked inhibitor of apoptosis protein inhibitor |
|
Noxopharm Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-06 |
| CORIMUNO-TOC: CORIMUNO-19 - Tocilizumab Trial - TOCI |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-03-31 |
2021-12-31 |
APHP200375-1, CORIMUNO-TOC, NCT04331808 |
Phase 2 Clinical |
Not yet recruiting |
0 |
21 Months |
240 |
Matthieu RESCHE-RIGON, MD PhD, Olivier HERMINE, MD-PhD |
2020-04-09 |
| Evaluation of Efficacy of Levamisole and Formoterol + Budesonide in Treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including budesonide + formoterol , hydoxychloroquine , levamisole , lopinavir + ritonavir |
HIV protease inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fasa University of Medical Sciences |
|
Iran |
2020-03-31 |
2020-05-20 |
97548, NCT04331470 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
1 Month |
30 |
Mojtaba Farjaam, MD, Siamack Afazeli, Siamack Afazeli, Pharm.D |
2020-04-06 |
| TOCOVID: Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , tocilizumab |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU |
Instituto de Salud Carlos III |
Spain |
2020-04-02 |
2020-10-31 |
IIBSP-COV-2020-23, NCT04332094, TOCOVID |
Phase 2 Clinical |
Recruiting |
1 |
6 Months |
276 |
Pere Domingo, MD, PhD |
2020-04-08 |
| GO2 PEEP: Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19 |
Coronavirus disease 19 infection |
GO2 PEEP Mouthpiece alone, PEEP therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Emory University |
|
US |
2020-04-30 |
2020-04-30 |
GO2 PEEP, NCT04331366, STUDY00000381 |
Phase Not Applicable |
Not yet recruiting |
0 |
|
5 |
Jeffrey Miller, MD |
2020-04-06 |
| Tofacitinib in SARS-CoV2 Pneumonia |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
tofacitinib alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universita Politecnica delle Marche |
|
Italy |
2020-04-10 |
2020-07-10 |
NCT04332042, TOFACOV |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
50 |
Armando Gabrielli, Armando Gabrielli, Prof, Giovanni Pomponio, Dr |
2020-04-06 |
| COVID CALL 15: Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patient's Triage |
Coronavirus disease 19 infection |
Moovcare alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Weprom |
Assistance Publique Hopitaux de Paris, DOCAPOSTE, Direction generale de l'offre de soins, Institut Pasteur |
France |
2020-03-17 |
2020-07-31 |
COVID CALL 15, NCT04331171, WP-2020-02 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
3000000 |
Fabrice DENIS, MD |
2020-04-07 |
| An Observational Study of Patients With Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
TARGET PharmaSolutions, Inc |
|
US |
2020-04-30 |
2021-03-31 |
NCT04331886, TARGET-COVID-19 |
Phase Not Applicable |
Not yet recruiting |
0 |
11 Months |
5000 |
Chuck Moser |
2020-04-10 |
| COVIDOSE: Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-04 |
2020-12-31 |
COVIDOSE, IRB20-0515, NCT04331795 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
50 |
Pankti Reid, MD, MPH |
2020-04-10 |
| INHASCO: Protective Role of Inhaled Steroids for Covid-19 Infection |
Coronavirus disease 19 infection |
Usual practice alone, budesonide + formoterol fumarate, AstraZeneca alone |
Beta 2 adrenoceptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-07-31 |
2020-001306-35, INHASCO, NCT04331054, P 200394 |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
436 |
Bruno CRESTANI, MD, PhD, Camille TAILLE, MD, PhD |
2020-04-06 |
| Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
People's hospital of Zhengzhou University |
|
China |
2020-03-12 |
2021-03-11 |
ChiCTR2000031176 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
100 |
Zhang Yi |
2020-04-07 |
| The efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 who have not responded to standard three-drug protocol |
Coronavirus disease 19 infection |
intravenous immunoglobulin alone, heparin plus intravenous immunoglobulin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-04 |
|
IR.MUMS.REC.1399.013, IRCT20200325046859N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
50 |
Dr Mohsen Tafaghodi, Rozita Khodashahi |
2020-04-06 |
| Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
human embryonic stem cells derived M cells (CAStem) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Asian Ancestry |
Chinese Academy of Sciences |
Beijing YouAn Hospital |
China |
2020-01-27 |
2020-12-31 |
CHINESEASZQ-006, NCT04331613 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
11 Months |
9 |
Hao Jie, Doctor, Wang Liu, Doctor, Zhou Qi, Doctor |
2020-04-07 |
| A Phase I, First in Human trial to Assess The Effect of OpenCorona, Karolinska Institutet In Treatment of Coronavirus disease 19 infection (COVID-19) Patient |
Coronavirus disease 19 infection |
SARS-CoV-2 vaccine (coronavirus COVID-19 infection), Karolinska Institutet alone |
|
|
Cobra Biologics Holding AB, The European Union |
|
Sweden |
|
|
|
Phase 1 Clinical |
Planned |
1 |
|
|
|
2020-04-07 |
| Nosocomial infection of coronavirus disease 2019 in the hospital without negative pressure chamber |
Coronavirus disease 19 infection, Infectious disease |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oita San-ai Medical Center |
|
Japan |
2020-04-02 |
|
UMIN000040033 |
Phase Not Applicable |
Recruiting |
1 |
|
300 |
Ryota Sagami |
2020-04-06 |
| A clinical study of trans sodium crocetinate in patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
trans sodium crocetinate (intravenous), Diffusion Pharmaceuticals alone |
|
|
Diffusion Pharmaceuticals LLC, University of Virginia |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Dr. Andrew Southerland |
2020-04-03 |
| COLCOV19-BX: COVID-19 Biological Samples Collection |
Coronavirus disease 19 infection, SARS coronavirus infection |
biological sampling alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Bordeaux |
|
France |
2020-04-02 |
2023-03-31 |
CHUBX 2020/11, COLCOV19-BX, NCT04332016 |
Phase Not Applicable |
Recruiting |
1 |
35 Months |
2000 |
Aurelie POUZET, Aurélie POUZET, Isabelle PELLEGRIN |
2020-04-07 |
| A proof-of-concept clinical trial to assess rhu-pGSN in the treatment of patients suffering from severe lung injury due to COVID-19 pneumonia |
Coronavirus disease 19 infection, Lung injury, Viral pneumonia |
gelsolin, BioAegis Therapeutics alone |
Actin antagonist |
|
BioAegis Therapeutics Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-06 |
| SARS-RAS: Renin-angiotensin System Inhibitors and COVID-19 |
Coronavirus disease 19 infection, Hypertension, SARS coronavirus infection |
RAS inhibitor therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Societa Italiana dell'Ipertensione Arteriosa |
|
Italy |
2020-03-10 |
2020-04-30 |
NCT04331574, SARS-RAS, SARS-RAS |
Phase 4 Clinical |
Recruiting |
1 |
1 Month |
2000 |
Claudio Borghi, MD, Claudio Ferri, MD, Guido Grassi, MD, Guido Iaccarino, MD, Guido Iaccarino, MD, PhD, Leonardo Sechi, MASSIMO VOLPE, MD, MariaLorenza Muiesan, MD, Marialorenza Muiesan |
2020-04-06 |
| Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
Standard of Care (SoC) alone, ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Incyte Corp, Novartis AG, The University Health Network |
|
Canada |
2020-04-06 |
2021-01-31 |
20-5315, NCT04331665, U-DEPLOY: RUX-COVID |
Phase 3 Clinical |
Not yet recruiting |
1 |
9 Months |
64 |
Steven Chan, M.D., Vikas Gupta, M.D. |
2020-04-08 |
| A clinical study to assess anti-androgen therapy in patients with COVID-19 infection |
Coronavirus disease 19 infection |
anti-androgen therapy alone |
|
|
Applied Biology Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Andy Goren, MD |
2020-04-04 |
| A clinical study to assess safety and efficacy of Lambda in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
peginterferon lambda-1a, Eiger BioPharmaceuticals alone |
Interferon receptor modulator, Interleukin-29 ligand |
|
Eiger BioPharmaceuticals Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-03 |
| Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients |
Coronavirus disease 19 infection |
convalescent plasma alone, plasma-derived immunoglobulin-enriched solution alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Ahvaz University of Medical Sciences |
|
Iran |
2020-03-24 |
|
IR.AJUMS.REC.1399.003, IRCT20200310046736N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
45 |
Mandana Puladzadeh, Mehdi Safdarian, Mohammad Badavi |
2020-04-06 |
| Treatment of patients with Coronavirus infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Septimeb alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-28 |
|
IR.TUMS.VCR.REC.1399.041, IRCT20200324046847N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
30 |
Dr. Mohammad Ali Sahraian, Hamidreza Khorram Khorshid, Minoo Mohraz |
2020-04-06 |
| COV-AID: Treatment of COVID-19 Patients With Anti-interleukin Drugs |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
anakinra alone, siltuximab alone, tocilizumab (intravenous), Roche/Chugai alone, Variable regimens including anakinra , siltuximab , tocilizumab (intravenous), Roche/Chugai |
Heat shock protein inhibitor, IL-6 receptor antagonist, IL-6 receptor modulator, Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Ziekenhuis Gent |
Belgium Health Care Knowledge Centre |
Belgium |
2020-04-30 |
2020-12-31 |
2020-001500-41, COV-AID, COV-AID, NCT04330638 |
Phase 3 Clinical |
Recruiting |
9 |
8 Months |
342 |
Anja Delporte, Bart Lambrecht, MD PhD, Bart Lambrecht, MD, PhD, CyrJean Yombi, MD PhD, Elisabeth Dewaele, HIRUZ CTU, Manu Malbrain, MD PhD, Maya Hites, MD PhD, Mesotten Dieter, MD PhD, Necsoi Coca, MD, Olivier Malaise, Sebastien Anguille, MD, Stefaan Vandecasteele, MD |
2020-04-09 |
| Comparison of the safety and efficacy of favipiravir and Kaletra in COVID-19 |
Coronavirus disease 19 infection |
routine care alone, favipiravir plus hydroxychloroquine |
RNA polymerase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-04-01 |
|
IR.BMSU.REC.1399.017, IR.IUMS.REC.1399.065, IRCT20200318046812N1 |
Phase 3 Clinical |
Recruiting |
11 |
|
324 |
Dr Behzad Einollahi, Dr Farhad Zamani, Dr Farzaneh Dastan, Dr Hossein Khalili, Dr Mansooreh Momen Heravi, Dr Mariam Qaraati, Dr Mohamad Memarian, Dr Mostafa Ghanee, Dr Ramin Sami, Dr Roya Qasemian, Dr Saeid Kalantari, Dr Shadi Ziaei, Dr. Mostafa Ghanei, Hossein Biganeh |
2020-04-06 |
| Effect of Licorice in COVID-19 |
Coronavirus disease 19 infection |
licorice extract syrup alone, standard treatment alone |
|
|
Artesh University of Medical Sciences |
|
Iran |
2020-03-23 |
|
IR.AJAUMS.REC.1398.267, IRCT20160316027081N1, LCT-19 |
Phase 3 Clinical |
Recruiting |
4 |
|
374 |
Dr. Ali Asgari, Dr. Amir Ezzati, Dr. Saeed Soleiman Meigooni, Dr. Saeed Soleiman-Meigooni, Dr.Mohammad Aminianfar, Dr.Saeed Soleiman-Meigooni, Ramin Hamidi Farahani |
2020-04-07 |
| Investigating the effectiveness of psychological interventions on mental health |
Coronavirus disease 19 infection, Psychiatric disorder |
Skype alone, WhatsApp alone, psychological counseling program alone |
|
|
Kerman University of Medical Sciences |
|
Iran |
2020-03-30 |
|
IR.KMU.REC.1398.737, IRCT20170611034452N11 |
Phase Not Applicable |
No longer recruiting |
1 |
|
60 |
Atefeh Ahmadi, Firoozeh Mirzaee, Masoome Ghazanfarpur |
2020-04-10 |
| A Trial of Ciclesonide in Adults With Mild COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca alone |
Glucocorticoid receptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Korea University Guro Hospital |
|
South Korea |
2020-04-01 |
2020-09-30 |
KUMC-COVID-19, NCT04330586 |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
141 |
Joon Young Song, MD, PhD, Woo Joo Kim, Professor |
2020-04-06 |
| A clinical study of first plasma therapy for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
convalescent serum therapy alone |
|
|
Houston Methodist |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
Eric Salazar, M.D., Ph.D |
2020-04-06 |
| CORONACION: Coronavirus ACEi/ARB Investigation |
Coronavirus disease 19 infection, Hypertension, SARS coronavirus infection |
amlodipine alone, bendroflumethiazide alone, chlorothiazide alone, chlorthalidone alone, diltiazem alone, felodipine alone, hydrochlorothiazide alone, indapamide alone, metolazone alone, nicardipine alone, nifedipine alone, nimodipine alone, nitrendipine alone, verapamil alone |
Calcium channel inhibitor, Calcium channel inhibitor L-type |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National University of Ireland Galway |
|
Ireland |
2020-03-30 |
2021-03-01 |
C.A. 2348, C.A. 2628, CORONACION, NCT04330300 |
Phase 4 Clinical |
Recruiting |
1 |
11 Months |
2414 |
Chee Hwui Liew, MSc, Darren Mylotte, MBBCh PhD, Faisal Sharif, MBBS PhD, John William McEvoy, MBBCh MHS |
2020-04-03 |
| A small field study to detect SARS-CoV-2 in unselected patient samples |
Coronavirus disease 19 infection |
pool testing of SARS-CoV-02 samples alone |
|
|
infektiologikum frankfurt |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
50 |
|
2020-04-02 |
| A validation study to test the efficacy of at-home COVID-19 test for the diagnosis of COVID19 infection |
Coronavirus disease 19 infection |
at-home COVID-19 test alone |
|
|
Care Access Research |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
500 |
|
2020-04-03 |
| A study of INOpulse inhaled nitric oxide system (iNO) in a patient with novel coronavirus disease (COVID-19) |
Coronavirus disease 19 infection |
nitric oxide (inhaled, INOpulse), Bellerophon alone |
|
|
Bellerophon Therapeutics LLC |
|
US |
2020-03-31 |
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-03 |
| HOPE: Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2 |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gangnam Severance Hospital |
|
South Korea |
2020-04-01 |
2022-03-30 |
3-2020-0036, HOPE, NCT04330144 |
Phase 3 Clinical |
Not yet recruiting |
1 |
23 Months |
2486 |
Yong Goo Song, Professor |
2020-04-03 |
| Evaluation of the effects of losartan in patients with Coronavirus disease 2019 |
Coronavirus disease 19 infection |
losartan alone, routine treatment protocol alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-03-31 |
|
IR.TBZMED.REC.1399.002, IRCT20180802040678N4 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Akbar Sharifi, Armin Sadeghi, Mohammad Samiei |
2020-04-06 |
| Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and/or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fundacion Instituto de Investigacion Marques de Valdecilla, IDIVAL |
|
|
2020-04-06 |
2020-11-06 |
ENCOVID-HIDROXICLOROQUINA, NCT04330495 |
Phase 4 Clinical |
Not yet recruiting |
0 |
7 Months |
800 |
Javier Crespo, MDPhD |
2020-04-06 |
| Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS) |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
BreathSpec alone, breath test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NHS Lothian |
|
|
2020-03-25 |
2020-03-25 |
282014, NCT04329507 |
Phase Not Applicable |
Not yet recruiting |
0 |
|
200 |
Michael Eddleston |
2020-04-03 |
| CATCO: Treatments for COVID-19: Canadian Arm of the Solidarity Trial |
Coronavirus disease 19 infection, SARS coronavirus infection |
lopinavir + ritonavir alone, standard of care alone |
HIV protease inhibitor |
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sunnybrook Health Sciences Centre |
AbbVie Inc |
Canada |
2020-03-18 |
2022-05-18 |
2114, CATCO, NCT04330690 |
Phase 2 Clinical |
No longer recruiting |
1 |
26 Months |
440 |
|
2020-04-08 |
| PERN-COVID-19: Clinical Characteristics and Outcomes of Pediatric COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University of Calgary |
|
Canada |
2020-03-18 |
2022-03-17 |
NCT04330261, PERN-COVID-19, REB18-0107-MOD9 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
12500 |
Anna Funk, PhD, Stephen Freedman, MD, Stephen Freedman, MDCM, MSc |
2020-04-03 |
| Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
standard care alone, azithromycin plus hydroxychloroquine sulfate |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
Prevent Senior Private Operadora de Saúde LTDA |
|
2020-04-03 |
2020-06-30 |
HIAPRE0320OR, NCT04329572 |
Phase 0 Clinical |
Not yet recruiting |
0 |
2 Months |
400 |
Alvaro Razuk Filho, Carla Morales Guerra Godoy, MD, PhD, Luciana Ferrara |
2020-04-03 |
| Alberta Hope COVID-19 for the Prevention of Severe COVID19 Disease |
Coronavirus disease 19 infection |
Plaquenil alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Calgary |
|
Canada |
2020-04-15 |
2020-08-31 |
ABCOV-01, ABCOV-01 version 1.1, NCT04329611 |
Phase 3 Clinical |
Not yet recruiting |
1 |
4 Months |
1660 |
Carol C Kenney, RN, CCRP, Dr. L Metz, MD, Dr. M Hill, MD, Dr. Michael Hill, Luanne M Metz, MD, FRCPC, Luanne Metz, MD, Michael D Hill, MD, Michael D Hill, MD.FRCPC |
2020-04-08 |
| Hydroxychloroquine for COVID-19 PEP |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine sulfate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Washington |
Bill & Melinda Gates Foundation, New York University |
US |
2020-03-31 |
2020-10-31 |
NCT04328961, STUDY00009750 |
Phase 1 Clinical |
Not yet recruiting |
0 |
7 Months |
2000 |
Anna Bershteyn, PhD, Christine Johnston, MD, Helen Stankiewicz Karita, MD, Justice Quame-Amaglo, Kirsten Hauge, Meighan Krows, Ruanne V. Barnabas, MBChB, DPhil |
2020-04-06 |
| HAHPS: Hydroxychloroquine versus Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Intermountain Health Care Inc |
University of Utah |
US |
2020-03-30 |
2021-12-31 |
1051355, HAHPS, NCT04329832 |
Phase 2 Clinical |
Recruiting |
0 |
21 Months |
300 |
David P Tomer, MS, Estelle Harris, MD, Samuel M Brown, MD MS, Valerie T Aston, MBA, Valerie T Aston, MD MS |
2020-04-10 |
| COVID-19 During Pregnancy: a Prospective, Observational, Cohort |
Coronavirus disease 19 infection, Pregnancy disorder, SARS coronavirus infection |
|
|
|
Máxima Medical Center |
|
Netherlands |
2020-03-27 |
2020-12-31 |
N20.035, NL8485 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
20 |
Marion Frenken |
2020-04-03 |
| A clinical trial of ALLTest Rapid Screen Antibody Test Cassette to evaluate the presence of the IgG and IgM antibodies to COVID-19 in whole blood, serum or plasma samples of COVID-19 patients |
Coronavirus disease 19 infection |
ALLTest Rapid Screen Antibody Test Cassette alone |
|
|
University of North Carolina |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-02 |
| A clinical study to detect COVID-19 using SeroFlash SARS-CoV-2 IgG/IgM Antibody Detection Kit |
Coronavirus disease 19 infection |
SeroFlash SARS-CoV-2 IgG/IgM Antibody Detection Kit alone |
|
|
Epigentek Group Inc |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
267 |
|
2020-04-02 |
| ECMOCARD: ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19) |
Coronavirus disease 19 infection, Hypoxia, Respiratory disease |
|
|
|
ISARIC, Monash University, The Prince Charles Hospital |
Extracorporeal Life Support Organization |
Taiwan, Japan, Vietnam, Thailand, US, South Korea, UK, Hong Kong, Indonesia, Singapore, Australia, Italy |
2020-03-05 |
2020-07-31 |
ACTRN12620000421932, ECMOCARD |
Phase Not Applicable |
Recruiting |
18 |
4 Months |
400 |
A / Prof Gianluigi Li Bassi, Prof John Fraser |
2020-04-03 |
| Mesenchymal Stem Cell therapy in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-03-28 |
2020-04-29 |
IR.BMSU.REC.1399.007, IRCT20200325046860N2 |
Phase 1 Clinical |
Recruiting |
1 |
1 Month |
5 |
Hasan Abolghasemi, Hasan abolghasemi |
2020-04-03 |
| ACORES-2: ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic |
Coronavirus disease 19 infection, SARS coronavirus infection |
discontinuation of RAS blocker therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
Hopital Universitaire de la Pitie Salpetriere |
France |
2020-04-30 |
2020-05-31 |
ACORES-2, APHP200409, NCT04329195 |
Phase 3 Clinical |
Not yet recruiting |
1 |
1 Month |
554 |
Gilles MONTALESCOT, MD, PhD, Mathieu KERNEIS, MD |
2020-04-07 |
| COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicenter, Observational Study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hepatopancreatobiliary Surgery Institute of Gansu Province |
Affiliated Hospital of Jiangsu University, Ankang City Central Hospital, Dalian Sixth People's Hospital, Guangxi Zhuang Autonomous Region Guangxi, Hubei University for Nationalities, Hubei University of Medicine, LanZhou University, Lishui Central Hospital, Renmin Hospital of Wuhan University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, The Third People’s Hospital of Shenzhen, The sixth people's hospital of Shenyang, Tianjin Infectious Disease Hospital, Wuhan Union Hospital, China, XINGTAI PEOPLE HOSPITAL |
China |
2020-03-30 |
2021-06-29 |
CHESS2002, NCT04329559 |
Phase Not Applicable |
Recruiting |
15 |
15 Months |
50 |
Bin Xiong, MD, Chuxiao Shao, MD, Dengxiang Liu, MD, Fengmei Wang, MD, Guo Zhang, MD, Hongguang Zhang, MD, Hongmei Yue, MD, Hua Yang, MD, Mingkai Chen, MD, Qing He, MD, Xiaodan Li, MD, Xiaolong Qi, Xiaolong Qi, MD, Yanna Liu, MD, Ye Gu, MD, Yong Zhang, MD, Zhengyan Wang, MD, Zicheng Jiang, MD |
2020-04-03 |
| SEB-COVID-19: SEB-COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Likas |
|
Malaysia |
2020-04-01 |
2020-12-31 |
54437, NMRR-20-595-54437, SEB-COVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
9 Months |
|
Dr Cheah Phee Kheng |
2020-04-03 |
| PATCH: Prevention And Treatment of COVID-19 With Hydroxychloroquine |
Coronavirus disease 19 infection, Viral pneumonia |
Plaqeunil alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Pennsylvania |
|
US |
2020-04-08 |
2021-12-01 |
842838, NCT04329923, PATCH |
Phase 2 Clinical |
Not yet recruiting |
0 |
19 Months |
400 |
Amelia Anderson, Ravi Amaravadi, MD |
2020-04-08 |
| A phase I trial of COVID-19 Vaccine, Ad26 SARS-CoV-2, for treatment of COVID-19 |
Coronavirus disease 19 infection |
Ad26 SARS-CoV-2 alone |
|
|
Johnson & Johnson |
|
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-02 |
| Impact of the Coronavirus (COVID-19) on Patients With Cancer |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-04-30 |
2022-05-31 |
55596, NCT04330521 |
Phase Not Applicable |
Not yet recruiting |
0 |
25 Months |
50 |
Manali Indravadan Patel |
2020-04-06 |
| Evaluation of the performance of novel rapid diagnostics for COVID-19 at point-of-care |
Coronavirus disease 19 infection |
POC tests alone, standard PCR test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Heidelberg |
|
Germany |
2020-04-05 |
|
DRKS00021220, S-180/2020 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
2000 |
Claudia Denkinger |
2020-04-03 |
| COVit: Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease |
Coronavirus disease 19 infection |
nicotinamide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitatsklinikum Schleswig-Holstein Campus Kiel |
|
Germany |
2020-04-06 |
|
A 107/20, COVit, DRKS00021214 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1300 |
Stefan Schreiber |
2020-04-03 |
| UKOSS: Pandemic COVID-19 in pregnancy |
Coronavirus disease 19 infection, Pregnancy disorder |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
University of Oxford |
National Institute for Health Research (NIHR) |
UK |
2020-01-24 |
2022-12-31 |
CPMS 14162, IRAS 112935, ISRCTN40092247 |
Phase Not Applicable |
Recruiting |
1 |
35 Months |
500 |
Prof Knight |
2020-04-07 |
| COVIDENCE: Longitudinal. Population-based, Observational Study of Coronavirus Disease in the UK Population |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Queen Mary University of London |
King's College London, London School of Hygiene and Tropical Medicine |
UK |
2020-04-02 |
2025-04-01 |
COVIDENCE, COVIDENCE, NCT04330599 |
Phase Not Applicable |
Not yet recruiting |
1 |
60 Months |
12000 |
Adrian Martineau, PhD, Hayley Holt, MSc |
2020-04-06 |
| Effects of High-dose Vitamin C on COVID-19 |
Coronavirus disease 19 infection |
standard treatment alone, vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-03 |
|
IR.TUMS.VCR.REC.1399.056, IRCT20190917044805N2 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Kourosh Sadeghi, Mohammad Ali Sahraian |
2020-04-07 |
| Effect of oral multi-herbal preparation on COVID-19 |
Coronavirus disease 19 infection |
routine treatment alone, capsule (dried extract of Hyssopus officinalis L., Punica granatum L.) plus decoction (Glycyrrhiza glabra L., Althaea officinalis L., Ziziphus jujuba Mill) |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-23 |
|
IR.TUMS.VCR.REC.1399.024, IRCT20180712040449N2 |
Phase 3 Clinical |
Recruiting |
3 |
|
68 |
Mehrdad Karimi, Mohammad Ali Sahraian, Samaneh Soleymani |
2020-04-07 |
| CORKUM: COVID-19 Registry of the LMU Hospital Munich |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Universitat Muenchen |
|
Germany |
2020-04-02 |
|
20-245, CORKUM, DRKS00021225 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1500 |
Johannes Hellmuth, Maximilian Münchhoff |
2020-04-03 |
| Efficacy and Safety of Siltuximab versus Corticosteroids in Hospitalized Patients With COVID19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
siltuximab alone |
Heat shock protein inhibitor, IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundacion Clinic per a la Recerca Biomédica |
|
Spain |
2020-04-01 |
2020-05-20 |
NCT04329650, SILCOR-COVID-19 |
Phase 2 Clinical |
Not yet recruiting |
2 |
1 Month |
100 |
Alex Soriano, MD, Felipe García, MD, Judit Pich Martínez, Clinical Research Manager |
2020-04-07 |
| A Phase II Study to Assess The Effect of anti-Covid vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency in the Treatment of Coronavirus disease 19 infection (Covid 19) Patient |
Coronavirus disease 19 infection |
prototype vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency alone |
|
|
Federal Medical Biological Agency |
|
|
2021-03-31 |
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-03 |
| A Phase I Study to Assess The Effect of anti-Covid vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency in the Treatment of Coronavirus disease 19 infection (Covid 19) Patient |
Coronavirus disease 19 infection |
prototype vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency alone |
|
|
Federal Medical Biological Agency |
|
|
2020-12-31 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-03 |
| Understanding COVID |
Coronavirus disease 19 infection, SARS coronavirus infection |
sampling alone |
|
|
Hopitaux Universitaires De Geneve |
University of Geneva |
Switzerland |
2020-03-27 |
2022-03-31 |
2020-00516, NCT04329546 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
250 |
Angela Huttner, MD, Claire-Anne Siegrist, MD |
2020-04-03 |
| TBA: A weapon against COVID-19: (Social) media and influencers |
Coronavirus disease 19 infection, SARS coronavirus infection |
social media and influencers alone |
|
|
Fred Foundation, Noaber Foundation |
|
Netherlands |
2020-03-16 |
2020-03-29 |
METc VUmc 2020.141, NL8483, TBA |
Phase Not Applicable |
Recruiting |
1 |
|
17000 |
Hamza Yousuf |
2020-04-06 |
| HB-MCO-Covid19: HB-MCO-Covid19 |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-01 |
2020-05-31 |
54511, HB-MCO-Covid19, NMRR-20-634-54511 |
Phase Not Applicable |
Status not specified |
1 |
2 Months |
|
Norbaidurah binti Ithnain |
2020-04-06 |
| A clinical study to assess bucillamine in the treatment of subjects with COVID-19 infection |
Coronavirus disease 19 infection |
repurposed formulation of bucillamine (gout/cystinuria/Wilson disease), Revive Therapeutics alone |
Xanthine oxidase inhibitor |
|
Revive Therapeutics Ltd |
|
South Korea, Japan |
|
|
|
Phase Not Applicable |
Planned |
2 |
|
|
|
2020-04-02 |
| Psychological effects of coronavirus disease 2019 (covid-19) amongst healthcare workers |
Coronavirus disease 19 infection, Psychiatric disorder |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-01 |
2020-05-31 |
54488, NMRR-20-633-54488 |
Phase Not Applicable |
Status not specified |
1 |
2 Months |
|
Mr Kamarul Zaman bin Salleh |
2020-04-02 |
| Phase III Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
FUJIFILM Toyama Chemical Co Ltd |
|
Japan |
2020-03-31 |
2020-06-30 |
JapicCTI-205238 |
Phase 3 Clinical |
Recruiting |
1 |
3 Months |
96 |
|
2020-04-02 |
| BCG-CORONA: Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine |
Coronavirus disease 19 infection, SARS coronavirus infection |
Bacillus Calmette-Guerin vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
Radboud University |
Netherlands |
2020-03-25 |
2020-12-25 |
BCG-CORONA, NCT04328441, NL73249.041.20, NL8477 |
Phase 3 Clinical |
Recruiting |
8 |
9 Months |
1500 |
Andreas Voss, MD, PhD, Angele Kerckhoffs, MD, PhD, Anna Roukens, MD, PhD, Bart Rijnders, MD, PhD, Jaap den Oever, MD, PhD, Karin Veerman, MD, Kees van Nieuwkoop, MD, PhD, MJM Bonten, Thijs ten Doesschate, MD, Thomas van der Vaart, MD, Wim Boersma, MD, PhD |
2020-04-06 |
| Clinical Characteristics and Prognostic Factors of Patients With COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai 10th People's Hospital |
Chibi People's Hospital |
China |
2020-01-30 |
2020-04-15 |
HBCBH-IEC-2020-101, NCT04328454 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
120 |
Ming Li, Ming Li, M.D. |
2020-04-02 |
| Prevention of COVID-19 infection in a medical institution and maintenance of medical system |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jichi Medical School |
|
Japan |
2020-04-01 |
|
UMIN000039997 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
3700 |
Hironori Yamamoto |
2020-04-02 |
| A clinical study of BOLD-100 in the treatment in patients of COVID-19 infection |
Coronavirus disease 19 infection |
IT-139 alone |
Grp78 calcium binding protein inhibitor, Jun N terminal kinase inhibitor, Transferrin modulator, p38 MAP kinase modulator |
|
Bold Therapeutics Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-02 |
| A study of hydroxychloroquine for the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
Sandoz International GmbH, US Department of Health and Human Services |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-02 |
| A phase I clinical study to assess immunogenicity of single-dose, intranasal AdCOVID in the treatment of COVID-19 |
Coronavirus disease 19 infection |
AdCOVID alone |
|
|
Altimmune Inc |
University of Alabama at Birmingham |
|
2020-09-30 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-06 |
| CRONOS: COVID-19 related obstetric and neonatal outcome study |
Coronavirus disease 19 infection |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Deutschen Gesellschaft für Perinatale Medizin e.V.c/o Conventus Congressmanagement & Marketing GmbH |
|
Germany |
2020-04-01 |
|
CRONOS, D 451/20, DRKS00021208 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
100 |
Ulrich Pecks |
2020-04-03 |
| A compassionate use program to assess PLX cell therapy in the treatment of patients with coronavirus infection (COVID-19) |
Cardiac failure, Coronavirus disease 19 infection, Inflammatory disease, Renal failure, Respiratory distress syndrome |
PLX stem cell therapy, Pluristem/Cha Bio & Diostech alone |
IL-6 receptor agonist |
|
Pluristem Therapeutics Inc |
Charite University |
Israel |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
7 |
|
2020-04-09 |
| Phase II clinical trial of antroquinonol to treat Covid-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
antroquinonol alone |
MEK-1 protein kinase inhibitor, Ras gene inhibitor |
|
Golden Biotechnology Corp |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-02 |
| COVID-19-HBO: Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
hyperbaric oxygen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Karolinska University Hospital |
Blekingesjukhuset, Karlskrona, Karolinska Institutet, University of California San Diego |
Sweden |
2020-04-25 |
2022-12-31 |
2020-001349-37, 4-1199/2020, COVID-19-HBO, K-2020-2611, NCT04327505 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
32 Months |
200 |
Anders Kjellberg, MD, Peter Lindholm, MD, PhD |
2020-04-02 |
| CODEX: COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III |
Adult respiratory distress syndrome, Coronavirus disease 19 infection |
dexamethasone alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sociedade Beneficiente De Senhoras Hospital Sirio Libanes |
Ache Laboratorios Farmaceuticos SA, Brazilian Research In Intensive Care Network, Hospital do Coracao, Sociedade Beneficente Israelita Brasileira Hospital Albert Einsten |
Brazil |
2020-04-01 |
2020-08-30 |
CODEX, CODEX_V1.1, NCT04327401 |
Phase 3 Clinical |
Not yet recruiting |
21 |
4 Months |
290 |
Adrian PM Kormann, MD, Bruno M Tomazini, MD, Bruno Tomazini, M.D, Carla MG Godoy, MD, Cintia MC Grion, MD, Cristina P Amendola, MD, Eduardo LV Costa, PhD, Eraldo A Lucio, MD, Felipe Dal Pizzol, MD, Fernando C Neuenschwander, MD, Fernando G Zampieri, MD, Flavia R Machado, MD, Frederico C DallOrto, MD, Israel S Maia, MD, Jorge LR Paranhos, MD, Luciano CP Azevedo, PhD, Luciano Cesar Pontes Azevedo, Ph.D, Luiz F. L. Reis, Ph.D., Marco AV Guedes, MD, Maria SM Paiva, MD, Mauro E Hernandes, MD, Otávio Berwanger, PhD, Rodrigo C Figueiredo, MD, Rodrigo S Biondi, MD, Viviane C Veiga, MD, Wilson J Lovato, MD |
2020-04-02 |
| A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Peking University Third Hospital |
|
China |
2020-03-28 |
2020-05-29 |
ChiCTR2000031376 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
600 |
Chunyang Wang, Dongyang Liu |
2020-04-06 |
| A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research |
Coronavirus disease 19 infection, SARS coronavirus infection |
Foam nasal swabs alone, Polyester nasal swabs alone |
|
|
UnitedHealth Group Inc |
Bill & Melinda Gates Foundation, Mayo Clinic Foundation, PATH (US) |
US |
2020-03-25 |
2020-04-10 |
20-002, NCT04327804 |
Phase Not Applicable |
Recruiting |
0 |
|
120 |
Ethan Berke, Yuan Po Tu, MD, Yuan Tu |
2020-04-02 |
| The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
focused lung ultrasound alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aarhus University |
|
Denmark |
2020-03-14 |
2020-05-15 |
COVID-FLUS, NCT04327674 |
Phase Not Applicable |
Recruiting |
2 |
2 Months |
375 |
Jesper Weile, Søren H Skaarup, Søren Helbo SH Skaarup, MD |
2020-04-02 |
| Mindfulness During COVID-19 |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection |
Mindfulness session(s) alone |
|
Healthy volunteers accepted |
Wake Forest University Health Sciences, US |
|
US |
2020-03-22 |
2020-12-31 |
IRB00064587, NCT04319445 |
Phase Not Applicable |
Recruiting |
0 |
9 Months |
200 |
Rebecca E Wells, MD, MPH, Rebecca Wells, MD |
2020-04-09 |
| COV19-PLASMA: Hyperimmune Plasma for Critical Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection |
hyperimmune plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fondazione IRCCS Policlinico San Matteo |
ASST Cremona, Carlo Poma Hospital, Lodi Hospital |
Italy |
2020-03-17 |
2020-05-31 |
COV19-PLASMA, IRCCSSANMATTEOH, NCT04321421 |
Phase 2 Clinical |
No longer recruiting |
1 |
2 Months |
49 |
Cesare Perotti, MD |
2020-04-02 |
| PROACTIVE-19: Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary |
Coronavirus disease 19 infection, Heart arrhythmia, Respiratory distress syndrome, Shock |
Personalized health education alone |
|
Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Of Pécs |
|
Hungary |
2020-04-01 |
2021-08-21 |
IV/2428- 2 /2020/EKU, NCT04321928, PROACTIVE-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
7576 |
Bálint Erőss, MD, Péter Hegyi, MD, PhD, DSc |
2020-04-02 |
| DISPOSE: DIgital Online SuPport for COVID-19 StrEss |
Acute stress disorder, Coronavirus disease 19 infection, Depression, Generalized anxiety disorder |
Guided online support program alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
International Psychoanalytic University |
Selfapy GmbH |
Germany |
2020-04-30 |
2021-12-31 |
DISPOSE, IPUB_2020_01, NCT04324190 |
Phase Not Applicable |
Not yet recruiting |
1 |
20 Months |
600 |
Gunther Meinlschmidt, Prof. Dr., Kati Bermbach |
2020-04-08 |
| Covid: Effectiveness of Hydroxychloroquine in Covid-19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Ayub Medical College |
|
Pakistan |
2020-03-28 |
2020-06-28 |
ATH/CT101/22/3, Covid, NCT04328272 |
Phase 3 Clinical |
Not yet recruiting |
2 |
3 Months |
75 |
Muhammad J Khan, MBBS, Prof. Dr. Umar Farooq, Dean, Umar Farooq, PhD, Umer Farooq, PhD |
2020-04-06 |
| Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study |
Anxiety disorder, Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-03-26 |
2020-04-28 |
NCT04327531, TURKISHCOVID19 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
200 |
Pınar Yalcin bahat |
2020-04-03 |
| COVID-19 Rapid Test Kit Use in Screening Center |
Coronavirus disease 19 infection |
COVID-19 IgG/IgM Rapid Test kit alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sabah Women and Children's Hospital |
|
Malaysia |
2020-04-10 |
2020-09-30 |
NMRR-20-640-54491 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
|
Darlene Flavius Ongkili, Dr Cheah Phee Kheng |
2020-04-02 |
| CORONA: Hydroxy Chloroquine, in open-labelled, Randomized intervention for prevention of new infection and adverse outcomes following COVID-19 infection -A Tertiary Hospital based study |
Coronavirus disease 19 infection |
hydroxychloroquine sulphate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aster Malabar Institute of Medical Sciences |
|
India |
2020-04-08 |
|
CORONA, CTRI/2020/03/024402 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
500 |
Dr Remesh Bhasi |
2020-04-02 |
| COVIDMED: Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine sulfate alone, lopinavir + ritonavir alone, losartan alone, standard care alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bassett Healthcare |
|
US |
2020-04-06 |
2021-04-01 |
1581969, COVIDMED, NCT04328012 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
11 Months |
4000 |
Daniel Freilich, MD, Jennifer Victory, RN, Kristin Pullyblank, RN, MS, daniel Freilich, MD, daniel freilich, MD |
2020-04-09 |
| Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
functional magnetic resonance imaging technology alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-04-01 |
2021-04-04 |
ChiCTR2000031356 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
600 |
Wenliang Fan |
2020-04-02 |
| COVIDAXIS: Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Saint Etienne |
Institut Pasteur |
France |
2020-03-30 |
2020-11-30 |
2020-001188-96, 20PH061, COVIDAXIS, NCT04328285 |
Phase 3 Clinical |
Not yet recruiting |
3 |
8 Months |
1200 |
Amandine GAGNEUX-BRUNON, Arnauld Garcin, Bernard TARDY, Bruno Hoen, MD, PhD, Elisabeth BOTELHO-NEVERS, Elisabeth Botelho-Nevers, MD, PhD, Isabelle PELLIER, Marc-Antoine CUSTAUD, Nathalie Jolly, Sandrine ACCASSAT, Vincent DUBEE, Xavier DUVAL |
2020-04-02 |
| A phase I clinical treatment to evaluate the safety and efficacy of COVID-19 vaccine for the potential prevention of coronavirus infection COVID-19 |
Coronavirus disease 19 infection |
SARS-CoV-2 recombinant adenoviral vector vaccine (AdVac/PER.C6, COVID-19), Johnson & Johnson/Biomedical Advanced Research and Development Authority/Beth Israel Deaconess Medical Center alone |
|
|
Beth Israel Deaconess Medical Center, Johnson & Johnson |
|
|
2020-09-30 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-02 |
| COVID-19 HOPE Trial: Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation of Pulmonary Function |
Coronavirus disease 19 infection |
N-acetylcysteine plus heparin |
|
|
Atossa Genetics Inc |
|
|
|
|
COVID-19 HOPE Trial |
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
Dr Steven Quay |
2020-04-02 |
| A clinical study of CytoSorb for the treatment of in patients infected with COVID-19 |
Coronavirus disease 19 infection |
CytoSorb alone |
|
|
CytoSorbents Corp |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-06 |
| Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis |
Coronavirus disease 19 infection, Fever, Influenza virus infection |
medical records based analysis alone |
|
|
Chinese PLA General Hospital |
|
China |
2020-04-01 |
2020-05-31 |
ChiCTR2000031366 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
5000 |
Bin Liu, Kun Xiao |
2020-04-02 |
| BRACE: BCG Vaccination to Protect Healthcare Workers Against COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
BCG vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Murdoch Childrens Research Institute |
Royal Childrens Hospital, Melbourne |
Australia |
2020-03-30 |
2022-03-30 |
62586, BRACE, NCT04327206 |
Phase 3 Clinical |
Recruiting |
9 |
24 Months |
4170 |
A/Prof Tony Korman, MBBS FRACP, Dr Laurens Manning, MBChB PhD, Dr Nicole Tan, MBBS FANZCA, Kaya Gardiner, Prof Michaela Lucas, MD PhD, Prof Nigel Curtis, Prof Nigel Curtis, MBBS PhD, Prof Peter Richmond, MBBS FRACP |
2020-04-08 |
| To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients |
Coronavirus disease 19 infection, Viral pneumonia |
LC-MS-based metabolomic analysis alone, TMT-based quantitative proteomics alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Westlake University |
|
China |
|
|
ChiCTR2000031365 |
Phase 0 Clinical |
Recruiting |
1 |
|
|
Bo Shen, Haixiao Chen |
2020-04-02 |
| COLCOVID: The ECLA PHRI COLCOVID Trial |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
colchicine alone, local standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Estudios Clinicos Latino America |
Population Health and Research Institute, Trivandrum, Kerala, india |
|
2020-03-31 |
2020-06-30 |
COLCOVID, COLCOVID VERSION1.2, NCT04328480 |
Phase 3 Clinical |
Not yet recruiting |
0 |
3 Months |
2500 |
Andres Orlandini, MD, Rafael Diaz, MD |
2020-04-02 |
| TPB-COVID-19 |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
Ministry of Health, Malaysia |
Malaysia |
2020-04-01 |
2020-06-30 |
54505, NMRR-20-632-54505 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
|
MUHAMMAD RIDZWAN BIN ZAKARIA |
2020-04-03 |
| VICO: The Vietnam Chloroquine Treatment on COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
chloroquine phosphate alone, standard of care therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oxford University Clinical Research Unit, Vietnam |
Can Gio COVID Hospital, Cho Ray Hospital, Cu Chi COVID Hospital, Department of Health, Ho Chi Minh city, Ministry of Health and Welfare, Vietnam, National Institute for Infectious And Tropical Diseases, The Hospital for Tropical Diseases |
Vietnam |
2020-04-01 |
2022-04-01 |
COVID, NCT04328493, VICO |
Phase 2 Clinical |
Not yet recruiting |
5 |
24 Months |
250 |
Dung Nguyen, PhD. MD, Guy Thwaites, PhD. MD, Hung Le Quoc, MD, Jeremy Day, PhD. MD, Manh Hung Le, Nguyen Huy Man Dinh, Dr, Phuong Thao Huynh, Phar, Thach N Pham, PhD. MD, Thach N Pham, PhD.MD, Thanh Dung Nguyen, Thanh Dung Nguyen, Dr, Thanh Phong Nguyen, Dr, Thanh Truong Nguyen, Dr, Van Vinh Chau Nguyen, Dr, Van Vinh Chau Nguyen, PhD, MD |
2020-04-03 |
| Audio Data Collection for Identification and Classification of Coughing |
Allergic rhinitis, Asthma, Chronic obstructive pulmonary disease, Common cold, Coronavirus disease 19 infection, Coronavirus infection, Cough, Influenza virus infection, Respiratory tract infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HealthMode Inc. |
|
US |
2020-03-25 |
2022-09-25 |
HM070102, NCT04326309 |
Phase Not Applicable |
Recruiting |
0 |
30 Months |
1000 |
Daniel R Karlin, MD, MA |
2020-04-02 |
| COntAGIouS: In-depth Immunological Investigation of COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
Patient sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitaire Ziekenhuizen Leuven |
|
|
2020-03-27 |
2020-09-30 |
CONTAGIOUS, COntAGIouS, NCT04327570 |
Phase Not Applicable |
Not yet recruiting |
0 |
6 Months |
100 |
Joost Wauters, MD PhD |
2020-04-02 |
| A randomized trial to evaluate the effectiveness and safety of COVID-19 convalescent plasma for both treatment of COVID-19 positive patients at all stages of disease progression as well as prevention of infection after high-risk exposure |
Coronavirus disease 19 infection |
COVID-19 convalescent plasma alone |
|
Healthy volunteers accepted |
Johns Hopkins University |
Albert Einstein College of Medicine, Bloomberg Philanthropies, Mayo Clinic, Minnesota, Stanford University Medical Center |
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Arturo Casadevall |
2020-04-02 |
| A Phase I/II safety trial of ST-266 for Treatment of the Severe Inflammatory cytokine storm Response Associated with COVID-19 |
Coronavirus disease 19 infection |
ST-266 alone |
|
|
Noveome Biotherapeutics Inc |
|
|
2020-12-31 |
|
|
Phase 1/Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-07 |
| Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection |
Cardiovascular disease, Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitatsklinikum Essen |
|
Germany |
2020-03-26 |
2026-03-25 |
20-9213-BO, NCT04327479 |
Phase Not Applicable |
Recruiting |
1 |
72 Months |
6000 |
Amir A Mahabadi, MD, Matthias Totzeck, MD, Tienush Rassaf, MD |
2020-04-03 |
| EDPREPA: Covid-19 preparedness among Emergency Departments: a cross-sectional study in France |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universite Paris Est |
|
France |
2020-03-24 |
|
EDPREPA, TCTR20200324001 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
650 |
Enrique Casalino |
2020-04-09 |
| Pre-exposure Prophylaxis for SARS-coronavirus-2 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Minnesota |
|
US |
2020-04-06 |
2020-08-31 |
NCT04328467, RAJASINGHAM, STUDY00009414 |
Phase 3 Clinical |
Recruiting |
0 |
4 Months |
3500 |
Radha Rajasingham (Please Email), MD, Radha Rajasingham, MD, Sarah Lofgren |
2020-04-11 |
| Antivirals for COVID-19: Covid-19: A randomized, open-label, adaptive, proof-of-concept clinical trial of new antiviral drug candidates against SARS-CoV-2 |
Coronavirus disease 19 infection |
itraconazole alone |
Lanosterol-14 demethylase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
UZ Leuven-University Hospitals |
|
Belgium |
2020-04-26 |
|
2020-001243-15, Antivirals for COVID-19, S63874 |
Phase 2 Clinical |
No longer recruiting |
1 |
|
200 |
Laurens Liesenborghs |
2020-04-02 |
| N-ReCOVID 19: A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) |
Coronavirus disease 19 infection |
Plaquenil plus remdesivir |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oslo University Hospital |
|
Norway |
2020-03-26 |
|
2020-000982-18, N-ReCOVID 19, WHO-NOR-COVID-19 |
Phase 3 Clinical |
No longer recruiting |
1 |
|
443 |
Sect. Clin. Imm. & Infect. Diseases |
2020-04-02 |
| A medical records based study for novel coronavirus pneumonia (COVID-19) patients undergoing endotracheal intubation |
Coronavirus disease 19 infection, Viral pneumonia |
endotracheal intubation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-04 |
2020-03-12 |
ChiCTR2000031439 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
59 |
Hongbo Zheng, Li Wan |
2020-04-03 |
| The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of Immunological, biochemical, and Metabolic Parameters: a Retrospective, Observational Study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000031429 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
2000 |
Ji-Xin Zhong, Lingli Dong |
2020-04-03 |
| Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial |
Coronavirus disease 19 infection |
|
|
|
First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) |
Taizhou Zecheng Biotechnology Co. Ltd. |
China |
2020-03-01 |
2020-03-25 |
ChiCTR2000031427 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
200 |
Pang Jifeng, Xiang Changgang |
2020-04-02 |
| COVID-19-FR: COVID-19 Registry Freiburg |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Heart Centre Freiburg-Bad Krozingen |
|
Germany |
2020-03-26 |
|
153/20, COVID-19-FR, DRKS00021206 |
Phase Not Applicable |
Recruiting |
1 |
|
400 |
Achim Lother, Mr. Prof. Dr. Daniel Dürschmied |
2020-04-02 |
| Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan Asia Heart Hospital |
|
China |
2020-02-05 |
2020-10-04 |
ChiCTR2000031428 |
Phase Not Applicable |
No longer recruiting |
1 |
8 Months |
500 |
Qingkun Fan, Zejin Liu |
2020-04-02 |
| Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis |
Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia |
Conventional treatment regimen alone, human umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
302 Military Hospital of China |
|
China |
2020-03-14 |
2021-12-31 |
ChiCTR2000031430 |
Phase 2 Clinical |
Recruiting |
4 |
21 Months |
200 |
Fu-Sheng Wang, Lei Shi |
2020-04-03 |
| A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adults |
Coronavirus disease 19 infection, Viral pneumonia |
microRNA2911 plasmid alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Nanjing Drum Tower Hospital, Nanjing University |
|
China |
2020-04-01 |
2020-08-31 |
ChiCTR2000031432 |
Phase 1 Clinical |
Not yet recruiting |
1 |
5 Months |
15 |
Chenyu Zhang, Yanbo Wang |
2020-04-06 |
| Treating COVID-19 With a Bidirectional Oxygenation Valve |
Coronavirus disease 19 infection |
bidirectional oxygenation mouthpiece alone, non-rebreather face mask alone, oxygen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
TMC HealthCare |
PEEP Medical, LLC |
US |
2020-03-27 |
2020-06-01 |
COVID19PEEP2020, GO2 PEEP Study, NCT04326452 |
Phase Not Applicable |
Recruiting |
0 |
2 Months |
15 |
Ashvinder Khanna, MD, Jeffrey Miller, MD, Joseph Levitt, MD, Matthew Weiner, MD, Natalia Elias Calles, MPH, Sonya Mathewson, RN |
2020-04-02 |
| PREDICT: Prediction of Diagnosed Covid-19 Infection in IUC Patients |
Coronavirus disease 19 infection, Respiratory tract infection |
PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-03-30 |
2021-09-30 |
2020-A00763-36, 2020_20, NCT04327180, PREDICT |
Phase Not Applicable |
Recruiting |
1 |
18 Months |
500 |
Julien Goutay, MD, Julien Poissy, MD,PhD, Martine Remy-Jardin, MD,PhD, Morgan Caplan, MD, Philippe Mathurin, MD,PhD, Sophie Susen, MD,PhD |
2020-04-07 |
| Efficacy of Tumor Necrosis Factor-Alpha Inhibitor in COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
Variable regimens including etanercept biosimilar, AryoGen , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor, TNF antagonist, TNF binding agent, Type II TNF receptor modulator |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-27 |
|
IR.TUMS.VCR.REC.1399.034, IRCT20200312046749N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
80 |
Mohammad Ali Sahraian, Raheleh Assari, Vahid Ziaee |
2020-04-02 |
| GARM-COVID19: Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection |
Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome |
Centricyte 1000 (Healeon Medical) alone, Microcannula Closed System (Tulip Med) alone, autologous cellular stromal vascular fraction alone, lipoaspiration alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HEALEON MEDICAL INC |
Robert W. Alexander, MD |
US |
2020-03-25 |
2021-12-31 |
GARM COVID19, GARM-COVID19, NCT04326036 |
Phase 0 Clinical |
Recruiting |
0 |
21 Months |
10 |
Robert W Alexander, MD |
2020-04-02 |
| EC-COVID-RCT: Early CPAP in COVID Patients With Respiratory Failure |
Coronavirus disease 19 infection, Respiratory failure |
continuous positive airway pressure ventilation alone, current clinical practice alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Istituto di Ricerche Farmacologiche Mario Negri |
|
Italy |
2020-04-06 |
2020-11-09 |
EC-COVID-RCT, EC-COVID-RCT-FENICE, NCT04326075 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
900 |
Elena Garbero, M.Sc., Guido Bertolini, MD |
2020-04-02 |
| Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong |
Coronavirus disease 19 infection, Viral pneumonia |
laboratory monitoring alone, nasopharyngeal aspiration alone, sputum collection alone, swab flocking alone, tracheal aspiration alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
|
Hong Kong |
2020-02-24 |
2021-06-17 |
COVID-19 STUDY 2020.076, NCT04325919 |
Phase Not Applicable |
Recruiting |
1 |
15 Months |
170 |
Paul CHAN, Paul KS Chan |
2020-04-03 |
| Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Prone positioning alone, high flow nasal cannula alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rush University Medical Center |
Medical College of Wisconsin |
US |
2020-04-06 |
2020-06-30 |
COVID-19-HFNC+PP, NCT04325906 |
Phase Not Applicable |
Not yet recruiting |
0 |
2 Months |
346 |
David Vines, PhD, Jennifer Peterson, PhD, Jie Li, PhD, Kellianne Fleming, MS, Rahul Nanchal, MD, Sara Mirza, MD, Victoria Arinta, MS |
2020-04-04 |
| Psychological distress of the COVID-19 pandemic: A comparison between cancer patients and healthy controls |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinik fur Psychosomatische Medizin und Psychotherapie, Univeristat Duisburg-Essen |
|
Germany |
2020-03-16 |
|
19-8834-BO, DRKS00021164 |
Phase Not Applicable |
Recruiting |
1 |
|
220 |
Venja Musche |
2020-04-02 |
| COVIDx: Evaluation of Novel Diagnostic Tests for 2019-nCOV |
Coronavirus disease 19 infection |
CT scan alone, SAMBA II device alone, chest X-ray alone, polymerase chain reaction alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cambridge University Hospitals NHS Foundation Trust |
|
UK |
2020-04-08 |
2021-10-07 |
COVIDX, COVIDx, NCT04326387 |
Phase Not Applicable |
Not yet recruiting |
1 |
18 Months |
200 |
Anne-Laure Vallier, PhD., Ravindra Prof. Gupta, BMBCh, Richard D. Skells, BSc. |
2020-04-01 |
| Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19 |
Coronavirus disease 19 infection |
Power-breath device alone, Winner-flow device alone, expiratory training alone, inspiratory training alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad Complutense de Madrid |
|
Spain |
2020-04-26 |
2020-10-12 |
COVID_ISCIII 20/265-E_BS, NCT04326114 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
240 |
César Calvo Lobo, César Calvo Lobo, PhD |
2020-03-31 |
| GRECCO-19: The GReek Study in the Effects of Colchicine in COVID-19 complications prevention |
Coronavirus disease 19 infection, Myocardial infarction, SARS coronavirus infection, Viral pneumonia |
Colchicine alone, Standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ELPEN Pharmaceutical Co Inc, Hellenic Society of Rhythmology, National and Kapodistrian University of Athens |
|
Greece |
2020-04-06 |
2020-09-30 |
2020-001455-40, 906295542, GRECCO-19, NCT04326790 |
Phase 2 Clinical |
Recruiting |
1 |
5 Months |
180 |
Hellenic Society of Rhythmology, Spyridon Deftereos |
2020-04-07 |
| CoV-Ak-Test: Development of a test to measure the immune response in patients with Covid-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
SARS-CoV-2 antibody ELISA alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institut für Virologie, Universitätsklinikum Leipzig |
|
Germany |
2020-03-30 |
|
124/20-ek, CoV-Ak-Test, DRKS00021166 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
15 |
Christian Jassoy |
2020-04-02 |
| Clinical study of recombinant protein subunit vaccine (COVID-19) |
Coronavirus disease 19 infection |
recombinant protein subunit vaccine (COVID-19), SK Bioscience alone |
|
|
SK Bioscience |
|
|
2020-09-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-02 |
| A Phase I Study to Assess the Effect of Gimsilumab in The Treatment of COVID-19 Associated With Acute Respiratory Distress Syndrome (ARDS) Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
gimsilumab alone |
GM-CSF ligand inhibitor |
|
Altasciences Company Inc, Roivant Sciences Ltd |
|
|
|
2020-03-27 |
|
Phase 1 Clinical |
Completed |
0 |
|
|
|
2020-03-31 |
| Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020 |
Coronavirus disease 19 infection, Viral pneumonia |
beta-blocker therapy alone, calcium channel blocker therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-05 |
|
IR.TUMS.VCR.REC.1399.028, IRCT20151113025025N3 |
Phase 4 Clinical |
Recruiting |
1 |
|
60 |
Maryam Bahreini, Mohammad Ali Sahraian |
2020-04-06 |
| Convalescent Plasma therapy for COVID-19 Patients |
Coronavirus disease 19 infection |
convalescent plasma alone, current treatment alone |
|
|
Darman Ara, Iran Blood Transfusion Organization |
|
Iran |
2020-03-15 |
|
IR.BMSU.REC.1398.434, IR.TMI.REC.1398.031, IRCT20200325046860N1 |
Phase 2 Clinical |
Recruiting |
4 |
|
200 |
Abbas Ali Imani Fooladi, Dr Ehsan Sharifipour, Dr Hassan Abolghasemi, Dr Masoud Reza Sohrabi, Dr. Payam Tabarsi, Hassan Abolghasemi |
2020-04-02 |
| The effect of naproxen on the healing process of patients with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including chloroquine phosphate , hydroxychloroquine sulfate , lopinavir + ritonavir , naproxen |
HIV protease inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Abadan School of Medical Sciences |
|
Iran |
2020-03-28 |
|
IR.ABADANUMS.REC.1398.115, IRCT20200324046850N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Sara Mobarak |
2020-04-02 |
| Effect of Benson Relaxation on Quality of Life and job stress in nurses |
Acute stress disorder, Coronavirus disease 19 infection |
Benson relaxation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Sabzevar University of Medical Sciences |
|
Iran |
2020-02-28 |
|
IR.MEDSAB.REC.1398.141, IRCT20131113015393N6 |
Phase Not Applicable |
Recruiting |
1 |
|
62 |
Ali Taj Abadi, Narjes Heshmati Far, Narjes Heshmatifar |
2020-04-02 |
| Active Monitoring And Determinants of Incidence Infection of COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundacion Teofilo Hernando |
|
Spain |
2020-03-23 |
2020-09-20 |
AMADIICH, NCT04326400 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
1000 |
Artuto García, Joan Soriano, MD, PhD, Marcos Maroto |
2020-04-02 |
| A single-center, open-label, randomized, and controlled trial of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed COVID-19 patients |
Coronavirus disease 19 infection |
darunavir + cobicistat (fixed dose, HIV infection), Janssen R&D/ Gilead alone |
Cytochrome P450 3 inhibitor, HIV-1 protease inhibitor |
|
Johnson & Johnson |
|
China |
|
|
|
Phase 2 Clinical |
Status not specified |
1 |
|
30 |
|
2020-04-07 |
| Effect of metformin in COVID-19 mortality rate and symptom improvement |
Coronavirus disease 19 infection, Viral pneumonia |
metformin hydrochloride alone, standard regimen therapy alone |
AMP activated protein kinase stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-03-20 |
|
IR.TBZMED.REC.1398.1310, IRCT20160310026998N11 |
Phase 3 Clinical |
Recruiting |
1 |
|
200 |
Saba Ghaffary |
2020-04-06 |
| Effect of vitamin A in patients with COVID-19 |
Coronavirus disease 19 infection |
vitamin A alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-03 |
|
IR.TBZMED.REC.1398.1305, IRCT20170117032004N3 |
Phase 2 Clinical |
Recruiting |
1 |
|
30 |
Dr. Mohammad Sameiee, Zeinab Niknaiz, Zeinab Nikniaz |
2020-04-06 |
| Sarilumab COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
sarilumab alone, supportive care alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sanofi SA, Sanofi-Aventis Research and Development |
Regeneron Pharmaceuticals Inc |
Russian Federation, Italy, France, Germany, Canada, Spain |
2020-03-29 |
2021-06-30 |
2020-001162-12, EFC16844, NCT04327388, U1111-1249-6021 |
Phase 2/Phase 3 Clinical |
Recruiting |
16 |
15 Months |
300 |
Clinical Sciences & Operations |
2020-04-10 |
| Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia |
Coronavirus disease 19 infection |
Variable regimens including Plaquenil , vitamin A , vitamin C , vitamin D , zinc |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istinye Universitesi |
|
Turkey |
2020-03-20 |
2020-09-01 |
2020-2/1, NCT04326725 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
80 |
Istinye University M ozmen, Prof, Mahir M Ozmen, Professor, Mehmet Mahir Ozmen |
2020-04-01 |
| ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection |
Coronavirus disease 19 infection, Lung injury |
tradipitant alone |
NK1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanda Pharmaceuticals Inc |
|
US |
2020-04-01 |
2020-08-31 |
NCT04326426, ODYSSEY, ODYSSEY, VLY-686-3501 |
Phase 3 Clinical |
Not yet recruiting |
0 |
5 Months |
300 |
Vasilios Polymeropoulos, MD |
2020-04-07 |
| HYCOVID: Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
Monaco, France |
2020-04-30 |
2020-09-30 |
49RC20_0071, HYCOVID, NCT04325893 |
Phase 3 Clinical |
Recruiting |
37 |
5 Months |
1300 |
Alina Tone, MD, Aurélie Baldolli, MD, Aurélien Lorleac'h, MD, Bernard Louis, MD, Blandine Rammaert, MD, DRCI ANGERS, Edouard Devaud, MD, Elisabeth Bothelo-Nevers, MD, Emma D'Anglejean, MD, François Laterza, MD, Guillaume Martin-Blondel, MD, Jean-Baptiste LAINE, Jean-François Faucher, MD, Jean-Philippe Lanoix, MD, Jean-Philippe Talarmin, MD, Julia Brochard, MD, Karine Lacombe, MD, Lionel Piroth, MD, Marie Gousseff, MD, Martin Martinot, MD, Olivier Grossi, MD, Olivier Robineau, MD, Patrick Rispal, MD, Philippe Prazuck, MD, Philippe RAFFI, MD, Raphaël Lepeule, MD, Robin Dhote, MD, Rodolphe Buzele, MD, Roxane Courtois, MD, Rémi VATAN, MD, Simon Sunder, MD, Sylvain Diamantis, MD, Séverine Ansart, MD, Thomas Gey, MD, Thomas Guimard, MD, Valérie Pourcher, MD, Vincent DUBEE, Vincent Dubée, Yann-Erick Claessens, MD |
2020-04-09 |
| A trial to evaluate transplantation of ACE2-mesenchymal stem cells in patients diagnosed with COVID-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
ACE2-mesenchymal stem cells alone |
|
|
Celltex Therapeutics Corp |
|
China |
|
|
|
Phase 2 Clinical |
Status not specified |
1 |
|
7 |
|
2020-04-01 |
| A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury |
Coronavirus disease 19 infection, Heart injury, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
China-Japan Union Hospital of Jilin University, Tongji Hospital, Huazhong University of Science and Technology |
Jilin Provincial Science & Technology Department |
China |
2020-03-27 |
2020-04-27 |
ChiCTR2000031301 |
Phase Not Applicable |
Not yet recruiting |
2 |
1 Month |
100 |
Si Daoyuan |
2020-04-01 |
| A trial to evaluate human umbilical cord mesenchymal stem cells for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
allogenic human umbilical cord mesenchymal stem cells alone |
|
Female |
Chinese Academy of Sciences |
|
|
|
|
|
Phase 2 Clinical |
Status not specified |
0 |
|
1 |
|
2020-03-31 |
| Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
allogeneic human dental pulp mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Renmin Hospital of Wuhan University |
|
China |
2020-04-01 |
2020-07-31 |
ChiCTR2000031319 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
20 |
Dr. Chenliang Zhou, Prof Qingsong Ye |
2020-04-01 |
| A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Jinyebaidu granule alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-02-12 |
2020-05-30 |
ChiCTR2000029755, ChiMCTR2000002999 |
Phase 4 Clinical |
Recruiting |
1 |
3 Months |
120 |
Chen Qian, Liu Dong |
2020-04-01 |
| Risk factors of death from coronavirus disease 2019 |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
|
Yokohama City University |
|
Japan |
2020-03-28 |
|
UMIN000039986 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
Nobuyuki Horita |
2020-04-01 |
| Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Healthy volunteers accepted |
Sichuan University, West China Hospital |
|
China |
2020-02-10 |
2022-02-10 |
ChiCTR2000029754 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
1500 |
Chen Lei, Lai Wanlin |
2020-04-01 |
| Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Public Health Clinical Center |
|
China |
2020-03-23 |
2020-09-30 |
ChiCTR2000031174 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
1000 |
Lu Shuihua, Xia Lu |
2020-04-01 |
| Evaluation of the effectiveness of Ipecac homeopathic remedy in control of Clinical manifestations of COVID-19 |
Coronavirus disease 19 infection |
alcohol plus ipecac homeopathic remedy with C30 potency, Hellios homeopathy pharmacy |
|
|
Iran University of Medical Sciences |
|
Iran |
2020-04-03 |
|
IR.IUMS.REC.1399.039, IRCT20140907019073N4 |
Phase 3 Clinical |
Recruiting |
2 |
|
60 |
Ali Mazaherinezhad, Farbod Rahnama Chitsaz, Proffessor A.Motevalian, Somaye Mahroozade |
2020-04-06 |
| Persian Medicine Products in Covid-19 |
Coronavirus disease 19 infection |
Iranian medicine alone, herbal therapy alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-03 |
|
IR.TBZMED.REC.1398.1318, IRCT20140617018126N2 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Hojjat Pourfathi Nematabad, Mohammad Samiei |
2020-04-06 |
| A medical records based retrospective study for novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan third Hospital |
|
China |
2020-03-23 |
2020-04-30 |
ChiCTR2000031187 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
1292 |
Pengcheng Luo, Yilin Yin |
2020-04-01 |
| Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
interferon plus lopinavir + ritonavir |
HIV protease inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
302 Military Hospital of China |
|
China |
2020-01-10 |
2020-12-31 |
ChiCTR2000031196 |
Phase 2 Clinical |
Recruiting |
1 |
11 Months |
90 |
Zhe Xu |
2020-04-01 |
| Clinical features and prognosis of invasive mechanical ventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Renmin Hospital of Wuhan University |
|
China |
2020-03-26 |
2020-04-06 |
ChiCTR2000031227 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
40 |
Qianqian Qiao, Qingta Meng |
2020-04-06 |
| Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a medical records based study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-25 |
2020-08-25 |
ChiCTR2000031244 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
200 |
Shabei Xu, Wei Wang |
2020-04-01 |
| Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients: a medical records based retrospective study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Renmin Hospital of Wuhan University |
|
China |
2020-01-25 |
2020-03-12 |
ChiCTR2000031245 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
2000 |
Jiabao HOU |
2020-04-01 |
| A clinical study of ACE-MAB to potentially treat SARS-CoV-2 |
Coronavirus disease 19 infection, SARS coronavirus infection |
ACE-MAB (COVID-19), Mabpharm alone |
|
|
Sorrento Therapeutics Inc |
Mabpharm Ltd |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-01 |
| A clinical study to assess efficacy of alpha-1 antitrypsin in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
alpha-1 antitrypsin alone |
|
|
Grifols SA |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-31 |
| A clinical study to assess efficacy of intravenous immunoglobulin in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
immunoglobulin alone |
|
|
Grifols SA |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-31 |
| Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Chongqing Medical University |
|
China |
2020-03-01 |
2021-04-30 |
ChiCTR2000031246 |
Phase Not Applicable |
Not yet recruiting |
2 |
14 Months |
68 |
Kun Chu, Xiaojun Tang |
2020-04-06 |
| Study on the mental state of medical staff during the epidemic period of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
West China Hospital |
|
China |
2020-03-01 |
2021-03-01 |
ChiCTR2000031247 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
500 |
Qingqing Xiao, Xiandong Meng |
2020-04-01 |
| Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Chongqing Medical University |
|
China |
2020-01-29 |
2020-06-30 |
ChiCTR2000031252 |
Phase Not Applicable |
No longer recruiting |
2 |
5 Months |
60 |
Qiuling Shi, Yang Pu |
2020-04-01 |
| Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-16 |
2020-05-16 |
ChiCTR2000031293 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
240 |
Xiaoping Luo, Xiuyun Zhou, Yan Hao |
2020-04-01 |
| The effect of Trachyspermum copticum syrup on clinical manifestations of patients with COVID-19 |
Coronavirus disease 19 infection |
Trachyspermum copticum syrup alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Arak University of Medical Sciences and Health Services |
|
Iran |
2020-04-08 |
|
IR.ARAKMU.REC.1398.342, IRCT20180610040049N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Alireza Kamali, Seied Amirhosein Latifi |
2020-04-09 |
| A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First College Of Clinical Medical Science, China Three Gorges University |
|
China |
2020-01-14 |
2020-03-19 |
ChiCTR2000031296 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
200 |
Zhang Rong, Zhou Fating |
2020-04-01 |
| Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients |
Coronavirus disease 19 infection, Viral pneumonia |
Cordio App (Cordio Medical Ltd) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cordio Medical Ltd |
|
Israel |
2020-04-30 |
2021-09-30 |
COV001, NCT04325048 |
Phase Not Applicable |
Not yet recruiting |
1 |
17 Months |
5000 |
Miri Yafee, MSc, Zaher Azzam, Prof |
2020-04-01 |
| Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
anakinra alone, emapalumab alone |
Interferon gamma ligand inhibitor, Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Swedish Orphan Biovitrum AB |
|
Italy |
2020-04-02 |
2020-09-30 |
2020-001167-93, NCT04324021, SOBI.IMMUNO-101 |
Phase 2/Phase 3 Clinical |
Recruiting |
4 |
5 Months |
54 |
Antonio Pesenti, Prof, Cristina de Min, MD / CMO, Emanuele Nicastri, Dr, Emanuele Nicastri, MD, Franco Franceschini, Prof, Gabriele Missale, Prof, Karin Becker, MSc, Prof |
2020-04-10 |
| VIRUS: Viral Infection and Respiratory Illness Universal Study [VIRUS]: COVID19 Registry |
Coronavirus disease 19 infection, Viral infection |
|
|
|
Mayo Clinic Foundation |
|
US |
2020-03-30 |
2021-04-30 |
20-002610, NCT04323787, VIRUS |
Phase Not Applicable |
Recruiting |
0 |
13 Months |
50000 |
Ayan Sen, MD, Devang Sanghavi, MD, Ognjen Gajic, MD, Rahul Kashya, MBBS, Rahul Kashyap, Vishakha Kumar, MD |
2020-04-04 |
| ACT COVID19: Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial |
Coronavirus disease 19 infection |
azithromycin plus chloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Population Health Research Institute |
|
Canada |
2020-04-01 |
2020-12-31 |
ACT COVID19, NCT04324463, PHRI.ACT.COVID19 |
Phase 3 Clinical |
Not yet recruiting |
1 |
9 Months |
1500 |
ACT COVID-19 Study Coordinator, Emilie Belley-Cote, MD PhD, Richard Whitlock, MD PhD |
2020-04-01 |
| CYCOV: Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
CytoSorb adsorber alone, Extracorporeal Membrane Oxygenation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-03-27 |
2020-11-26 |
CYCOV, CYCOV, CYCOV_ECMO_2020, DRKS00021300, NCT04324528 |
Phase Not Applicable |
Recruiting |
2 |
8 Months |
30 |
Alexander Supady, Dr., MPH |
2020-04-09 |
| CORIMUNO-19: Cohort, Multiple-Randomized, Controlled Trials, Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
immune modulatory drug therapy alone, sarilumab alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-03-27 |
2021-12-31 |
2020-001246-18, APHP200375, CORIMUNO-19, NCT04324047 |
Phase Not Applicable |
Recruiting |
4 |
21 Months |
1000 |
Cécile Kedzia, Matthieu RESCHE-RIGON, MD PhD, Olivier HERMINE, MD-PhD |
2020-04-02 |
| CORONADO: 'Coronavirus SARS-CoV2 and Diabetes Outcomes' |
Coronavirus disease 19 infection, Diabetes mellitus |
antidiabetic treatment alone, antihypertensive treatment alone |
|
|
CHU De Nantes |
|
France |
2020-03-10 |
2020-05-08 |
CORONADO, NCT04324736, RC20_0148 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
1000 |
Bertrand Cariou, PU-PH, Bertrand Cariou, Pr |
2020-04-09 |
| CORIMUNO-SARI: Cohort, Multiple, Randomized, Controlled Trials, Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial |
Coronavirus disease 19 infection, Lung disease, Viral pneumonia |
sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-03-27 |
2021-12-31 |
APHP200375-2, CORIMUNO-SARI, NCT04324073 |
Phase 2/Phase 3 Clinical |
Recruiting |
4 |
21 Months |
240 |
Matthieu RESCHE-RIGON, MD PhD, Olivier HERMINE, MD-PhD, Xavier Mariette, MD-PHD, matthieu resche-rigon, MD-PhD, olivier HERMINE, MD PHD |
2020-04-02 |
| A Study of a Candidate COVID-19 Vaccine |
Coronavirus disease 19 infection, Viral pneumonia |
ChAdOx1 nCoV-19 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
University of Oxford |
United Kingdom Research & Innovation |
UK |
2020-04-30 |
2021-05-31 |
2020-001072-15, COV001, CPMS 45367, IRAS 281259, ISRCTN15281137, NCT04324606 |
Phase 1/Phase 2 Clinical |
Recruiting |
5 |
13 Months |
510 |
Andrew Pollard, Prof, Dr Andrew Pollard, Mrs Emma Plested, Volunteer Recruitment Co-ordinator |
2020-04-08 |
| Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) versus Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
anti-SARS-CoV-2 plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
|
2020-05-01 |
2023-01-31 |
CSSC-001, IRB00245634, NCT04323800 |
Phase 2 Clinical |
Not yet recruiting |
0 |
33 Months |
150 |
Shmuel Shoham, MD |
2020-04-09 |
| PRIORITY: COVID-19 Pregnancy CoRonavIrus Outcomes RegIsTrY |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California San Francisco |
University of California Los Angeles |
US |
2020-03-20 |
2024-03-31 |
20-30410, NCT04323839, PRIORITY |
Phase Not Applicable |
Recruiting |
0 |
48 Months |
1000 |
Ruth Gebrezghi, Study Coordinator, Vanessa Monzon, Vanessa Vacoby, MD, MAS |
2020-04-08 |
| EC-COVID-PCS: Early CPAP in COVID Patients With Respiratory Failure: a Prospective, Cohort Study |
Coronavirus disease 19 infection, Respiratory failure |
ACE inhibitor therapy alone, antiviral therapy alone, sartans therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istituto di Ricerche Farmacologiche Mario Negri |
|
Italy |
2020-04-06 |
2020-11-09 |
EC-COVID-PCS, EC-COVID-PCS-FENICE, NCT04323878 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
3000 |
Elena Garbero, M.Sc, Guido Bertolini, MD |
2020-04-01 |
| The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Nanjing Drum Tower Hospital |
|
|
2020-01-01 |
2021-01-01 |
ChiCTR2000031324 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
300 |
Wei Min |
2020-03-31 |
| Convalescent Plasma to Limit Coronavirus Associated Complications |
Coronavirus disease 19 infection, SARS coronavirus infection |
c,anti-SARS-CoV-2 onvalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mayo Clinic Foundation |
|
|
2020-04-01 |
|
20-002864, NCT04325672 |
Phase 2a Clinical |
Terminated |
0 |
|
|
Michael Joyner, MD |
2020-04-09 |
| A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Renmin Hospital of Wuhan University |
|
China |
2020-02-20 |
2021-02-20 |
ChiCTR2000029803 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
320 |
Shoumeng Han, Zhan Zhang |
2020-04-01 |
| Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universita di Verona |
Azienda Ospedaliera Universitaria Integrata Di Verona |
Italy |
2020-04-01 |
2020-12-31 |
GISONDI 4, NCT04324866 |
Phase Not Applicable |
Not yet recruiting |
1 |
9 Months |
300 |
Paolo Gisondi |
2020-03-31 |
| A clinical study to assess anti-SARS-CoV-2 hyperimmune globulin therapy as a therapy for the treatment of patients with COVID-19 disease |
Coronavirus disease 19 infection |
hyperimmune globulin alone |
|
|
Grifols SA |
Biomedical Advanced Research and Development Authority (BARDA), Food and Drug Administration |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-31 |
| Comparison of vitamin D3 and N-acetylcysteine prescription in COVID-19 patients and their effect on recovery process |
Coronavirus disease 19 infection |
N acetylcysteine alone, Vitamin D3 alone, standard treatment alone, N acetylcysteine plus Vitamin D3 |
|
|
Abadan School of Medical Sciences |
|
Iran |
2020-03-29 |
|
IR.ABADANUMS.REC.1398.118, IRCT20200324046850N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Sara Mobarak |
2020-03-31 |
| Efficacy of the myrtle syrup in the treatment of novel corona |
Coronavirus disease 19 infection, Viral pneumonia |
myrtle (Myrtus Communis) syrup alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Kerman University of Medical Sciences |
|
Iran |
2020-04-02 |
|
IR.KMU.REC.1399.015, IRCT20180923041093N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Abbas Pardakhti, Maryam Azimi |
2020-04-03 |
| Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
Shen-Fu injection alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Peking University Third Hospital |
|
China |
2020-02-01 |
2020-12-31 |
ChiCTR2000030043 |
Phase 4 Clinical |
Not yet recruiting |
14 |
11 Months |
300 |
Ma Penglin, Wang Zongyu |
2020-03-31 |
| A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xiangya Hospital Of Central South University |
|
China |
2020-03-24 |
2020-05-31 |
ChiCTR2000031199 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
150 |
Fan Rong, Wang Yang |
2020-03-31 |
| Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
moxibustion treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
People’s Hospital of Zhengzhou |
|
China |
2020-03-01 |
2022-02-28 |
ChiCTR2000031203, ChiMCTR2000003156 |
Phase 0 Clinical |
Recruiting |
1 |
24 Months |
28 |
Fu Liran |
2020-04-01 |
| Cancelled by the investigator A clinical study for 'Huo-Shen' particles in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Huo-Shen particles alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenzhen national medicine inheritance medical research institute co. LTD |
|
China |
2020-03-24 |
|
ChiCTR2000030118, ChiMCTR2000003048 |
Phase 0 Clinical |
Terminated |
1 |
|
120 |
Yuan Yongming, Zhang Jingsha |
2020-03-31 |
| Cancelled by the investigator Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
psychological and physical rehabilitation based humanistic care alone, routine regimen alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Second Hospital of Xi'An Jiaotong University |
|
China |
2020-02-24 |
|
ChiCTR2000030136 |
Phase 0 Clinical |
Terminated |
1 |
|
130 |
Gong Shouping, Ma Xiaorong |
2020-03-31 |
| Efficacy of the barley-based remedy in the treatment of novel corona |
Coronavirus disease 19 infection, Viral pneumonia |
barley-based medication alone, drug pack therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Kerman University of Medical Sciences |
|
Iran |
2020-04-02 |
|
IR.KMU.REC.1399.014, IRCT20180923041093N4 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Abbas Pardakhti, Maryam Azimi |
2020-04-03 |
| Cancelled by the investigator Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Depression, Post traumatic stress disorder, Viral pneumonia |
humanistic care alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
The Second Hospital of Xi'An Jiaotong University |
|
China |
2020-02-24 |
|
ChiCTR2000030137 |
Phase 0 Clinical |
Terminated |
1 |
|
130 |
Gong Shouping, Ma Xiaorong |
2020-03-30 |
| Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID-19) outbreak: an online survey |
Coronavirus disease 19 infection, Viral pneumonia |
health advice based on online survey alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
The Jockey Club School of Public Health and Primary Care |
|
China |
2020-02-20 |
2022-05-19 |
ChiCTR2000030223 |
Phase Not Applicable |
Recruiting |
1 |
27 Months |
5000 |
Daisy Dexing Zhang |
2020-03-30 |
| Efficacy evaluation of an herbal compound 'Fluherb' on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients: a controlled, randomized clinical trial |
Coronavirus disease 19 infection |
Fluherb supplement alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-03-28 |
|
IR.MUMS.REC.1398.315, IRCT20200323046841N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
30 |
Dr. Mohsen Tafaghodi, Mahdi Yousefi |
2020-03-30 |
| Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
angiotensin II receptor blockers (ARBs) alone, angiotensin-converting enzyme inhibitors (ACEIs) alone |
|
|
The First Affiliated Hospital of Wenzhou Medical University |
|
China |
2020-03-02 |
|
ChiCTR2000030453 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
100 |
Yanling Shi |
2020-03-30 |
| JYCO: A multicenter, single-blind, randomized, controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine phosphate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Beijing Institute of Pharmacology and Toxicology, Beijing YouAn Hospital |
|
China |
2020-01-30 |
|
ChiCTR2000031204, JYCO, JYCO |
Phase 2 Clinical |
Recruiting |
3 |
|
300 |
Jin Ronghua, Zhong Wu |
2020-03-30 |
| Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Rehabilitation Hospital of Shanghai, Wuhan third Hospital |
|
China |
2020-03-31 |
2022-03-31 |
ChiCTR2000031214 |
Phase 0 Clinical |
Not yet recruiting |
1 |
24 Months |
60 |
GAO Tian-lin, ZHOU Zhe |
2020-03-31 |
| Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
extracorporeal membrane oxygenation (ECMO) alone |
|
|
Capital Medical University, Wuhan Jinyintan Hospital |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-02-01 |
2021-01-31 |
ChiCTR2000029804 |
Phase Not Applicable |
Recruiting |
3 |
12 Months |
100 |
Liu Ying, Wu Wenjuan |
2020-04-02 |
| The effect of stem cell transplantation in the treatment of COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
cord-derived mesenchymal stem cells (SinaCell) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
MOM research and innovation center |
|
Iran |
2020-03-24 |
|
IR.IUMS.REC.1398.1400, IRCT20140528017891N8 |
Phase 3 Clinical |
Recruiting |
1 |
|
10 |
Amirhossein Asgary, Elham Jamshidi, Nader Tavakoli, Omid Moradimoghadam |
2020-04-02 |
| DEXA-COVID19: Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
dexamethasone (Indukern) alone, standard intensive care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dr. Negrin University Hospital |
Centro De Investigación Biomédica En Red De Enfermedades Hepáticas Y Digestivas (Ciberehd), Li Ka Shing Knowledge Institute |
Spain |
2020-04-03 |
2020-10-30 |
2020-001278-31, DEXA-COVID19, NCT04325061 |
Phase 4 Clinical |
Recruiting |
19 |
6 Months |
200 |
Ainhoa Serrano, MD, Alberto Martínez-Ruiz, MD, PhD, Alfonso Ambrós, MD, PhD, Arthur Slutsky, MD, Carlos Ferrando, MD, PhD, Carlos García-Palenciano, MD, Carmen Martín, MD, César Aldecoa, MD, PhD, César Pérez-Calvo, MD, Domingo Martínez, MD, Emilio Maseda, MD, PhD, Eugenia Durán-González, MD, Fernando Ramasco, MD, PhD, Fernando Suarez-Sipmann, MD, PhD, Gerardo Aguilar, MD, PhD, Gonzalo Tamayo, MD, PhD, Irene Faura-Nuñez, MD, Iñaki Bilbao-Villasante, MD, Javier Fernández, MD, Jesús Rico, MD, Jesús Sanchez-Ballesteros, MD, Jesús Villar, MD, Joan R Badia, MD, Josep Trenado, MD, José A Carbonell, MD, José C Mondéjar, MD, José Ferreres, MD, PhD, José I Gómez-Herreras, MD, PhD, José M Añón, MD, PhD, Juan A Soler, MD, PhD, Juan C Figueira, MD, Lorena Fernández, MD, PhD, Manuel Castellá, MD, Mar Fernández, MD, Mar Juan, MD, Marina Varela, MD, PhD, Mario Lorenzo-López, MD, María J Asensio, MD, María L Blasco, MD, Nieves Carbonell, MD, Pablo Blanco, MD, Pablo Serna-Grande, MD, Pedro Castro, MD, Piedad Martínez-Gil, MD, Pilar Diaz-Parada, MD, Rafael del Campo, MD, Ricard Mellado-Artigas, MD, Tomás Muñoz, MD, PhD, Ánxela Vidal, MD |
2020-04-10 |
| Comparison of the Effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 |
Coronavirus disease 19 infection |
daclatasvir+ sofosbuvir alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Abadan School of Medical Sciences |
|
Iran |
2020-03-18 |
|
IR.ABADANUMS.REC.1398.113, IRCT20200324046850N2 |
Phase 2 Clinical |
Recruiting |
1 |
|
60 |
Sara Mobarak, Sara Mobark |
2020-03-31 |
| ENACOVID: Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
Standard of care alone, naproxen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-03-27 |
2021-06-27 |
APHP200387, ENACOVID, NCT04325633 |
Phase 3 Clinical |
Not yet recruiting |
1 |
15 Months |
584 |
Anny SLAMA SCHWOK, MD, Frédéric ADNET, MD, PhD |
2020-03-31 |
| CAPACITY-COVID: Cardiac Complications in Patients With SARS Coronavirus 2 Registry |
Cardiovascular disease, Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
|
Netherlands |
2020-03-23 |
2021-06-23 |
20-161/C, CAPACITY-COVID, NCT04325412 |
Phase Not Applicable |
Recruiting |
1 |
15 Months |
1000 |
Folkert W. Asselbergs, MD, PhD, Marijke Linschoten, MD, Prof. Dr. F.W. Asselbergs |
2020-04-02 |
| Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Western medicine therapy alone, traditional Chinese medicine therpy alone |
|
|
The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine |
Science & Technology Department of Sichuan Province |
China |
2020-02-03 |
2020-05-01 |
ChiCTR2000029549, ChiMCTR2000002983 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
400 |
Tang Shiyun, Xie Chunguang |
2020-04-01 |
| A phase I clinical study of STI-6991 (I-Cell) for the potential im prevention of coronavirus COVID-19 caused by SARS-CoV-2 (2019-nCoV) |
Coronavirus disease 19 infection, SARS coronavirus infection |
STI-6991 alone |
|
|
Sorrento Therapeutics Inc |
|
US |
2020-06-30 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-02 |
| A clinical study to assess Ampligen for the potential treatment of subjects with COVID-19 |
Coronavirus disease 19 infection |
rintatolimod alone |
2,5-Oligoadenylate synthetase stimulator, Interferon type I receptor agonist, Ribonuclease stimulator, TLR-3 agonist |
|
AIM ImmunoTech Inc |
National Institute of Infectious Diseases Japan |
Japan |
|
|
|
Phase Not Applicable |
Not yet recruiting |
2 |
|
|
Dr. Hideki Hasegawa, Dr. Takeshi Ichinohe |
2020-04-01 |
| Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial |
Coronavirus disease 19 infection, Viral pneumonia |
traditional Chinese medicine therapy alone, western medicine therapy alone |
|
|
Zhejiang Chinese Medical University |
|
China |
2020-02-06 |
2020-04-30 |
ChiCTR2000029578 |
Phase 0 Clinical |
Recruiting |
1 |
2 Months |
1000 |
Chengping Wen, Zhijun Xie |
2020-04-01 |
| DAS-181 for Severe COVID-19: Compassionate Use |
Coronavirus disease 19 infection, Hypoxia, SARS coronavirus infection, Viral pneumonia |
DAS-181 alone |
Exo-alpha sialidase modulator, Muscarinic receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Renmin Hospital of Wuhan University |
Ansun BioPharma Inc |
China |
2020-03-06 |
2020-04-30 |
DAS181-SARS-COV-2, NCT04324489 |
Phase 2 Clinical |
Recruiting |
1 |
1 Month |
4 |
Ke Hu, MD, Zuojiong Gong, MD, Zuojiong Guong, MD |
2020-04-08 |
| Clinical characteristics and death risk factors in severe novel coronavirus pneumonia (COVID-19) patients: a single-center respective analysis based on medical records |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Medical College |
|
China |
2020-04-01 |
2020-04-10 |
ChiCTR2000031327 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
120 |
Hong Qiu, Hui Peng |
2020-04-01 |
| A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Jinyebaidu granule alone, angiotensin II receptor blockers therapy alone, other prophylactic drugs therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-12 |
2020-05-30 |
ChiCTR2000029728 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
500 |
Chen Qian, Liu Dong |
2020-04-01 |
| The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients |
Coronavirus disease 19 infection, Viral pneumonia |
basic therapy alone, sleep-aid music therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
|
China |
2020-03-13 |
2020-04-30 |
2020003, ChiCTR2000031328 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
60 |
Yuan-hao Wu |
2020-04-01 |
| NIKE-C19: Prognostic Factors Keeping Track for Covid19 Pneumonia |
Cardiovascular disease, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Hypertension, Non-insulin dependent diabetes, Obesity, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Catholic University of the Sacred Heart |
|
Italy |
2020-03-31 |
2020-05-30 |
20202503, NCT04324684, NIKE-C19 |
Phase Not Applicable |
Recruiting |
2 |
2 Months |
198 |
Anna Caprodossi, Antonio Gasbarrini, MD, Francesco Franceschi, MD, Geltrude Mingrone, Geltrude Mingrone, MD PhD, Gian Ludovico Rapaccini, MD, Giovanni Addolorato, MD, Massimo Montalto, MD, Maurizio Pompili, MD |
2020-04-10 |
| A pilot study to diagnose COVID-19 in subject obtained oropharyngeal and salivary samples through FDA approved gold standard of COVID-19 testing |
Coronavirus disease 19 infection |
FDA approved gold standard of COVID-19 testing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ZoomCare Company |
PeaceHealth System Services |
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-02 |
| Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
The First People's Hospital of Huaihua |
Hunan Provincial Natural Science Foundation |
China |
2020-01-31 |
2020-08-07 |
ChiCTR2000029734 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
40 |
Chengfeng Qiu |
2020-03-31 |
| The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Qigong Yangfeifang alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Public Health Clinical Center, Shanghai University of Traditional Chinese Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine |
|
China |
2020-02-18 |
2022-02-19 |
ChiCTR2000029976, ChiMCTR2000003032 |
Phase 0 Clinical |
Recruiting |
1 |
24 Months |
80 |
Shan Chunlei, Xu Shutian |
2020-03-31 |
| Influence of novel coronavirus pneumonia (COVID-19) on disease activity, medical and mental condition of patients with rheumatic diseases |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangdong Provincial People's Hospital |
|
China |
2020-03-11 |
2023-12-31 |
ChiCTR2000031329 |
Phase Not Applicable |
Recruiting |
1 |
45 Months |
120 |
Tianwang Li |
2020-03-31 |
| Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gilead Sciences Inc |
|
US, France, UK, Italy |
|
|
2020-001453-49, GS-US-540-5821, NCT04323761 |
Phase Not Applicable |
Recruiting |
3 |
|
|
Gilead Clinical Study Information Center, Gilead Study Director |
2020-04-10 |
| A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients |
Candida infection, Coronavirus disease 19 infection, Viral pneumonia |
antifungal therapy alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-04-01 |
2020-08-31 |
ChiCTR2000030717 |
Phase Not Applicable |
Not yet recruiting |
3 |
5 Months |
260 |
Minghao Fang, Xiaojing Zou |
2020-04-01 |
| A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
ACE2 CAR-NK cells alone, IL-15 NK cells alone, NK cells alone, NKG2D CAR-NK cells alone, NKG2D-ACE2 CAR-NK cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chongqing Infectious Disease Medical Center |
Chongqing Sidemu Biotechnology Co. Ltd |
China |
2020-03-21 |
2020-09-30 |
CHONGQINGPUBLICHMC, NCT04324996 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
6 Months |
90 |
Jimin Gao, PhD, Min Liu, A.B |
2020-03-31 |
| AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
prognostic evaluation alone |
|
|
Huazhong University of Science and Technology |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000031336 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
1000 |
Fan Yang, Wenliang Fan |
2020-04-06 |
| Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Male |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-14 |
2020-04-30 |
ChiCTR2000030895 |
Phase 1 Clinical |
Not yet recruiting |
1 |
1 Month |
1000 |
Jingyu Hu, Jingzhi Ma |
2020-04-01 |
| A clinical trial of Standard Q COVID-19 IgM/IgG Rapid Antibody Test for the qualitative presumptive detection of specific IgM and IgG antibodies associated with the 2019 novel coronavirus (SARS-CoV-2) |
Coronavirus disease 19 infection, SARS coronavirus infection |
Standard Q COVID-19 IgM/IgG Rapid Antibody Test alone |
|
|
Henry Schein Inc |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-07 |
| Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR and CRP |
Coronavirus disease 19 infection, Viral pneumonia |
blood routine test alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kongjiang hospital |
|
China |
2020-01-21 |
2020-06-30 |
ChiCTR2000030942 |
Phase Not Applicable |
No longer recruiting |
1 |
5 Months |
191 |
MINGLI LIU |
2020-04-02 |
| Cancelled by investigator A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Cox regression analysis alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan Asia General Hospital |
|
China |
2020-02-01 |
2020-02-18 |
ChiCTR2000029820 |
Phase Not Applicable |
Suspended |
1 |
|
410 |
Huang Keqiang |
2020-03-31 |
| Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Peking Union Medical College Hospital, Wuhan Jinyintan Hospital |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-01-01 |
2021-01-31 |
ChiCTR2000029805 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
100 |
Liu Ying, Wu Wenjuan |
2020-03-31 |